



No. यू-25/12/RC/142C-146C&147BExtension/2023- चि.5 (ई-464432) / 375 Dated: 07.11.2024

सेवा में,

- Director (Medical) Delhi/ Director (Medical) Noida
- Deans- All PGIMSR's /Medical Colleges
- Medical Superintendents -All ESIC Hospitals.
- Directors, ESI Schemes- All states

विषय: **Extension of DG-ESIC Rate Contract Nos. 142C-146C -reg.**

महोदया/महोदय,

I am hereby directed to inform the approval of Director General, Employee State Insurance Corporation for extension of DG-ESIC Rate Contract No.142C, 143C, 144C, 145C and 146C **for 517 nos.** of Drugs as per the attached list (475 drugs manufactured by Indian manufacturers + 42 imported drugs where exemption has been accorded by Govt. of India, copy of OM dated 07.06.2024 enclosed) up to 30.04.2025 or till the finalization of New Rate Contract (whichever is earlier), subject to adherence to the following conditions:-

1. Supply order should be placed ONLY on First Preference holders.
2. Willingness of the firm to supply on the same Terms & Conditions, as approved in DG ESIC Rate Contract(s) 142C, 143C, 144C, 145C & 146C.
3. No order should be placed in respect of drugs, which have been found to be 'Not of Standard Quality' on test analysis.
4. Amendments / orders (if any) already issued (copy enclosed interalia), time to time in respect of drugs of DGESIC RC's 142C, 143C, 144C, 145C & 146C have to be taken into consideration while placing the supply orders.

It is also reiterated that Procurement of **44 drugs** which were earlier approved in the DG ESIC Rate Contracts 142C, 143C, 144C, 145C & 146C & for which exemption has not been accorded by GoI, should be purchased as per purchase guidelines of Govt. of India giving due diligence to GoI initiative for Make in India items.

This issues with the approval of Director General

भवदीय,

- संलग्न: 1. List of 517 drugs in RC 142C to 146C under extension
2. List of 42 approved Imported Drugs _Exempted in GTE
3. List of 86 approved Imported Drugs in RC 142C to 146C
4. Copy of Amendments and NSQ's in RC 142C to 146C

DY. MEDICAL COMMISSIONER (RC)

उप चिकित्सा आयुक्त (दर सविदा/प्रापण शाखा)

Copy for information to:-

1. PPS/ PS to DG, FC, MC
2. Account Branch V, Hqrs. Office
3. Zonal Medical Commissioners (North, South, East, West, North East).
4. Website Content Manager with request for uploading on ESIC Website.
5. Hindi Division for translation.
6. Guard file.

DY. MEDICAL COMMISSIONER (RC)

उप चिकित्सा आयुक्त (दर सविदा/प्रापण शाखा)

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
1	142C	Wallace Pharmaceuticals Pvt. Ltd.	8	Metoclopramide Tab/Cap- Each Tab/Cap to contain: Metoclopramide Hcl 10mg	1 Tab/Cap	FIRST
2	142C	Wallace Pharmaceuticals Pvt. Ltd.	16	Antispasmodic Drop/Susp- Each ml to contain: Dicyclomine Hcl 10 mg, Activated Dimethicone 40mg	10 ml. Bott	FIRST
3	142C	Hab Pharmaceuticals & Research Ltd	213	Ciprofloxacin Eye/Ear Drop- Each Vial to contain: Ciprofloxacin 0.3% w/v. 5 to 10ml vial	1ml	FIRST
4	142C	East India Pharmaceutical Works Limited	219	Oxymetazoline Nasal Drop- Each Vial to contain: Oxymetazoline 0.05% w/v.	10ml Vial	FIRST
5	142C	Brawn Laboratories Ltd	220	Xylometazoline Nasal Drop- Each Vial to contain: Xylometazoline 0.1% w/v.	10ml Vial	FIRST
6	142C	Micron Pharmaceuticals	345	Antacid Tab/Cap- Each Tab/Cap to contain :Dried Aluminium Hydroxide Gel 250 mg, Magnesium Hydroxide 250 mg, Methyl Polysiloxane/Activated Dimethicone 50 mg	1 Tab/Cap	FIRST
7	142C	Micron Pharmaceuticals	358	Haemorrhoidal Cream- Each Tube to contain: Beclomethasone Dipropionate 0.025 %, Phenylephrine Hydrochloride 0.1 %, Lignocaine Hydrochloride 2.5 %.	20 gm Tube	FIRST
8	142C	Hab Pharmaceuticals & Research Ltd	371	Analgesic Gel- Each gm to contain: Nimesulide 10mg, Methyl Salicylate 100mg, Menthol 50mg, Capaicin 0.25mg in Cream Base	30gm Tube	FIRST
9	142C	Tablets (India) Limited	388	Ondansetron Inj- Each ml to contain: Ondansetron 2 mg	4ml Vial/Amp	FIRST
10	142C	Vivimed Labs Ltd.	392	Saline Nasal Drop- Each phial to contain: Sodium Chloride 0.65%, Benzalkonium Chloride 0.001 %, Phenyl Mercuric Acetate 0.002 %.	15ml Phial	FIRST
11	142C	Wallace Pharmaceuticals Pvt. Ltd.	427	Sulphasalazine Tab/Cap- Each Tab/Cap to contain: Sulphasalazine 500mg	1 Tab/Cap	FIRST
12	142C	Hindustan Laboratories Limited	512	Itopride Tab/Cap- Each Tab/Cap to contain: Itopride Hydrochloride 50mg	1 Tab/Cap	FIRST
13	142C	Galpha Laboratories Limited	536	Pantoprazole Inj- Each Inj to contain: Pantoprazole 40mg	1 Vial/Amp	FIRST

Handwritten signature
7/11/2024

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
14	142C	Psychotropics India Limited	577	Ursodesoxycholic Acid Tab/Cap- Each Tab/Cap to contain: Ursodesoxycholic Acid 150mg.	1 Tab/Cap	FIRST
15	142C	Overseas Healthcare Pvt Ltd	599	Doxylamine + Pyridoxin Tab/Cap- Each Tab/Cap to contain: Doxylamine Succinate 10mg, Pyridoxin 10mg	1 Tab/Cap	FIRST
16	142C	Micron Pharmaceuticals	1002	Antacid Gel- Each 5ml to contain: Oxetacaine 10 mg, Al. Hydroxide 291 mg, Mag. Hydroxide 98 mg	200ml Bott	FIRST
17	142C	Micron Pharmaceuticals	1010	Laxative Liquid- Each 15 ml to contain: Milk Of Magnesia 11.25 ml, Liquid Paraffin 3.75 ml	170ml Bott	FIRST
18	142C	Overseas Healthcare Pvt Ltd	1019	Drotaverine Tab/Cap- Each Tab/Cap to contain:Drotavarine Hcl 80 mg	1 Tab/Cap	FIRST
19	142C	East India Pharmaceutical Works Limited	1028	Enzyme Syp- Each 10 ml to contain: Fungal Diastase (1:2000) 40 mg, (Aspergillus Oryzae Enzyme), Cinnamon Oil 0.25mg, Caraway Oil 0.5mg, Cardamon Oil 0.5 mg in Glycerol Sorbitol Base.	200ml Bott	FIRST
20	142C	Hab Pharmaceuticals & Research Ltd	1083	Tramadol Tab/Cap- Each Tab/Cap to contain: Tramadol Hcl 50 mg	1 Tab/Cap	FIRST
21	142C	Lark Laboratories (India) Ltd.	1092	Ibuprofen Oral Susp- Each 5 ml to contain: Ibuprofen 100 mg	60ml Bott	FIRST
22	142C	Overseas Healthcare Pvt Ltd	1093	Ibuprofen And PCM Oral Susp- Each 5 ml to contain: Ibuprofen 100 mg, Paracetamol 162.5 mg	60ml Bott	FIRST
23	142C	Lark Laboratories (India) Ltd.	1108	Trypsin Chymotrypsin Tab/Cap- Each Tab/Cap to contain: 1,00,000 Armour Units Of Enzymatic Activity Supplied By A Purified Concentrate Which Has Specific Trypsin And Chymotrypsin Activity In A Ratio Of Approximately Six To One	1 Tab/Cap	FIRST
24	142C	Glaxo Smithkline Pharmaceuticals Ltd	1211	Antibiotic Eye Oint- Each Gram to contain:Polymyxin B Sulphate 5000 IU, Neomycin Sulphate 3400 IU, Zinc Bacitracin 400 IU, Hydrocortisone 10 mg in White Sterilised Petroleum Jelly Base.	5gm Tube	FIRST
25	142C	FDC Limited	1212	Flurbiprofen Eye Drop- Eacl Vial to contain; Flurbiprofen 0.03% w/v	5ml Vial	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
26	142C	Vivimed Labs Ltd.	1234	Wax Softner Ear Drop- Each Vial to contain: Para Dichlorobenzene 2% w/v, Benzocaine 2.7% w/v, Chlorbutol 5%, Turpentine Oil 15% w/v	10ml Vial	FIRST
27	142C	Vivimed Labs Ltd.	1237	Oxymetazoline Nasal Drop- Each Vial to contain: Oxymetazoline 0.025% w/v	10ml Vial	FIRST
28	142C	Cipla Limited	1239	Budesonide Nasal Spray- Each Actuation To Deliver: Budesonide 100 mcg.	150 doses	FIRST
29	142C	Galpha Laboratories Limited	1345	Laxative Enema- Each Bott to contain: Glycerin I.P.15%, Sodium Chloride I.P.15%	30ml Bott	FIRST
30	142C	Indoco Remedies Ltd	1346	Dicyclomine + Mefenamic Tab/Cap- Each Tab/Cap to contain: Dicyclomine 10mg, Mefenamic Acid 250mg	1 Tab/Cap	FIRST
31	142C	Sanofi Healthcare India Pvt.Ltd (formerley known as Sanofi - Synthelabo (India) Private Limited)	1347	Thiocolchicoside Tab/Cap- Each Tab/Cap to contain: Thiocolchicoside 4mg	1 Tab/Cap	FIRST
32	142C	Micron Pharmaceuticals	1371	Mebeverine Tab/Cap- Each Tab/Cap to contain: Mebeverine Hydrochloride 135mg	1 Tab/Cap	FIRST
33	142C	Bajaj Healthcare Limited	1376	Hydroxy Chloroquine Tab/Cap- Each Tab/Cap to contain: Hydroxy Chloroquine Sulfate 200mg	1 Tab/Cap	FIRST
34	142C	Lark Laboratories (India) Ltd.	1415	Ornidazole Tab/Cap- Each Tab/Cap to contain: Ornidazole 500mg	1 Tab/Cap	FIRST
35	142C	Unimarck Pharma (I) Ltd	1489	Drotaverine Inj- Each ml to contain: Drotaverine 20mg	2ml Vial/Amp	FIRST
36	142C	Micron Pharmaceuticals	1495	Antacid Gel- Each 5ml to contain: Dried Aluminium Hydroxide Gel 300mg Magnesium Hydroxide 250mg, Activated Simethicone 40mg	170ml Bott.	FIRST
37	142C	Medley Pharmaceuticals Ltd	1503	Liver Disorders Syp- Each 5ml to contain: Tricholine Citrate 250 mg, Kalmegh IP Eq. to Andrographolides 250mcg, Sorbitrol-Solution I.P. (70%) in a Flavoured Base	200ml Bott	FIRST
38	142C	Laboratoires Griffon Pvt. Ltd	1504	Liver Disorders Syp- Each 10ml to contain: Tricholine Citrate 0.55gm, Sorbitol 7.15gm.	200 ml Bott	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
39	142C	Hab Pharmaceuticals & Research Ltd	1546	Spray- Each pack to contain: Spray Diclofenac Diethylmine 1.16%, Methyl Salicylate 10% w/w, Linseed Oil (Oleum Lini) 3% w/w, Menthol 5% w/w, Excipients & Propellant Q.S. 100 % w/w	100gm Pack	FIRST
40	142C	Indoco Remedies Ltd	1547	Analgesic Cream- Each Tube to contain: Cream Methyl Salicylate 8% w/w, Mephenesin 5% w/w, Methyl Nicotinate 1% w/w, Menthol 2% w/w	20 gm Tube	FIRST
41	142C	Ajanta Pharma Limited	1594	Gatifloxacin Eye Drop- Each Vial to contain: Gatifloxacin Soln 0.3% w/v	5ml Vial	FIRST
42	142C	Ajanta Pharma Limited	1598	Moxifloxacin + Prednisolone Eye Drop- Each ml to contain: Moxifloxacin 0.5%, Prednisolone Acetate 1%,	5ml Vial	FIRST
43	142C	Ajanta Pharma Limited	1602	Travoprost Eye Drop- Each Vial to contain: Travoprost 0.004%	2.5ml Vial	FIRST
44	142C	Ajanta Pharma Limited	1607	Latanoprost Eye Drop- Each ml to contain: Latanoprost 50mcg, Aqueous Buffered Vehicle Q.S	2.5ml Vial	FIRST
45	142C	Intas Pharmaceuticals Ltd	1677	Etanercept Inj- Each PFP/PFS to contain: Etanercept 50mg	1 PFS/PFP	FIRST
46	142C	Intas Pharmaceuticals Ltd	1783	Ranibizumab Inj- Each ml to contain: Ranibizumab 10 mg	0.23 ml Vial	FIRST
47	142C	Abbott India Limited	1822	Lactulose Syp- Each 15ml to contain: Lactulose 10gm	200ml Bott	FIRST
48	142C	Panacea Biotec Pharma Limited	1823	Lactulose Syp- Each 15ml to contain: Lactulose 10gm	450ml Bott	FIRST
49	142C	Lark Laboratories (India) Ltd.	1829	Mefenamic Acid Tab/Cap- Each Tab/Cap to contain : Mefenamic Acid 500mg	1 Tab/Cap	FIRST
50	142C	Panacea Biotec Pharma Limited	1836	Haemorrhoidal Cream- Each gm to contain: Euphorbia Prostrata Dry Extract Ethanolic 80% (v/v) ((35-70):1) 10 mg (Containing 0.315 -0.825 mg Total Flavonoids Calculated as Apigenin-7 Glucoside And 1.26-4.40 mg Total Phenolics Calculated as Gallic Acid) Cream Base Q.S.	30gm Tube	FIRST
51	142C	Hab Pharmaceuticals & Research Ltd	1855	Tramadol and Acetaminophen Tab/Cap- Each Film Coated Tab/Cap to contain: Tramadol Hydrochloride IP 18.75mg, Acetaminophen IP 162.5mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
52	142C	Psychotropics India Limited	1856	Tramadol and Paracetamol Tab/Cap- Each Tab/Cap to contain: Tramadol 37.50 mg, Paracetamol 325mg	1 Tab/Cap	FIRST
53	142C	Sanofi India Limited	1866	Analgesic Cream- Each Tube to contain: Methyl Salicylate 30% w/w, Menthol 10 % w/w, Camphor 4 % w/w, Excipients Q.S.	30 gm Tube	FIRST
54	142C	Ajanta Pharma Limited	1912	Besifloxacin Eye Drop- Each ml to contain: Besifloxacin 0.6% (6mg/ml)	5ml Bott	FIRST
55	142C	Cipla Limited	1923	Carboxy Methyl Cellulose Eye Drop- Each ml to contain: Sodium Carboxy Methyl Cellulose 5mg	10ml Vial	FIRST
56	142C	Ajanta Pharma Limited	1925	Travoprost And Timolol Eye Drop- Each Vial to contain: Travoprost 0.004%, Timolol 0.5%	2.5ml Vial	FIRST
57	142C	FDC Limited	1927	Hydroxypropylmethylcellulose Eye Drop- Each Vial to contain: Hydroxypropylmethylcellulose 0.3% 5 to 10ml	1ml	FIRST
58	142C	Indoco Remedies Ltd	1936	Chlorhexidine Soln- Each Bott to contain: Chlorhexidine Gluconate 0.2% Solution	150ml Bott	FIRST
59	142C	Indoco Remedies Ltd	1937	Potassium Nit. & Sod. Monofluoro Phosphate Paste- Each Tube to contain: Potassium Nitrate 5% w/w, Sodium Monofluoro Phosphate 0.7% w/w	100gm Tube	FIRST
60	142C	Tablets (India) Limited	1991	Liver Disorders Syp- Each 15ml to contain: DL-Methionine BP 100mg, Choline Dihydrogen Citrate NFXII 100mg, L-Leucine USP 19mg, L-Isoleucine USP 10mg ,L-Valine USP11mg , Pyridoxine Hcl IP 1.5mg, Nicotinamide IP 22.5mg, Biotin USP 0.1mg , Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 mcg, Inositol BP 50mg	200ml Bott	FIRST
61	142C	Tablets (India) Limited	1992	Liver Disorders Tab/Cap- Each Tab/Cap to contain: DL-Methionine BP 200mg , Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-Isoleucine USP 10mg, L-Valine USP 11mg, Pyridoxine Hydrochloride IP 1.5mg, Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 mcg, Inositol BP 50 mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
62	142C	Cipla Limited	2009	Lansoprazole Tab/Cap- Each Orally Disintegrated Tab/Cap to contain: Lansoprazole 15mg (As Enteric Coated Pellets)	1 Tab/Cap	FIRST
63	142C	Revat Laboratories Pvt. Ltd.	2011	Sucralfate Susp- Each 5 ml to contain: Sucralfate 1 g	100ml Bott.	FIRST
64	142C	Glaxo Smithkline Pharmaceuticals Ltd	2024	Paracetamol Tab/Cap- Each Tab/Cap to contain: Paracetamol 650mg	1 Tab/Cap	FIRST
65	142C	Unimarck Pharma (I) Ltd	2027	Diclofenac IV Inj- Each ml to contain: Diclofenac 75mg IV	1ml Amp	FIRST
66	142C	Signature Phytochemical Industries	2053	Rabeprazole + Domperidone Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Rabeprazole Sodium IP 20 mg (As Enteric Coated Pellets), Domperidone IP 30 mg (As Sustained Release Pelletes)	1 Tab/Cap	FIRST
67	142C	Sun Pharma Laboratories Limited	2054	Mesalazine Tab/Cap- Each Enteric Coated Tab/Cap (As Extended Release) to contain: Mesalamine/ Mesalazine USP 1.2gm.	1 Tab/Cap	FIRST
68	142C	Overseas Healthcare Pvt Ltd	2056	Chlordiazepoxide+ Clidinium Bromide Tab/Cap- Each Tab/Cap to contain : Chlordiazepoxide 5mg, Clidinium Bromide 2.5mg	1 Tab/Cap	FIRST
69	142C	Psychotropics India Limited	2057	Ursodoxycholic Acid Tab/Cap- Each Tab/Cap to contain: Ursodoxycholic Acid 300mg	1 Tab/Cap	FIRST
70	142C	Abbott India Limited	2058	Pancreatin + Activated Dimethicone Tab/Cap- Each Enteric Coated Tab/Cap to contain: Pancreatin 170mg, Activated Dimethicone 80mg	1 Tab/Cap	FIRST
71	142C	Troikaa Pharmaceuticals Limited	2084	Diclofenac Diethyl Amine, Methyl Salicylate, Menthol And Absolute Alcohol Topical Solution - Each pack to contain: Diclofenac Diethyl Amine BP-2.32% w/v Equivalent to Diclofenac Sodium IP 2% w/v, Methyl Salicylate IP 10% w/v, Menthol IP 5.0% w/v Absolute Alcohol IP 10% v/v, Intopical Solution Base (Non Aqueous) QS	30ml Pack	FIRST
72	142C	Ajanta Pharma Limited	2097	Bepotastine Besilate Ophthalmic Solution 1.5% w/v Each ml to contain: Bepotastine Besilate 15 mg, Sterile Aqueous Vehicle QS	5ml Vial	FIRST
73	142C	Ajanta Pharma Limited	2098	Bimatoprost Eye Drop- Each Vial to contain : Bimatoprost 300mcg, Timolol Maleate 6.8mg Equivalent To Timolol 5 mg	3ml Vial	FIRST

M. S. S.
27/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
74	142C	Ajanta Pharma Limited	2099	Bimatoprost Ophthalmic Solution- Each Vial to contain: Bimatoprost 0.01%	3ml Vial	FIRST
75	142C	Tablets (India) Limited	2189	Polyethylene Glycol Sachet: Each Sachet (17.1g) to contain: Polyethylene Glycol 4000 IP 14.6g, Potassium Chloride IP 0.18g, Sodium Chloride IP 0.36g, Sodium Bicarbonate IP 0.42g, Anhydrous Sodium Sulphate BP 1.42g, Activated Dimethicone IP 0.01g	1 Sachet	FIRST
76	142C	Aristo Pharmaceuticals Pvt. Ltd.	2191	Lactobacillus Plantarum Tab/Cap- Each Tab/Cap Contains: Lactobacillus Plantarum LP 299v 10 Billion CFU	1 Tab/Cap	FIRST
77	142C	Pulse Pharmaceutical Pvt Ltd	2197	Paracetamol Tab/Cap- Each Tab/Cap to contain: Paracetamol IP 325mg Instant Release + 675mg Extended Release	1 Tab/Cap	FIRST
78	142C	Bajaj Healthcare Limited	2249	Hyoscine Butylbromide Tab/Cap- Each Tab/ Cap to contain: Hyoscine Butylbromide 10 mg	1 Tab/Cap	FIRST
79	142C	Overseas Healthcare Pvt Ltd	2251	Drotaverine Hcl Tab/Cap- Each Tab/Cap to contain: Drotaverine Hcl 40mg	1 Tab/Cap	FIRST
80	142C	Micron Pharmaceuticals	2252	Antacid Syp/Susp: Each 10ml to contain: Magnesium Hydroxide I.P 185 mg (Added As Paste), Simethicone I.P 50 mg, Sodium Carboxymethylcellulose I.P 100 mg, Dried Aluminium Hydroxide Gel I.P 830 mg (Added As Paste) in a Flavoured Sugar-Free Base	200ml Bott	FIRST
81	142C	Abbott India Limited	2253	Antacid Tab/Cap- Each Uncoated Chewable Tab/Cap to contain: Dried Aluminium Hydroxide Gel I.P 300 mg, Magnesium Aluminium Silicate Hydrate 50 mg, Magnesium Hydroxide I.P 25 mg, Simethicone I.P 25 mg	1 Tab/Cap	FIRST
82	142C	Wallace Pharmaceuticals Pvt. Ltd.	2254	Colistin Sulphate Syp/Susp- Each 5ml to contain -Colistin Sulphate I.P. 25mg	30ml Bott	FIRST
83	142C	Hindustan Laboratories Limited	2256	Dicyclomine Hcl and Activated Dimethicone Syp- Each ml to contain: Dicyclomine Hcl 10 mg, Activated Dimethicone 40mg.	30ml Bott	FIRST
84	142C	Tablets (India) Limited	2258	Amino Acid Granules: Each 10g Sachet to contain: L-Valine USP 1144mg, L-Isoleucine USP 952mg, L-Leucine USP 1904mg	1 SACHET	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
85	142C	Psychotropics India Limited	2260	Diclofenac Sodium & Thiocolchicoside Tab/Cap- Each Tab/ Cap to contain: Diclofenac Sodium 50mg, Thiocolchicoside 4mg	1 Tab/Cap	FIRST
86	142C	Hindustan Laboratories Limited	2263	Paracetamol Drop- Each ml to contain: Paracetamol 150mg	15ml Bott	FIRST
87	142C	G.M.H Laboratories	2264	Paracetamol Syp/Susp- Each 5ml to contain: Paracetamol 250mg	60ml Bott	FIRST
88	142C	Emcure Pharmaceuticals Ltd	2265	Analgesic Cream/Oint- Each Tube to contain: S(+)-Etodolac 5% w/w, Camphor 4% w/w, Menthol 10% w/w, Methyl Salicylate 5% w/w, Linseed Oil 3% w/w	30 gm Tube	FIRST
89	142C	Centaur Pharmaceuticals Pvt. Ltd.	2269	Polymyxin B +Chloramphenicol Eye Drop- Each ml to contain: Polymyxin B 5000 IU, Chloramphenicol 4mg	5ml Vial	FIRST
90	142C	Centaur Pharmaceuticals Pvt. Ltd.	2270	Polymyxin B + Chloramphenicol Eye Oint/Cream- Each gm to contain: Polymyxin B 10000 IU, Chloramphenicol 10mg	5gm Tube	FIRST
91	142C	Glaxo Smithkline Pharmaceuticals Ltd	2272	Polymyxin B +Neomycin + Hydrocortisone Ear Drop- Each ml to contain: Polymyxin B 10000 IU, Neomycin 3400 IU, Hydrocortisone 10mg	5ml Vial	FIRST
92	142C	Ajanta Pharma Limited	2273	Brinzolamide 1% Eye Drop- Each ml to contain: Brinzolamide 1%	5 ml Vial	FIRST
93	142C	Centaur Pharmaceuticals Pvt. Ltd.	2274	Brimonidine Eye Drop- Each ml to contain: Brimonidine 0.1 %	5 ml Vial	FIRST
94	142C	Centaur Pharmaceuticals Pvt. Ltd.	2288	Tobramycin Eye Drop- Each ml to contain: Tobramycin 0.3% w/v	5ml Vial	FIRST
95	142C	FDC Limited	2292	Ofloxacin Eye Drop- Each ml to contain: Ofloxacin 0.3%	5ml Vial	FIRST
96	142C	Unimarck Pharma (I) Ltd	1082b	Tramadol Inj- Each ml to contain: Tramadol Hydrochloride 50 mg	2ml Vial/Amp	FIRST
97	142C	FDC Limited	1218b	Timolol Maleate Eye Drop- Each ml to contain: Timolol Maleate 6.8 Mg. (Eqv. To Timolol 5.0 Mg.)	5 ml. Vial	FIRST
98	142C	Bajaj Healthcare Limited	428a	Acetyl Salicylic Acid Tab/Cap- Each Gastro-Resistant Tab/Cap to contain: Acetyl Salicylic Acid 75 Mg	1 Tab/Cap	FIRST
99	142C	Bajaj Healthcare Limited	428b	Acetyl Salicylic Acid Tab/Cap- Each Enteric Coated Tab/Cap to contain: Acetyl Salicylic Acid 150 Mg	1 Tab/Cap	FIRST
100	142C	USV Private Limited	428c	Acetyl Salicylic Acid Tab/Cap- Each Enteric Coated Tab/Cap to contain: Acetyl Salicylic Acid IP 325 Mg.	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
101	143C	Hindustan Laboratories Limited	33	Bronchodilator Syp- Each 5ml to contain: Theophyllin Ethanoate Of Piperazine 80mg, Eph. Hcl.12mg, Guaiphenesin 50mg, Alcohol 0.55ml, Absolute Alcohol Content 10.44 %.	200ml Bott	FIRST
102	143C	Micron Pharmaceuticals	60	Frusemide Tab/Cap- Each Tab/Cap to contain: Frusemide 40mg	1 Tab/Cap	FIRST
103	143C	Juggat Pharma (Pharma Division Of Jagdale Industries Private Limited)	63	Isoxsuprine Inj- Each ml to contain: Isoxsuprine 5mg	2ml Vial/Amp	FIRST
104	143C	Sai Parenterals Pvt. Ltd.	71	Heparin Sodium Inj- Each ml to contain: Heparin Sod. 5000 IU	5ml Vial/Amp	FIRST
105	143C	FDC Limited	75	Flunarizine Tab/Cap- Each Tab/Cap to contain: Flunarizine 10mg	1 Tab/Cap	FIRST
106	143C	Hab Pharmaceuticals & Research Ltd	97	Fluoxetine Tab/Cap- Each Tab/Cap to contain: Fluoxetine 20mg	1 Tab/Cap	FIRST
107	143C	Revat Laboratories Pvt. Ltd.	98	Phenytoin Sodium Tab/Cap- Each Tab/Cap to contain: Phenytoin Sodium 100mg	1 Tab/Cap	FIRST
108	143C	Micron Pharmaceuticals	103	Trihexyphenidyl Tab/Cap- Each Tab/Cap to contain: Trihexyphenidyl Hydrochloride 2mg	1 Tab/Cap	FIRST
109	143C	Cipla Limited	362	Budesonide Inhaler- Each Metered Dose to contain : Budesonide 100 mcg	Equal to or more than 120 MDI	FIRST
110	143C	Hab Pharmaceuticals & Research Ltd	365	Losartan+Hydrochlorthiazide Tab/Cap- Each Tab/Cap to contain: Losartan Potassium 50 mg, Hydrochlorthiazide 12.5 mg	1 Tab/Cap	FIRST
111	143C	Micron Pharmaceuticals	367	Fenofibrate Tab/Cap- Each Tab/Cap to contain: Fenofibrate (Micronised) 200 mg	1 Tab/Cap	FIRST
112	143C	Midas Care Pharmaceuticals Pvt. Ltd.	421	Ipratropium + Salbutamol Inhaler- Each Metered Dose to contain: Ipratropium I.P.20mcg., Salbutamol I.P.100mcg	Equal to or more than 120 MDI	FIRST
113	143C	Signature Phytochemical Industries	422	Amiodarone Tab/Cap- Each Tab/Cap to contain: Amiodarone Hcl 100mg	1 Tab/Cap	FIRST
114	143C	Modi Mundipharma Private Limited	425	Indapamide SR Tab/Cap- Each SR Tab/Cap to contain : Indapamide 1.5 mg	1 Tab/Cap	FIRST
115	143C	Pulse Pharmaceutical Pvt Ltd	429	Clopidogrel Tab/Cap- Each Tab/Cap to contain: Clopidogrel 75mg	1 Tab/Cap	FIRST

[Handwritten signature]
7/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
116	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	471	Tianeptine Tab/Cap- Each Tab/Cap to contain: Tianeptine Sodium 12.5mg	1 Tab/Cap	FIRST
117	143C	Cipla Limited	481	Ipratropium Resp. Soln- Each ml to contain: Ipratropium Bromide 250 mcg	15ml Bott	FIRST
118	143C	Micron Pharmaceuticals	516	Etophylline & Theophylline Syp- Each 5 ml to contain: Etophylline 46.5mg, Theophylline 14mg	100ml Bott	FIRST
119	143C	Hindustan Laboratories Limited	518	Cough Sedative Syp- Each 5ml to contain: Chlorpheniramine Meleate 2.5mg, Guaiphenesin 100mg, Noscapine 15mg, Sodium Citrate 60 mg.	100ml Bott	FIRST
120	143C	Psychotropics India Limited	521	Tranexamic Acid Tab/Cap- Each Tab/Cap to contain: Tranexamic Acid 500mg	1 Tab/Cap	FIRST
121	143C	Psychotropics India Limited	522	Tranexamic Acid Inj- Each 5ml to contain: Tranexamic Acid 500mg	1 Amp	FIRST
122	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	540	Sulbutiamine Tab/Cap- Each Tab/Cap to contain: Sulbutiamine 200mg	1 Tab/Cap	FIRST
123	143C	Cipla Limited	550	Fluticasone+Salmeterol Rotacap- Each Rotacap to contain: Fluticasone 250 mcg, Salmeterol 50 mcg	1 Rotacap	FIRST
124	143C	Cipla Limited	574	Metoprolol Inj- Each ml to contain: Metoprolol 1mg	5ml Vial/Amp	FIRST
125	143C	Juggat Pharma (Pharma Division Of Jagdale Industries Private Limited)	580	Coagulant Solution- Each ml to contain: Aqueous Solution Of Haemocoagulase Isolated From Bothrops Atrox Or Bothrops Jararaca 0.2CU, Chlorhexadine Gluconate Soln.0.1percent (As Preservative), Water For Injection Q.S.	10ml Bott	FIRST
126	143C	Micron Pharmaceuticals	1032	Etophylline & Theophylline Tab/Cap- Each Tab/Cap to contain: Etophylline 77 mg, Theophylline 23 mg	1 Tab/Cap	FIRST
127	143C	Midas Care Pharmaceuticals Pvt. Ltd.	1041	Salbutamol + Beclomethasone Inhaler- Each Metered Dose to contain: Salbutamol 100 mcg., Beclomethasone Dipropionate 50 mcg.	Equal to or more than 120 MDI	FIRST
128	143C	Hindustan Laboratories Limited	1050	Pediatric Cough Linctus Syp - Each ml to contain : Noscapine 1.83mg, Citric Acid 5.8mg, Sod. Citrate 0.67mg, Amm. Chloride 7mg	50ml Bott	FIRST

List of 517 Drugs in DG-ESIC RC 142C-146C

SI.No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
129	143C	Intas Pharmaceuticals Ltd	1055	Bisoprolol Tab/Cap- Each Tab/Cap to contain: Bisoprolol Fumerate 5 mg	1 Tab/Cap	FIRST
130	143C	Themis Medicare Limited	1063	Trimetazidine Tab/Cap- Each Tab/Cap to contain: Trimetazidine Hcl 20 mg	1 Tab/Cap	FIRST
131	143C	Overseas Healthcare Pvt Ltd	1074	Isoxsuprine Tab/Cap- Each Tab/Cap to contain: Isoxsuprine Hcl 10 mg	1 Tab/Cap	FIRST
132	143C	Juggat Pharma (Pharma Division Of Jagdale Industries Private Limited)	1078	Haemo-Coagulant Inj- Each ml to contain : Aqueous Solution Of Haemocoagulase (One I U/CU/NIH Unit) Isolated From Venom Of Bothrops, Jararaca Or Bothrops Atrox Containing Sodium Chloride 0.9%	1ml Vial/ Amp	FIRST
133	143C	USV Private Limited	1124	Nimodipine Tab/Cap- Each Tab/Cap to contain: Nimodipine 30 mg	1 Tab/Cap	FIRST
134	143C	Hab Pharmaceuticals & Research Ltd	1131	Sodium Valproate Tab/Cap - Each Tab/Cap to contain: Sodium Valproate 200mg.	1 Tab/Cap	FIRST
135	143C	Sun Pharma Laboratories Limited	1132	Levodopa & Carbidopa Tab/Cap- Each Tab/Cap to contain: Levodopa 250 mg, Carbidopa 25 mg	1 Tab/Cap	FIRST
136	143C	Lark Laboratories (India) Ltd.	1348	Valsartan Tab/Cap- Each Tab/Cap to contain: Valsartan 80mg	1 Tab/Cap	FIRST
137	143C	Zydus Healthcare Ltd	1349	Metolazone Tab/Cap- Each Tab/Cap to contain Metolazone 5mg	1 Tab/Cap	FIRST
138	143C	Cipla Limited	1370	Torsemide Tab/Cap- Each Tab/Cap to contain: Torsemide 10mg	1 Tab/Cap	FIRST
139	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	1372	Perindopril + Indapamide Tab/Cap- Each Tab/Cap to contain: Perindopril Erbumine 4mg, Indapamide 1.25mg	1 Tab/Cap	FIRST
140	143C	Hab Pharmaceuticals & Research Ltd	1393	Mefenamic + Tranexamic Acid Tab/Cap- Each Tab/Cap to contain: Mefenamic Acid 250mg, Tranexamic Acid 500mg	1 Tab/Cap	FIRST
141	143C	Pulse Pharmaceutical Pvt Ltd	1420	Telmisartan Tab/Cap- Each Tab/Cap to contain: Telmisartan 40mg	1 Tab/Cap	FIRST
142	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	1421	Perindopril + Amlodipine Tab/Cap- Each Tab/Cap to contain: Perindopril 4mg, Amlodipine 5mg	1 Tab/Cap	FIRST
143	143C	Psychotropics India Limited	1461	Hydroxyzine Hydrochloride Tab/Cap- Each Tab/Cap to contain: Hydroxyzine Hydrochloride 25mg	1 Tab/Cap	FIRST

Handwritten signature and date: 21/11/2019

List of 517 Drugs in DG-ESIC RC 142C-146C

SI.No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
144	143C	Cipla Limited	1522	Inhaler - Each Metered Dose to contain: Ipratropium 20mcg, Levosalbutamol 50mcg	Equal to or more than 120 MDI	First
	143C	Midas Care Pharmaceuticals Pvt. Ltd.				
145	143C	Cipla Limited	1524	Budesonide Respuir- Each 2ml to contain :Budesonide 1mg Steroid Nebulizing Fluid	2ml Amp	FIRST
146	143C	Cipla Limited	1525	Tiotropium Bromide Rotacap- Each Rotacap to contain : Tiotropium Bromide IP/BP Eqv. to Tiotropium Bromide Monohydrate 18mcg.	1 Rotacap	FIRST
147	143C	Macleods Pharmaceuticals Limited	1530	Ivabradine Tab/Cap- Each Tab/Cap to contain: Ivabradine 5mg	1 Tab/Cap	FIRST
148	143C	Psychotropics India Limited	1668	Olmесartan Tab/Cap- Each Tab/Cap to contain : Olmesartan 20mg	1 Tab/Cap	FIRST
149	143C	Sun Pharma Laboratories Limited	1674	Sumatriptan Tab/Cap- Each Tab/Cap to contain: Sumatriptan 50mg	1 Tab/Cap	FIRST
150	143C	Pulse Pharmaceutical Pvt Ltd	1681	Citicoline Tab/Cap- Each Tab/Cap to contain: Citicoline 500 mg	1 Tab/Cap	FIRST
151	143C	Pulse Pharmaceutical Pvt Ltd	1682	Divalproex Sod. Tab/Cap- Each SR/ER/CR Tab/Cap to contain: Divalproex Sod. 250mg	1 Tab/Cap	FIRST
152	143C	Pulse Pharmaceutical Pvt Ltd	1683	Divalproex Sod. Tab/Cap- Each SR/ER/CR Tab/Cap to contain: Divalproex Sod. 500mg	1 Tab/Cap	FIRST
153	143C	Midas Care Pharmaceuticals Pvt. Ltd.	1749	Inhaler- Each Metered Dose to contain: Levosalbutamol Tartrate 50mcg	Equal to or more	FIRST
154	143C	Macleods Pharmaceuticals Limited	1751	Nebivolol Tab/Cap- Each Tab/Cap to contain: Nebivolol 5mg	1 Tab/Cap	FIRST
155	143C	Gennova Biopharmaceuticals Ltd.	1752	Tenecteplase 40mg Inj- Each Vial to contain: Tenecteplase 40mg	1 Vial	FIRST
156	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	1754	Indapamide SR + Amlodipine Tab/Cap- Each Tab/Cap to contain: Tab/Cap Indapamide SR 1.5 mg, Amlodipine Besylate Equivalent To Amlodipine 5 mg	1 Tab/Cap	FIRST
157	143C	Midas Care Pharmaceuticals Pvt. Ltd.	1840	Inhaler- Each Delivered Dose to contain: Salmeterol Xinafoate IP Equivalent to Salmeterol IP 25 µg, Fluticasone Propionate IP 250µg, Excipients & Propellant 1, 1,1,2 Tetrafluoro Ethane HFA 134a	Equal to or more	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
158	143C	Cipla Limited	1843	Autohaler- Each Actuation delivers:Salmeterol..25mcg (As Salmeterol Xinafoate) IP 25 mcg, Fluticasone Propionate.. 250mcg Suspended In Propellant 134a Q.S. (Contains Absolute Alcohol IP 3.07% v/v)	Equal to or more than 120 MDI	FIRST
159	143C	Pulse Pharmaceutical Pvt Ltd	1845	Metoprolol Succinate SR Tab/Cap- Each SR Tab/Cap to contain: Metoprolol Succinate 23.75mg Equivalent To Metoprolol Tartrate 25mg	1 Tab/Cap	FIRST
160	143C	Mesmer Pharmaceuticals	1869	Amisulpride Tab/Cap- Each Tab/Cap to contain: Amisulpride 50mg	1 Tab/Cap	FIRST
161	143C	Mesmer Pharmaceuticals	1870	Quetiapine Tab/Cap- Each Tab/Cap to contain: Quetiapine 25 mg	1 Tab/Cap	FIRST
162	143C	Mesmer Pharmaceuticals	1871	Quetiapine Tab/Cap- Each Tab/Cap to contain: Quetiapine 100 mg	1 Tab/Cap	FIRST
163	143C	Intas Pharmaceuticals Ltd	1873	Paroxetine CR Tab/Cap- Each CR Tab/Cap to contain: Paroxetine 25mg	1 Tab/Cap	FIRST
164	143C	Pulse Pharmaceutical Pvt Ltd	1879	Levetiracetam Tab/Cap- Each Tab/Cap to contain: Levetiracetam 500mg	1 Tab/Cap	FIRST
165	143C	Pulse Pharmaceutical Pvt Ltd	1880	Levetiracetam Tab/Cap- Each Tab/Cap to contain: Levetiracetam 250mg	1 Tab/Cap	FIRST
166	143C	Intas Pharmaceuticals Ltd	1883	Lamotrigine Tab/Cap- Each Tab/Cap to contain: Lamotrigine 100mg	1 Tab/Cap	FIRST
167	143C	Lark Laboratories (India) Ltd.	2014	Montelukast Sodium Tab/Cap- Each Tab/Cap to contain: Montelukast Sodium 10mg	1 Tab/Cap	FIRST
168	143C	Cipla Limited	2015	Beclomethasone Dipropionate IP 200mcg (HFA Technology) Inhaler- Each Metered Dose to contain: Beclomethasone Dipropionate IP 200mcg (HFA Technology)	Equal to or more than 120 MDI	FIRST
169	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	2019	Indapamide (As SR)1.5mg , Amlodipine Besilate Equivalent to Amlodipine 2.5mg, Excepients QS Film Coated Bi-Layered Tab/Cap- Each Film Coated Bi-Layered Tab/Cap Contains: Indapamide (As SR)1.5mg , Amlodipine Besilate Equivalent To Amlodipine 2.5mg, Excepients QS	1 Tab/Cap	FIRST
170	143C	Macleods Pharmaceuticals Limited	2022	Acenocoumarol / Nicoumalone Tab/Cap- Each Tab/Cap to contain: Acenocoumarol / Nicoumalone 2mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
171	143C	Tablets (India) Limited	2060	Ambroxol + Terbutaline Tab/Cap- Each Uncoated Tab/Cap to contain: Ambroxol Hrdrochloride 30 mg, Terbutaline Sulphate Equivalent to Terbutaline 2.5 mg	1 Tab/Cap	FIRST
172	143C	Tablets (India) Limited	2061	Ambroxol + Terbutaline Syp- Each 5 ml to contain: Ambroxol Hrdrochloride IP 30 mg, Terbutaline Sulphate IP Equivalent to Terbutaline 2.50 mg, Guaiphenesin IP 50 mg, Menthol IP 0.5 mg	100ml Bottt	FIRST
173	143C	Midas Pharmaceuticals Ltd.	Care Pvt. 2063	Inhaler- Each Inhaler to contain: Fluticasone Propionate 250mcg, Formoterol Fumarate 6mcg	Equal to or more than 120 MDI	FIRST
174	143C	Zuventus Healthcare Limited	2067	S(-)Metoprolol Tab/Cap- Each Prolonged Release Film Coated Tab/Cap to contain : S(-)Metoprolol Succinate 47.50 mg Eqv. to S(-) Metoprolol Tartrate 50 mg	1 Tab/Cap	FIRST
175	143C	Zuventus Healthcare Limited	2068	S(-)Metoprolol Tab/Cap- Each CR/PR/DR/SR/MR Tab/Cap to contain : S(-)Metoprolol Succinate 23.75 mg Eqv. to S(-) Metoprolol Tartrate 25 mg	1 Tab/Cap	FIRST
176	143C	Bajaj Healthcare Limited	2069	Ticagrelor Tab/Cap- Each Tab/Cap to contain:Ticagrelor 90mg	1 Tab/Cap	FIRST
177	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	2074	Indapamide + Amlodipine Tab/Cap- Each Film Coated Bilayered Tab/Cap to contain Indapamide (As Sustained Release) 1.5mg and Amlodipine Besilate Equivalent to Amlodipine 10mg	1 Tab/Cap	FIRST
178	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	2076	Micronised - Purified Flavonoid Tab/Cap- Each Film Coated Tab/Cap to contain: Micronised - Purified Flavonoid Fraction 1000mg-Composed Of Diosmin 900mg (90%) And Flavonoids Expressed As Hesperidin 100mg (10%)	1 Tab/Cap	FIRST
179	143C	Precise Chemipharma Pvt Ltd	2080	Dabigatran Tab/Cap- Each Tab/Cap to contain: Dabigatran Etxilate 110 mg	1 Tab/Cap	FIRST
180	143C	Wallace Pharmaceuticals Ltd.	Pvt. 2203	Terbutaline + Guiaphenesin + Ambroxol Syp- Each 5 ml to contain: Terbutaline I.P 1.25mg + Guiaphenesin I.P 50mg + Ambroxol I.P 15mg Syrup Base QS	100 ml Bott	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
181	143C	Zenith Drugs Pvt. Ltd.	2204	Dextromethorphan + CPM Syp- Each 5 ml to contain: Dextromethorphan I.P 10mg + Chlorpheniramine Maleate I,P 2mg Syrup Base QS	100ml Bott	FIRST
182	143C	Zuventus Healthcare Limited	2205	Ibutilide- Each ml to contain: Ibutilide Fumarate 0.1mg (Equivalent To Ibutilide Freebase 0.087mg), Water For Injection	10ml	FIRST
183	143C	Medley Pharmaceuticals Ltd	2207	Glyceryl Trinitrate Spray- Each Metered Dose to contain: Glyceryl Trinitrate Spray -0.4 Mg	200 MD	FIRST
184	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	2211	Micronized - Purified Flavonoid Tab/Cap- Each Film Coated Tab/Cap to contain : Micronized - Purified Flavonoid Fraction 500mg Composed Of Diosmin 450mg (90%) And Flavonoids Expressed As Hesperidine 50mg (10%)	1 Tab/Cap	FIRST
185	143C	USV Private Limited	2299	Telmisartan Tab/Cap: Each Tab/Cap to contain: Telmisartan 20mg	1 Tab/Cap	FIRST
186	143C	Precise Chemipharma Pvt Ltd	2302	Dabigatran Etxilate Tab/Cap- Each Tab/Cap to contain: Dabigatran Etxilate 150mg	1 Tab/Cap	FIRST
187	143C	Cipla Limited	2303	Acetyl Salicylic Acid + Atorvastatin Tab/Cap- Each Tab/Cap to contain: Acetyl Salicylic Acid 75mg, Atorvastatin 20mg	1 Tab/Cap	FIRST
188	143C	Modi Mundipharma Private Limited	2306	Diltiazem CR/ SR/ DR/ MR Tab/Cap- Each CR/ SR/ DR/ MR Tab/Cap to contain: Diltiazem 90mg	1 Tab/Cap	FIRST
189	143C	Windlas Biotech Limited	2309	Codein Lint. Syp/Susp- Each 5ml to contain: Chlorpheniramine Maleate 4mg, Codeine Phosphate 10mg	100ml Bott	FIRST
190	143C	Pulse Pharmaceutical Pvt Ltd	2312	Gabapentin + Nortriptyline Tab/Cap- Each Tab/Cap to contain: Gabapentin 100mg, Nortriptyline 10mg	1 Tab/Cap	FIRST
191	143C	Cipla Limited	2317	Pregabalin Tab/Cap- Each PLAIN/SR/CR/DR/ER/MR Tab/Cap to contain: Pregabalin 75mg	1 Tab/Cap	FIRST
192	143C	Midas Care Pharmaceuticals Pvt. Ltd.	1040b	Beclomethasone Inhaler- Each Metered Dose to contain: Beclomethasone Dipropionate 100mcg.	Equal to or more than 120 MDI	FIRST
193	143C	Cipla Limited	1043a	Salbutamol Rotacap- Each Rotacap to contain : Salbutamol 200mcg	1 Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
194	143C	Psychotropics India Limited	1056a	Metoprolol Tab/Cap- Each Tab/Cap to contain : Metoprolol Tartrate 50 mg	1 Tab/Cap	FIRST
195	143C	Wallace Pharmaceuticals Pvt. Ltd.	1060a	Iso-Sorbide Mononitrate Tab/Cap- Each Tab/Cap to contain: Iso-Sorbide-5-Mononitrate 20 mg	1 Tab/Cap	FIRST
196	143C	Hindustan Laboratories Limited	1067b	Prazosin SR Tab/Cap- Each SR Tab/Cap to contain: Prazosin Hcl 2.5 mg	1 Tab/Cap	FIRST
197	143C	Hindustan Laboratories Limited	1067c	Prazosin SR Tab/Cap- Each SR Tab/Cap to contain: Prazosin Hcl 5mg	1 Tab/Cap	FIRST
198	143C	Cipla Limited	1068b	Ramipril Tab/ Cap- Each Tab/ Cap to contain: Ramipril 2.5mg	1 Tab/Cap	FIRST
199	143C	Cipla Limited	1068c	Ramipril Tab/Cap- Each Tab/Cap to contain: Ramipril 5mg	1 Tab/Cap	FIRST
200	143C	Intas Pharmaceuticals Ltd	1115b	Phenobarbitone Tab/Cap- Each Tab/Cap to contain: Phenobarbitone-30mg	1 Tab/Cap	FIRST
201	143C	Sun Pharma Laboratories Limited	1127a	Carbamazepin CR Tab/Cap- Each CR Tab/Cap to contain: Carbamazepin 200mg	1 Tab/Cap	FIRST
202	143C	Cipla Limited	1370b	Torsemide Tab/Cap- Each Tab/Cap to contain: Torsemide 20mg	1 Tab/Cap	FIRST
203	143C	Psychotropics India Limited	1430b	Mirtazapine Tab/Cap- Each Tab/Cap to contain: Mirtazapine 15mg	1 Tab/Cap	FIRST
204	143C	Intas Pharmaceuticals Ltd	324a	Clobazam Tab/Cap- Each Tab/Cap to contain: Clobazam 5 mg	1 Tab/Cap	FIRST
205	143C	Intas Pharmaceuticals Ltd	324b	Clobazam Tab/Cap- Each Tab/Cap to contain: Clobazam I.P.10 mg	1 Tab/Cap	FIRST
206	143C	Cipla Limited	32b	Salbutamol Resp. Soln- Each ml to contain: Salbutamol Sulphate Eqv. to Salbutamol 5 mg. In Normal Saline Soln.	15 ml Bott	FIRST
207	143C	Themis Medicare Limited	336b	Carvedilol Tab/Cap- Each Tab/Cap to contain: Carvedilol 6.25mg	1 Tab/Cap	FIRST
208	143C	Bharat Serums And Vaccines Limited	366a	Enoxaprin Inj- Each PFS to contain Enoxaprin Sodium 20 mg / 0.2 ml.	1 PFS	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
209	143C	Virchow Biotech Pvt. Ltd	366c	Enoxaparin 60 mg/0.6ml Inj- Each PFS to contain: Enoxaparin 60 mg/0.6ml	1 PFS	FIRST
210	143C	Midas Care Pharmaceuticals Pvt. Ltd.	420a	Fluticasone + Salmeterol Inhaler- Each Metered Dose to contain: Salmeterol 25mcg, Fluticasone 50mcg	Equal to or more than 120 MDI	FIRST
211	143C	Macleods Pharmaceuticals Limited	423a	Nicorandil Tab/Cap- Each Tab/Cap to contain: Nicorandil 5mg	1 Tab/Cap	FIRST
212	143C	Pulse Pharmaceutical Pvt Ltd	433b	Sodium Valproate + Valproic Acid CR Tab/Cap- Each CR Tab/Cap to contain: (Sodium Valproate + Valproic Acid) Eqv. to Sodium Valproate 500mg.	1 Tab/Cap	FIRST
213	143C	Intas Pharmaceuticals Ltd	44b	Propranolol Tab/Cap- Each Tab/Cap. to contain: Propranolol 40mg	1 Tab/Cap	FIRST
214	143C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	470a	Perindopril Tab/Cap- Each Tab/Cap to contain: Perindopril 2mg	1 Tab/Cap	FIRST
215	143C	Zim Laboratories Limited	470c	Perindopril Tab/Cap- Each Tab/Cap to contain: Perindopril Erbumine 8mg	1 Tab/Cap	FIRST
216	143C	Mesmer Pharmaceuticals	473A	Resperidone Tab/Cap- Each Tab/Cap to contain: Resperidone 1mg	1 Tab/Cap	FIRST
217	143C	Hab Pharmaceuticals & Research Ltd	474b	Olanzapine Tab/Cap- Each Tab/Cap to contain: Olanzapine 5mg	1 Tab/Cap	FIRST
218	143C	Micron Pharmaceuticals	475b	Haloperidol Tab/Cap- Each Tab/Cap to contain: Haloperidol 5mg	1 Tab/Cap	FIRST
219	143C	Mesmer Pharmaceuticals	477A	Amitriptyline Tab/Cap- Each Tab/Cap to contain: Amitriptyline 10mg	1 Tab/Cap	FIRST
220	143C	Mesmer Pharmaceuticals	477B	Amitriptyline Tab/Cap- Each Tab/Cap to contain: Amitriptyline 25mg	1 Tab/Cap	FIRST
221	143C	Zydus Healthcare Ltd	486a	Paroxetine Tab/Cap- Each Tab/Cap to contain: Paroxetine 10mg	1 Tab/Cap	FIRST
222	143C	Zydus Healthcare Ltd	486b	Paroxetine Tab/Cap- Each Tab/Cap to contain: Paroxetine 20mg	1 Tab/Cap	FIRST

Handwritten signature and date: 2/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
223	143C	Pulse Pharmaceutical Pvt Ltd	525a	Metoprolol ER Tab/Cap- Each ER Tab/Cap to contain: Metoprolol Succinate 47.5mg Equivalent to Metoprolol Tartrate 50mg.	1 Tab/Cap	FIRST
224	143C	Signature Phytochemical Industries	527a	Gabapentin Tab/Cap- Each Tab/Cap to contain: Gabapentin 300mg	1 Tab/Cap	FIRST
225	143C	Mesmer Pharmaceuticals	555A	Clozapine Tab/Cap- Each Tab/Cap to contain: Clozapine 25mg	1 Tab/Cap	FIRST
226	143C	Psychotropics India Limited	555b	Clozapine Tab/Cap- Each Tab/Cap to contain: Clozapine 100mg	1 Tab/Cap	FIRST
227	143C	Hab Pharmaceuticals & Research Ltd	556a	Escitalopram Tab/Cap- Each Tab/Cap to contain: Escitalopram 10 mg	1 Tab/Cap	FIRST
228	143C	Mesmer Pharmaceuticals	556B	Escitalopram Tab/Cap- Each Tab/Cap to contain: Escitalopram 20 mg	1 Tab/Cap	FIRST
229	143C	Windlas Biotech Limited	68a	Ethamsylate Tab/Cap- Each Tab/Cap to contain Ethamsylate 250 mg	1 Tab/Cap	FIRST
230	143C	Bharat Serums And Vaccines Limited	74a	Streptokinase Inj- Each Vial to contain: Streptokinase I.P 7.5 Lac IU	1 Vial	FIRST
231	144C	Micron Pharmaceuticals	287	Hydroxy Urea Tab/Cap- Each Tab/Cap to contain: Hydroxy Urea 500 mg	1 Tab/Cap	FIRST
232	144C	Bajaj Healthcare Limited	406	Azathioprine Tab/Cap- Each Tab/Cap to contain: Azathioprine 50 mg	1 Tab/Cap	FIRST
233	144C	Intas Pharmaceuticals Ltd	490	Mycophenolate Mofetil Tab/Cap- Each Tab/Cap to contain: Mycophenolate Mofetil 500mg	1 Tab/Cap	FIRST
234	144C	Cosmas Reasearch Lab Ltd	1404	Docetaxel Inj- Each Vial to contain: Docetaxel 80mg	1 Vial	FIRST
235	144C	Biocon Biologics Limited	1448	Nimotuzumab Inj- Each Vial to contain: Nimotuzumab 50mg	10 ml Vial	FIRST
236	144C	Intas Pharmaceuticals Ltd	1466	Each PFS to contain: Peg-Filgrastim 6mg	1 PFS	FIRST
237	144C	Dr. Reddy'S Laboratories Limited	1477	Pemetrexed Disod. Inj- Each Vial to contain: Pemetrexed Disod. 500mg	1 Vial	FIRST
238	144C	Sun Pharma Laboratories Limited	1643	Sevelamer Tab/Cap- Each Tab to contain: Sevelamer 400mg	1 Tab/Cap	FIRST
239	144C	Intas Pharmaceuticals Ltd	1647	Bevacizumab Inj- Each Vial to contain: Inj Bevacizumab 100mg	1 Vial	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
240	144C	Intas Pharmaceuticals Ltd	1648	Trastuzumab Inj- Each Vial to contain: Inj Trastuzumab 440mg	1 Vial	FIRST
241	144C	Wallace Pharmaceuticals Pvt. Ltd.	1708	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.03%	10gm Tube	FIRST
242	144C	Ajanta Pharma Limited	1709	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.1% 5gm to 10gm	1 gm	FIRST
243	144C	Virchow Biotech Pvt. Ltd	1731	Rasburicase Inj- Each Vial to contain: Rasburicase 1.5 mg	1ml Vial	FIRST
244	144C	Intas Pharmaceuticals Ltd	1736	Bicalutamide Tab/Cap- Each Tab/Cap to contain: Bicalutamide 50mg	1 Tab/Cap	FIRST
245	144C	Sun Pharma Laboratories Limited	1738	Sevelamer Hcl Tab/Cap- Each Tab/Cap to contain: Sevelamer Hcl 800mg	1 Tab/Cap	FIRST
246	144C	Concord Biotech Limited	1804	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 1mg	1 Tab/Cap	FIRST
247	144C	Concord Biotech Limited	1805	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 2mg	1 Tab/Cap	FIRST
248	144C	Cosmas Research Lab Ltd	1809	Bortezomib Inj- Each Vial to contain: Bortezomib 3.5 mg	1 Vial	FIRST
249	144C	Bharat Serums And Vaccines Limited	1814	Immunoglobulin- Each Inj to contain: Rho (D) Immune Globulin (Human) 1500 IU(300mcg)	1 inj	FIRST
250	144C	Paviour Pharmaceuticals Pvt. Ltd.	1819	Immunoglobulin- Each 1 ml Solution to contain: Active Substance(S) Human Plasma Proteins 50 mg, IgM 6 mg (12%) , IgA 6 mg (12%) IgG 38 mg (76%)	10ml Vial	FIRST
251	144C	Panacea Biotec Pharma Limited	1968	Valganciclovir Tab/Cap- Each Tab/Cap to contain: Valganciclovir 450mg	1 Tab/Cap	FIRST
252	144C	Concord Biotech Limited	1969	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 180mg	1 Tab/Cap	FIRST
253	144C	Concord Biotech Limited	1970	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 360mg	1 Tab/Cap	FIRST
		Intas Pharmaceuticals Ltd				
254	144C	Panacea Biotec Pharma Limited	1971	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 540mg	1 Tab/Cap	FIRST

MS-24
7/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
255	144C	Bharat Serums And Vaccines Limited	1972	Leuprolide Inj- Each PFS/Vial to contain: Leuprolide Acetate Depot 3.75mg	1 PFS/Vial	FIRST
256	144C	Cosmas Reasearch Lab Ltd	1984	Paclitaxel Inj- Each Vial to contain: Paclitaxel 260mg	1 Vial	FIRST
257	144C	Concord Biotech Limited	1988	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 0.5mg	1 Tab/Cap	FIRST
258	144C	Cipla Limited	2120	Tofacitinib Tab/Cap- Each Film Coated Tab/Cap to contain : Tofacitinib Citrate Equivalent to Tofacitinib 5mg	1 Tab/Cap	FIRST
259	144C	Fresenius Kabi India Pvt Ltd	2146	Paracetamol IV Inj- Each 50ml to contain Paracetamol IV 500mg	50ml	FIRST
260	144C	Panacea Biotec Pharma Limited	2159	Azacitidine Inj- Each Vial to contain: Azacitidine 100 mg	1 Vial	FIRST
261	144C	Intas Pharmaceuticals Ltd	2170	Transtuzumab Inj- Each Vial to contain: Transtuzumab 150mg	1 Vial	FIRST
262	144C	Troikaa Pharmaceuticals Limited	2183	Heparin Topical Solution- Each ml to contain: Heparin Sodium IP 1000 IU, Absolute Alcohol IP 10% v/v	5ml	FIRST
263	144C	Bharat Serums And Vaccines Limited	2186	Snake Anti Venin (Polyvalent) IP 10ml (Enzyme Refined Equine Globulins)- Each 1ml Neutralises: 0.60mg Of Cobra Venom (Naja Naja), 0.45mg Of Common Krait Venom(Bungarus Caeruleus), 0.60mg Of Ruseells Viper Venom (Vipera Russell), 0.45mg Of Saw Scaled Viper Venom (Echis Carinatus)	10ml	FIRST
264	144C	Panacea Biotec Pharma Limited	2225	Paclitaxel (Protein Bound Particales)- Each Inj to contain: Paclitaxel (Protein Bound Particales) For Injectable Suspension 100 Mg And This Is An Albumin-Bound Form Of Paclitaxel And This Is Presented As 100 Mg Of Paclitaxel In A Single Use 50 ml USP Type 1 Molded Glass Vial Individually Packaged In a Carton	1 inj	FIRST
265	144C	Cosmas Reasearch Lab Ltd	2320	Cytarabine Inj- Each ml to contain: Cytarabine 1 gm	1Vial/Amp	FIRST

Handwritten signature and date: 21/11/20

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
266	144C	Cosmas Reasearch Lab Ltd	2321	Daunorubicin Inj- Each Vial/Amp to contain: Daunorubicin-20 Mg	1Vial/Amp	FIRST
267	144C	Cosmas Reasearch Lab Ltd	2323	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 20mg	1Vial/Amp	FIRST
268	144C	Cosmas Reasearch Lab Ltd	2324	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 120mg	1Vial/Amp	FIRST
269	144C	Intas Pharmaceuticals Ltd	2329	Denosumab Inj- Each PFS to contain: Denosumab 60mg	1 PFS	FIRST
270	144C	Bharat Serums And Vaccines Limited	2334	Anti Rabies Serum Equine Inj- Each ml to contain: Equine Antirabies Immunoglobulin 300 IU	5ml Vial	FIRST
271	144C	Cipla Limited	2343	Remdesivir Inj- Each Vial/Amp to contain: Remdesivir 100mg	1 Vial/Amp	FIRST
272	144C	Bharat Serums And Vaccines Limited	1339a	Human Tetanus Specific Immunoglobulin- Each Vial to contain: Human Tetanus Specific Immunoglobulin 250 Units.	1 Vial	FIRST
273	144C	Bharat Serums And Vaccines Limited	1339b	Human Tetanus Specific Immunoglobulin- Each Vial to contain: Human Tetanus Specific Immunoglobulin 500 Units.	1 Vial	FIRST
274	144C	Intas Pharmaceuticals Ltd	1454b	Capecitabine Tab/Cap- Each Tab/Cap to contain: Capecitabine 500mg	1 Tab/Cap	FIRST
275	144C	Bajaj Healthcare Limited	1476b	Deferasirox Tab/Cap- Each Tab/Cap to contain Deferasirox 400mg	1 Tab/Cap	FIRST
276	144C	Intas Pharmaceuticals Ltd	1650a	Filgrastim Inj- Each PFS/Vial to contain: Filgrastim 150 mcg	1 PFS/ Vial	FIRST
277	144C	Cosmas Reasearch Lab Ltd	459b	Gemcitabine Inj- Each Vial to contain: Gemcitabine 1gm	1 Vial	FIRST
278	144C	Cosmas Reasearch Lab Ltd	487a	Paclitaxel Inj- Each Vial to contain: Paditaxel 100mg	1 Vial	FIRST
279	144C	Trolkaa Pharmaceuticals Limited	578b	Alendronate Tab/Cap- Each Tab/Cap to contain: Alendronate 70mg	1 Tab/Cap	FIRST
280	145C	Psychotropics India Limited	133	Dexamethasone Inj- Each ml to contain: Dexamethasone Sodium Phosphate 4 mg.	1 Vial	FIRST

Handwritten signature and date: 21/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
281	145C	Macleods Pharmaceuticals Limited	135	Thyroxine Sodium Tab/Cap- Each Tab/Cap to contain: Thyroxine Sodium 100 mcg	1 Tab/Cap	FIRST
282	145C	Macleods Pharmaceuticals Limited	136	Carbimazole Tab/Cap- Each Tab/Cap to contain: Carbimazole 5 mg.	1 Tab/Cap	FIRST
283	145C	Lupin Limited	168	Cephalexin Syp- Each 5ml to contain: Cephalexin 125mg	30ml Bott	FIRST
284	145C	Lark Laboratories (India) Ltd.	183	Amoxy & Clavulanic Acid Dry Syp- Each 5ml to contain: Amoxycillin 200 mg, Clavulanic Acid 28.5 mg	30ml Bott	FIRST
285	145C	Lupin Limited	191	Pyrazinamide Kid PLAIN/DISPERSIBLE Tab/Cap- Each Kid PLAIN/DISPERSIBLE Tab/Cap to contain: Pyrazinamide 300mg	1 Tab/Cap	FIRST
286	145C	Lark Laboratories (India) Ltd.	199	Quinine Tab/Cap- Each Tab/Cap to contain: Quinine Sulphate 300mg.	1 Tab/Cap	FIRST
287	145C	Glaxo Smithkline Pharmaceuticals Ltd	201	Diethyl Carbamazine Tab/Cap- Each Tab/Cap to contain: Diethyl Carbamazine Citrate 100mg.	1 Tab/Cap	FIRST
288	145C	Themis Medicare Limited	258	Atracurium Inj- Each ml to contain: Atracurium Besylate 10mg.	2.5ml Vial/Amp	FIRST
289	145C	Albert David Limited	279	Sodium Chloride Inj (For IV Infusion)- Each Bott to contain: Containing: Sodium Chloride 0.9% w/v	500ml Bott	FIRST
290	145C	Albert David Limited	280	Sodium Chloride & Dextrose Inj(For I.V.Infusion)- Each Bott to contain: Dextrose Anhydrous 5% w/v, Sodium Chloride 0.9% w/v	500ml Bott	FIRST
291	145C	Aqua Vitoe Laboratories	332	Vancomycin Inj- Each Vial to contain: Vancomycin Hcl. Eqv. to Vancomycin 500mg.	1 Vial	FIRST
292	145C	Macleods Pharmaceuticals Limited	343	Thyroxine Sodium Tab/Cap- Each Tab/Cap to contain: Thyroxine Sodium IP 50mcg.	1 Tab/Cap	FIRST
293	145C	Lark Laboratories (India) Ltd.	379	Norfloxacin Syp- Each 30ml to contain: Norfloxacin 400mg.	30ml Bott	FIRST
294	145C	Micron Pharmaceuticals	382	Ethionamide Tab/Cap- Each Tab/Cap to contain: Ethionamide 250mg.	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
295	145C	Lupin Limited	383	Cycloserine Tab/Cap- Each Tab/Cap to contain: Cycloserine 250mg.	1 Tab/Cap	FIRST
296	145C	Aqua Vitoe Laboratories	467	Methylprednisolone Sod. Succinate Inj- Each Vial/Amp to contain: Methylprednisolone Sod. Succinate 40 mg	1ml Vial/Amp	FIRST
297	145C	Lark Laboratories (India) Ltd.	505	Cefuroxime Dry Syp- Each 5 ml to contain: Cefuroxime 125mg.	30ml Bott	FIRST
298	145C	Hab Pharmaceuticals & Research Ltd	568	Cabergoline Tab/Cap- Each Tab/Cap to contain: Cabergoline 0.5mg.	1 Tab/Cap	FIRST
299	145C	Biocon Biologics Limited	1172	Human Insulin Mixed (50% + 50%)- Each Vial to contain: Human Insulin 50% Soluble +50% NPH 40 Units / ml	10ml Vial	FIRST
300	145C	Bal Pharma Limited	1174	Gliclazide Tab/Cap- Each Tab/Cap to contain: Gliclazide 80mg.	1 Tab/Cap	FIRST
301	145C	Albert David Limited	1319	Dextrose With Nad Soln- Each 100ml to contain: Dextrose Anhydrous 5gm, Sodium Chloride 0.45 gm.	500ml Bott	FIRST
302	145C	Albert David Limited	1320	Maintenance Solution For Paediatric Use- Each 100 ml to contain (in mmol/ L) Sodium 23.0, Chloride 20.0, Potassium 20.0, Acetate 23.0, Magnesium 1.50, Phosphate 1.50.	500 ml Bott	FIRST
303	145C	Sai Parenterals Pvt. Ltd.	1357	Methylprednisolone Sod. Succinate Inj- Each Vial to contain: Methyl Prednisolone Sod. Succinate 500mg.	1 Vial	FIRST
304	145C	Overseas Healthcare Pvt Ltd	1379	Azithromycin Syp- Each 5ml to contain: Azithromycin 100mg	15ml Bott	FIRST
305	145C	Lark Laboratories (India) Ltd.	1381	Cefixime Dry Syp- Each 5ml to contain: Cefixime 50mg	30ml Bott	FIRST
306	145C	Precise Chemipharma Pvt Ltd	1462	Itraconazole Tab/Cap- Each Tab/Cap to contain: Itraconazole 100mg	1 Tab/Cap	FIRST
307	145C	Gufic Biosciences Limited	1480	Clarithromycin Inj- Each Vial to contain: Clarithromycin 500mg	1 Vial	FIRST
308	145C	Biocon Biologics Limited	1486	Insulin Glargine Inj- Each Vial to contain: Insulin Glargine 100 Units / ml	3 ml Vial	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
309	145C	MSD Pharmaceuticals Private Ltd	1490	Sitagliptin Tab/Cap- Each Tab/Cap to contain: Sitagliptin 100mg	1 Tab/Cap	FIRST
310	145C	Aqua Vitoe Laboratories	1564	Artisunate Inj- Each Vial to contain: Artisunate 60 mg	1 Vial	FIRST
311	145C	Rusan Pharma Ltd	1585	Noradrenaline Inj- Each 2ml to contain: Noradrenaline 4 mg.	2ml Amp	FIRST
312	145C	Macleods Pharmaceuticals Limited	1688	Thyroxine Sodium Tab/Cap- Each Tab/Cap to contain:Thyroxine Sodium 25mcg	1 Tab/Cap	FIRST
313	145C	Bajaj Healthcare Limited	1690	Vildagliptin Tab/Cap- Each Tab/Cap to contain: Vildagliptin 50mg	1 Tab/Cap	FIRST
314	145C	Micron Pharmaceuticals	1693	Clarithromycin Tab/Cap- Each Tab/Cap to contain: Clarithromycin 500mg	1 Tab/Cap	FIRST
315	145C	Gufic Biosciences Limited	1694	Colistimethate Sodium Inj- Each Vial to contain: Colistimethate Sodium BP 10,00,000 I.U.	1 Vial	FIRST
316	145C	Gufic Biosciences Limited	1697	Caspofungin Acetate Inj- Each Vial to contain: Caspofungin Acetate 50mg	1 Vial	FIRST
317	145C	Hab Pharmaceuticals & Research Ltd	1698	Terbinafine Hydrochloride Tab/Cap- Each Tab/Cap to contain:Terbinafine Hydrochloride 250mg	1 Tab/Cap	FIRST
318	145C	Fresenius Kabi India Pvt Ltd	1726	Ringer Lactate Inj-Each to contain: Ringer Lactate 500ml Self Collapsible IV Fluid PVC Bag/ Self Collapsible container (FFS Technology)	500ml Bag	FIRST
319	145C	Albert David Limited	1727	DNS Inj- Each to contain:DNS 500ml Self Collapsible IV Fluid Bag / Self Collapsible container (FFS Technology)	500ml bag	FIRST
320	145C	Bajaj Healthcare Limited	1768	Vildagliptin 50 Mg + Metformin Hcl 500 Mg Tab/Cap- Each Tab/Cap to contain: Vildagliptin 50 mg, Metformin Hydrochloride 500 mg.	1 Tab/Cap	FIRST
321	145C	Gufic Biosciences Limited	1777	Amphotericin B Inj- Each Vial to contain: Amphotericin B 50 mg	1 Vial	FIRST

Handwritten signature and date: 7/11/14

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
322	145C	Albert David Limited	1796	Dextrose 5% Inj (IV Fluids)- Each to contain: Dextrose 5% Self Collapsible I.V. Fluid Bag/ Self Collapsible container (FFS Technology)	500ml Bag	FIRST
323	145C	Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited)	1897	Gliclazide & Metformin ER Tab/Cap- Each Uncoated Bi-Layered Scored Tab/Cap to contain: Gliclazide IP (ER) 60 Mg, Metformin Hydrochloride IP (ER) 500mg.	1 Tab/Cap	FIRST
324	145C	Biocon Biologics Limited	1899	Insulin Glargine Inj- Each ml to contain: 100 Units Insulin Glargine	3ml Cartridge	FIRST
325	145C	Overseas Healthcare Pvt Ltd	1903	Nitrofurantoin SR Tab/Cap- Each SR Tab/Cap to contain: Nitrofurantoin 100mg	1 Tab/Cap	FIRST
326	145C	Lupin Limited	1905	Rifaximin Tab/Cap- Each Tab/Cap to contain: Rifaximin 200mg	1 Tab/Cap	FIRST
327	145C	Cipla Limited	1907	Voriconazole Tab/Cap- Each Tab/Cap To Contain: Voriconazole 200mg	1 Tab/Cap	FIRST
328	145C	Bharat Serums And Vaccines Limited	1908	Liposomal Lyophilized -B Inj- Each Vial to contain : Liposomal Amphotericin - B P 50mg (Lyophilized)	1 Vial	FIRST
329	145C	Hab Pharmaceuticals & Research Ltd	1909	Anti-Malarial Kit- Each Combikit to contain: (A) 2 Tab/Cap Sulphadoxine 750mg & Pyrimethamine 37.5mg (B) 3 Tab/Cap Artesunate 200mg	1 Kit	FIRST
330	145C	Fresenius Kabi India Pvt Ltd	2035	Fluconazole IV Inj- Each 100ml to contain : Fluconazole 200mg	100ml Bott	FIRST
331	145C	Albert David Limited	2052	Dextrose Anhydrous 25% w/v Each 100ml to contain: Dextrose Anhydrous 25% w/v	100ml Bott	FIRST
332	145C	Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)	2090	Saroglitazar Tab/Cap- Each Uncoated Tab/Cap to contain: Saroglitazar 4 mg	1 Tab/Cap	FIRST
333	145C	Pulse Pharmaceutical Pvt Ltd	2092	Metformin + Glimepiride Tab/Cap- Each Uncoated Tab/Cap to contain: Metformin Hydrochloride IP 500 mg (As a Sustained Release, Glimepiride IP 2 mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
334	145C	Pulse Pharmaceutical Pvt Ltd	2093	Metformin + Glimepiride Tab/Cap- Each Uncoated Tab/Cap to contain: Metformin Hydrochloride IP 500 mg (As a Sustained Release) Glimepiride IP 1 mg	1 Tab/Cap	FIRST
335	145C	Brawn Laboratories Ltd	2095	Clarithromycin+Tinidazole+Lansoprazole Kit- Each Kit to contain: Tab/Cap Clarithromycin 250mg, Tab/Cap Tinidazole 500mg, Tab/Cap Lansoprazole 30mg	1 Kit	FIRST
336	145C	Zuventus Healthcare Limited	2096	Cefditoren Tab/Cap- Each Film Coated Tablet/Cap to contain: Cefditoren Pivoxil Equivalent to Cefditoren 200 mg Excipients Q.S.	1 Tab/Cap	FIRST
337	145C	Bajaj Healthcare Limited	2237	Vildagliptin +Metformin Tab/Cap- Each Tab/Cap to contain: Vildagliptin 50mg+Metformin Hydrochloride 1000mg	1 Tab/Cap	FIRST
338	145C	Galpha Laboratories Limited	2239	Amoxicillin+Clavulanic Acid Susp- Each 5ml Of Reconstituted Suspension to contains: Amoxicillin Trihydrate IP Equivalent to Amoxicillin 125mg, Potassium Clavulanate Diluted IP Equivalent to Clavulanic Acid 31.25mg	30ml Bott	FIRST
339	145C	Cipla Limited	2240	Fosfomycin Sachet- Each Sachet Contains: Fosfomycin Trometamol BP Equivalent To Fosfomycin 3.0 Gm Excipients Q.S (Net Wt: 8gm)	8gm Sachet	FIRST
340	145C	Brawn Laboratories Ltd	2243	Azithromycin Inj- Each Vial to contain: Azithromycin 500mg	1 Vial	FIRST
341	145C	Tablets (India) Limited	2245	Amino Acid Inj- Each ml to contain: L-Arginine Hydrochloride USP 8.0mg, L-Histidine Hydrochloride H2O BP 4.0mg, L-Isoleucine USP 5.5mg, L-Leucine USP 12.3mg, L-Lysine Hydrochloride USP 22.3mg, L-Methionine USP 7.1mg, L-Phenylalanine USP 8.7mg, L-Threonine USP 5.4mg, L-Tryptophan USP 1.8mg, L-Valine USP 6.1mg, Glycine IP 10.0mg, Sorbitol IP 50.0mg, Water for Injections IP Q.S	20ml Vial/Amp	FIRST
342	145C	Lupin Limited	2350	Rifaximin Tab/Cap: Each Tab/Cap to contain: Rifaximin 550mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
343	145C	Macleods Pharmaceuticals Limited	2355	Meropenem+Sulbactam Inj- Each Vial/Amp to contain: Meropenem 1gm, Sulbactam 500mg	1Vial/Amp	FIRST
344	145C	Psychotropics Limited India	2358	Cefoperazone Sodium+Sulbactam Inj- Each Vial/Amp to contain: Cefoperazone Sodium 1gm, Sulbactam 500mg	1 Vial/Amp	FIRST
345	145C	Lupin Limited	2359	Cefuroxime Sodium Inj- Each Vial/Amp to contain: Cefuroxime Sodium 1.5g	1 Vial/Amp	FIRST
346	145C	Albert David Limited	2360	Amino Acid Injection- Each ml to contain: L-Isoleucine USP 5.6mg, L-Leucine USP 12.5mg, L-Lysine Hydrochloride USP 11.0mg, L-Methionine USP 3.5mg, L-Phenylalanine USP 9.35mg, L-Threonine USP 6.5mg, L-Tryptophan USP 1.3mg, L-Valine USP 4.5mg, L-Alanine USP 6.2mg, L-Arginine Hydrochloride USP 9.55mg, L-Aspartic Acid BP 3.8mg, L-Cysteine Hydrochloride USP 1.45mg, L-Glutamic Acid BP 6.5mg, L-Histidine Hydrochloride H2O BP 8.11mg, L-Proline USP 3.3mg, L-Serine USP 2.2mg, L-Tyrosine USP 0.35mg, Glycine IP 10.7mg, Xylitol USP 50.0mg, Water for Injections IP Q.S *Concentration of Amino Acids 106.41mg (8EAA + 10NEAA with Xylitol)	500ml Bott	FIRST
347	145C	Fresenius Kabi India Pvt Ltd	2362	Hydroxyethyl Starch Soln- Each Bott to contain: Hydroxyethyl Starch 6% W/V, Sodium Chloride 0.9%, Water For Injection IP Q.S.	500ml Bott	FIRST
348	145C	Rusan Pharma Ltd	2365	Bupivacaine Hydrochloride + Anhydrous Dextrose Inj.- Each ml to contain: Bupivacaine Hydrochloride 5mg, Anhydrous Dextrose 80mg	4 ml Amp	FIRST
349	145C	Themis Limited Medicare	2368	Dexmedetomidine Inj- Each ml to contain: Dexmedetomidine 100 mcg	1 ml Amp	FIRST
350	145C	Themis Limited Medicare	2371	Lignocaine Hcl & Adrenaline Inj- Each Vial to contain: Lignocaine 2% With Adrenaline 1:200,000 Solution	30ml Vial	FIRST
351	145C	Sun Pharma Laboratories Limited	2386	Pyridostigmine Tab/Cap- Each Tab/Cap to contain: Pyridostigmine 60 mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
352	145C	Psychotropics India Limited	2388	Prednisolone Tab/Cap- Each Tab/Cap to contain: Prednisolone 20mg	1 Tab/Cap	FIRST
353	145C	Signature Phytochemical Industries	2389	Deflazacort Tab/Cap- Each Tab/Cap to contain: Deflazacort 6mg	1 Tab/Cap	FIRST
354	145C	Precise Chemipharma Pvt Ltd	2395	Silodosin Tab/Cap- Each Tab/Cap to contain: Silodosin 8mg	1 Tab/Cap	FIRST
355	145C	Bharat Serums And Vaccines Limited	2399	Human Menopausal Gonadotropin Inj- Each Vial/Amp to contain: Human Menopausal Gonadotropin 75 IU	1 Vial/Amp	FIRST
356	145C	Themis Medicare Limited	1118a	Midazolam Inj- Each ml to contain: Midazolam 5mg.	1ml Vial/Amp	FIRST
357	145C	Rusan Pharma Ltd	1118b	Midazolam Inj- Each ml to contain: Midazolam 1mg.	5ml Vial/Amp	FIRST
358	145C	Abbott India Limited	1148B	Dydrogesterone Tab/Cap- Each Tab/Cap to contain : Dydrogesterone I.P./U.S.P.10 mg.	1 Tab/Cap	FIRST
359	145C	Gufic Biosciences Limited	1157a	Human Chorionic Gonadotropin Inj- Each ml to contain: Human Chorionic Gonadotropin 2000 IU	1ml Amp	FIRST
360	145C	Gufic Biosciences Limited	1157c	Human Chorionic Gonadotrophin Inj- Each ml to contain : Human Chorionic Gonadotrophin 10000 IU	1ml Amp	FIRST
361	145C	Micron Pharmaceuticals	1210b	Levamisole Tab/Cap- Each Tab/Cap to contain: Levamisole 150 mg.	1 Tab/Cap	FIRST
362	145C	Psychotropics India Limited	1285c	Ketamine Inj- Each ml to contain: Ketamine Hcl 50mg.	10ml Vial	FIRST
363	145C	Micron Pharmaceuticals	132b	Danazol Tab/Cap- Each Tab/Cap to contain: Danazol 200mg.	1 Tab/Cap	FIRST
364	145C	Micron Pharmaceuticals	1353b	Cefaclor Tab/Cap- Each Tab/Cap to contain: Cefaclor 250mg.	1 Tab/Cap	FIRST
365	145C	Micron Pharmaceuticals	1485a	Entecavir Tab/Cap- Each Tab/Cap to contain: Entecavir 0.5mg	1 Tab/Cap	FIRST
366	145C	Cipla Limited	1485b	Entecavir Tab/Cap- Each Tab/Cap to contain Entecavir 1mg	1 Tab/Cap	FIRST
367	145C	Biocon Biologics Limited	1486b	Insulin Glargine Inj- Each Vial to contain: Insulin Glargine 100 Units/ml	10 ml	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
368	145C	FDC Limited	1552b	Cefuroxime + Clavulanate Potassium Tab/Cap- Each Tab/Cap to contain: Cefuroxime Axetil 250mg, Clavulanate Potassium 62.50mg	1 Tab/Cap	FIRST
369	145C	Macleods Pharmaceuticals Limited	1552c	Cefuroxime + Clavulanic Potassium Tab/Cap- Each Tab/Cap to contain: Cefuroxime Axetil 500mg, Clavulanic Potassium 125mg	1 Tab/Cap	FIRST
370	145C	Macleods Pharmaceuticals Limited	1557a	Ceftriaxone+Tazobactam Inj- Each Vial to contain: Ceftriaxone 250mg, Tazobactam Sodium 31.25mg	1 Vial	FIRST
371	145C	Galpha Laboratories Limited	1557c	Ceftriaxone+Tazobactam Inj- Each Vial to contain: Ceftriaxone 1gm, Tazobactam Sodium 125mg	1 Vial	FIRST
372	145C	Aqua Vitoe Laboratories	1558a	Cefuroxime Inj- Each Vial to contain: Cefuroxime 750mg	1 Vial	FIRST
373	145C	Lupin Limited	184a	Ethambutol Tab/Cap- Each Tab/Cap to contain: Ethambutol 200mg.	1 Tab/Cap	FIRST
374	145C	Themis Limited Medicare	249a	Bupivacaine Inj- Each Vial to contain: Bupivacaine Hcl 0.25%	20ml Vial	FIRST
375	145C	Themis Limited Medicare	249c	Bupivacaine Heavy Inj- Each Amp to contain: Bupivacaine Hcl 0.5%	4ml Amp	FIRST
376	145C	Albert David Limited	278a	Dextrose Inj(For I.V Infusion)- Each Bott to contain: Dextrose Anhydrous 5% w/v	500ml Bott	FIRST
377	145C	Albert David Limited	278b	Dextrose Inj(For I.V Infusion)- Each Bott to contain: Dextrose Anhydrous 10% w/v	500ml Bott	FIRST
378	145C	Micron Pharmaceuticals	319b	Ribavirin Tab/Cap- Each Tab/Cap to contain: Ribavirin 200mg.	1 Tab/Cap	FIRST
379	145C	Lark Laboratories (India) Ltd.	335a	Acyclovir Tab/Cap - Each Tab/Cap to contain: Acyclovir 200mg.	1 Tab/Cap	FIRST
380	145C	Lark Laboratories (India) Ltd.	335b	Acyclovir Tab/Cap- Each Tab/Cap to contain: Acyclovir 400mg.	1 Tab/Cap	FIRST
381	145C	Gufic Limited Biosciences	413b	Teicoplanin Inj- Each Vial to contain: Teicoplanin 400mg.	1 Vial	FIRST
382	145C	USV Private Limited	434a	Pioglitazone Tab/Cap- Each Tab/Cap to contain: Pioglitazone 15mg.	1 Tab/Cap	FIRST

Handwritten signature and date: 7/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
383	145C	USV Private Limited	434b	Pioglitazone Tab/Cap- Each Tab/Cap to contain: Pioglitazone 30mg.	1 Tab/Cap	FIRST
384	145C	Mesmer Pharmaceuticals	466b	Methylprednisolone Tab/Cap- Each Tab/Cap to contain: Methylprednisolone 16 mg	1 Tab/Cap	FIRST
385	146C	Micron Pharmaceuticals	119	Povidone Vaginal Tab/Cap- Each Tab/Cap to contain: Povidone Iodine 200mg.	1 Tab/Cap	FIRST
386	146C	Themis Medicare Limited	124	Cyproheptadine Tab/Cap- Each Tab/Cap to contain: Cyproheptadine 4mg.	1 Tab/Cap	FIRST
387	146C	Zenith Drugs Pvt. Ltd.	221	Miconazole Cream- Each Tube to contain: Miconazole Nitrate 2 %	15 gm Tube	FIRST
388	146C	Micron Pharmaceuticals	224	Benzyl Benzoate Application- Each Bott to contain: Benzyl Benzoate 25%	1 Ltr Bott	FIRST
389	146C	Micron Pharmaceuticals	229	Flucinolone Oint- Each tube to contain: Flucinolone Acetonide 0.025% W/W	15 gm Tube	FIRST
390	146C	Goldwin Medicare Ltd.	240	White Soft Paraffin- Each Pack to contain: White Soft Paraffin	500 gm Pack	FIRST
391	146C	Jyoti Capsulations Pvt. Ltd	260	Alfa Calcidol Tab/Cap- Each Tab/Cap to contain: Alfa Calcidol 0.25mcg.	1 Tab/Cap	FIRST
392	146C	Procter & Gamble Health Limited (Formerly Known As Merck Limited)	265	Vitamin Inj- Each 2ml to contain: Thiamine 10mg. Riboflavin 4 mg. Nicotinamide 40 mg. Cyanocobalamine 8 mcg. Pyridoxine 4mg. D-Panthenol 6mg. Benzyl Alcohol 0.9%	2 ml Amp	FIRST
393	146C	Zenith Drugs Pvt. Ltd.	272	Potassium Chloride Liquid- Each 15ml to contain: Potassium Chloride 1.5gm	200 ml Bott	FIRST
394	146C	Franco-Indian Remedies Pvt Ltd	394	Clotrimazole Lotion- Each ml to contain: Clotrimazole 10mg	15 ml Bott	FIRST
395	146C	Franco-Indian Pharmaceuticals Pvt Ltd	395	Clotri, Beclometh Oint- Each tube to contain: Clotrimazole 10mg, Beclomethasone Dipropionate 0.25mg	10 gm Tube	FIRST
396	146C	Zenith Drugs Pvt. Ltd.	448	Permethrin 5% Cream- Each Tube to contain: Permethrin 5%	30 gm Tube	FIRST
397	146C	Galpha Laboratories Limited	451	Calcium Syp- Each 5ml to contain: Vit. D3-200 IU, Vit. B12-2.5 mcg., Calcium -82 mg.	200 ml Bott	FIRST
398	146C	Intas Pharmaceuticals Ltd	464	Erythropoietin Inj- Each Pack to contain: Recombinant Human Erythropoietin 10000 Units	1 pack	FIRST
399	146C	Signature Phytochemical Industries	480	Mupirocin Oint- Each Tube to contain: Mupirocin 2%	5 gm Tube	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
400	146C	Hindustan Laboratories Limited	496	Vit. B Complex Symp- Each 5ml to contain: Vit. A 2500 IU, Cholecalciferol 200 IU, Thiamine 2mg, Riboflavin 1mg, Pyridoxine 1mg, Nicotinamide 15mg, Ascorbic Acid 50 mg, D -Panthenol 2.5mg, Cyanocobalamin 1mcg, Citrus Bioflavonoid Compound 5mg.	200 ml Bott	FIRST
401	146C	Pfizer Limited	501	Vit. B Complex + Vit.C Symp- Each 5ml to contain: Thiamine 2 mg, Riboflavin 2.54 mg, Pyridoxine 2 mg, Niacinamide 20 mg, D-Panthenol 6 mg, Ascorbic Acid 75 mg	120 ml Bott	FIRST
402	146C	Hab Pharmaceuticals & Research Ltd	510	Metronidazole + Povidone Iodine Oint- Each Tube to contain: Metronidazole 1%, Povidone Iodine 5%	15 gm Tube	FIRST
403	146C	Overseas Healthcare Pvt Ltd	553	Flavoxate Tab/Cap- Each Tab/Cap to contain: Flavoxate Hydrochloride 200 mg.	1 Tab/Cap	FIRST
404	146C	USV Private Limited	595	Calcuim (Absorbable) Tab/Cap- Each Tab/Cap to contain: Elemental Calcium 150mg. (In the form Of Calcium Hydroxide and Calcium Oxide and Pretreated with Heated Algae)	1 Tab/Cap	FIRST
405	146C	Hab Pharmaceuticals & Research Ltd	1135	Isoxsuprine SR Tab/Cap- Each SR Tab/Cap to contain: Isoxsuprine Hcl 40 mg.	1 Tab/Cap	FIRST
406	146C	Bharat Serums And Vaccines Limited	1137	Carboprost Inj- Each ml to contain: Carboprost 0.25mg.	1 ml Amp	FIRST
407	146C	Signature Phytochemical Industries	1145	Fexofenadine Tab/Cap- Each Tab/Cap to contain: Fexofenadine 120mg.	1 Tab/Cap	FIRST
408	146C	East India Pharmaceutical Works Limited	1241	Salicylic Acid Oint- Each Tube to contain: Salicylic Acid 6% w/w, Benzoic Acid 12% w/w, Hydrocortisone Acetate 0.5% w/w	15 gm Tube	FIRST
409	146C	Hindustan Laboratories Limited	1242	Urea+ Lactic Acid Cream- Each Jar to contain: Urea 12% w/w, Lactic Acid 6% w/w, Glycine 3% w/w, Ammonium Chloride 0.5% w/w, Sod. Chloride 0.5% w/w, Potassium Chloride 0.5% w/w, Calcium Lactate 0.5% w/w, Magnesium Chloride 0.3% w/w, Sod. Dihydrogen Phosphate 0.5 % w/w 50 to 75gm	1gm	FIRST
410	146C	Lark Laboratories (India) Ltd.	1252	Clobetasol Oint- Each Tube to contain: Clobetasol Propionate 0.05%	10 gm Tube	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
411	146C	Hab Pharmaceuticals & Research Ltd	1257	Tretinoin Cream- Each Tube to contain: Tretinoin (Trans Retinoic Acid) 0.05%	20 gm Tube	FIRST
412	146C	Goldwin Medicare Ltd.	1271	Glycerine- Each Bott to contain: Glycerine 500 gm	500 gm Bott	FIRST
413	146C	Zim Laboratories Limited	1308	Iron And Vitamin Tab/Cap- Each Tab/Cap to contain: Ferrous Fumarate 350 mg, Vit. C 150 mg, Vit B12 - 15 mcg, Folic Acid 1.5 mg.	1 Tab/Cap	FIRST
414	146C	East India Pharmaceutical Works Limited	1312	Iron + Vitamin Syp- Each 5ml to contain : Colloidal Iron Eqv to Elemental Iron 250 mg, Folic Acid 500 mcg, Vitamin B12- 5mcg	200 ml Bott	FIRST
415	146C	Hindustan Laboratories Limited	1313	Iron And Folic Acid Drop- Each ml to contain: Colloidal Iron Eqv. to Elemental Iron 25 mg, Lysine Hydrochloride 200 mg, Vit. B12- 5 mcg, Folic Acid 200 mcg	15 ml Vial	FIRST
416	146C	Micron Pharmaceuticals	1386	Sodium Fusidate Oint- Each 1gm to contain: Sodium Fusidate 20mg	5 gm Tube	FIRST
417	146C	Hindustan Laboratories Limited	1388	Mecobalamine + Lipoic Acid Tab/Cap - Each Tab/Cap to contain: Mecobalamine 0.5mg, Alpha Lipoic Acid 100mg	1 Tab/Cap	FIRST
418	146C	Micron Pharmaceuticals	1391	Acyclovir Cream- Each Tube to contain: Acyclovir 5% w/w	5 gm Tube	FIRST
419	146C	Hab Pharmaceuticals & Research Ltd	1397	Clotrimazole Gel- Each Tube to contain: Clotrimazole 2% w/w	30 gm Tube	FIRST
420	146C	Ajanta Pharma Limited	1403	Anti Oxidant Tab/Cap- Each Tab/Cap to contain: Carotenoids And Micronutrients From Carrots 100mg (Eqv. To 100mcg Of Carotenoids Calculated As Beta Carotene) Beta Carotene 7.5% Dispersion 40mg (Natural Carotenoids), Vit. C 150mg, Vit. E Acetate 25mg, Selenium Dioxide 75mcg (Eqv To 45.9mcg Of Selenium), Zinc Sulphate 70mg (Eqv To 15.9mg Zinc).	1 Tab/Cap	FIRST
421	146C	Overseas Healthcare Pvt Ltd	1424	Tamsulosine Tab/Cap- Each Tab/Cap to contain: Tamsulosine 0.4mg (As Modified Release)	1 Tab/Cap	FIRST
422	146C	Overseas Healthcare Pvt Ltd	1425	Tamsulosin + Dutasteride Tab/Cap- Each Tab/ Cap to contain: Tamsulosin 0.4mg (As Modified Release) + Dutasteride 0.5mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
423	146C	Hindustan Laboratories Limited	1436	Multivitamin Drop- Each ml to contain: Vitamin A Concentrate (As Palmitate) Oily Form:3000 IU, Cholecalciferol 400 IU, Ascorbic Acid 40mg, Thiamine Mononitrate:2mg, Riboflavin Sodium Phosphate Eqv To Riboflavin: 1mg, Nicotinamide 10.5mg, Pyridoxine Hydrochloride:1mg, D.Panthenol 3mg, Tocopheryl Acetate 5.25IU, Flavoured Aqueous Base(Appropriate Overages Of Vitamins Added To Compensate For Loss On Storage)	10 ml Phial	FIRST
424	146C	Sai Parenterals Pvt. Ltd.	1438	Iron Inj- Each ml to contain: Iron Sucrose 20mg	5 ml Amp	FIRST
425	146C	Themis Medicare Limited	1440	Feracrylum Gel - Each tube to contain: Feracrylum 1% w/w	15 gm Tube	FIRST
426	146C	Glaxo Smithkline Pharmaceuticals Ltd	1441	Zinc Bacitracin + Polymyxin B Sulphate + Neomycin Sulphate Powder- Each Phial to contain: Zinc Bacitracin 400U, Polymyxin B Sulphate 5000U, Neomycin Sulphate 3400U	10 gm Phial	FIRST
427	146C	Hab Pharmaceuticals & Research Ltd	1577	Dutasteride Tab/Cap- Each Tab/Cap to contain: Dutasteride 0.5 mg	1 Tab/Cap	FIRST
428	146C	Lark Laboratories (India) Ltd.	1579	Mix Lactobacilli Vaginal Tab/Cap- Each Vaginal Tab/Cap to contain: Mix Lactobacilli (L.Brevis,L.Salivarius And L.Planarum) 10E9	1 Tab/Cap	FIRST
429	146C	Biodeal Pharmaceuticals Pvt. Ltd.	1612	Sertaconazole Cream- Each Tube to contain: Sertaconazole Nitrate 2% Cream	10 gm Tube	FIRST
430	146C	Unimarck Pharma (I) Ltd	1617	Clobetasol+Salicylic Acid Oint- Each Tube to contain: Clobetasol Propionate 0.05% w/w, Salicylic Acid 6% w/w.	10 gm Tube	FIRST
431	146C	Unimarck Pharma (I) Ltd	1633	Methylcobalamin Inj- Each ml to contain: Methylcobalamin 500 mcg	1 ml Amp	FIRST
432	146C	Psychotropics India Limited	1685	Dexchlorpheniramine SR Tab/Cap- Each SR Tab/Cap to contain: Dexchlorpheniramine 6mg	1 Tab/Cap	FIRST
433	146C	Aristo Pharmaceuticals Pvt. Ltd.	1686	Fexofenadine Tab/Cap- Each Tab/Cap to contain: Fexofenadine 180mg	1 Tab/Cap	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
434	146C	Psychotropics India Limited	1687	Loratidine Tab/Cap- Each Tab/Cap to contain: Loratidine 10mg	1 Tab/Cap	FIRST
435	146C	Hab Pharmaceuticals & Research Ltd	1703	Terbinafine Ointment/ Cream - Each tube to contain: Terbinafine Hcl. 1%	10 gm Tube	FIRST
436	146C	Hab Pharmaceuticals & Research Ltd	1704	Acne Gel- Each Tube to contain: Adapalene 0.1% IP/BP/USP etc w/w (As Microspheres) Clindamycin Phosphate IP/BP/USP etc Equivalent To Clindamycin 1.0% w/w in an Aqueous Gel Base -O.S.	15 gm Tube	FIRST
437	146C	Vivimed Labs Ltd.	1711	Sertaconazole Nitrate Lotion- Each Phial to contain: Sertaconazole Nitrate 2% w/vPropylene Glycol Base Qs	15 ml phial	FIRST
438	146C	Micron Pharmaceuticals	1712	Benzoyl Peroxide Gel- Each pack to contain: Benzoyl Peroxide 2.5%	20 gm Pack	FIRST
439	146C	Unimarck Pharma (I) Ltd	1718	Adapalene Gel- Each Tube to contain: Adapalene 0.1percent	15 gm Tube	FIRST
440	146C	Midas Pharmaceuticals Care Pvt. Ltd.	1723	Isopropyl Alcohol Spray- Each pack to contain: Isopropyl Alcohol-55% w/w, Purified Water-10% w/w, Propellant Hydrocarbon-35% w/w	200 gm Pack	FIRST
441	146C	Vivimed Labs Ltd.	1793	Calcium Tab/Cap- Each Tab/Cap to contain: Calcium Citrate Malate Equivalent to Elemental Calcium 250mg, Calcitriol 0.25 mcg,Vitamin K2-7 50mcg.	1 Tab/Cap	FIRST
442	146C	Zim Laboratories Limited	1887	Sildenafil Tab/Cap - Each Tab/Cap to contain: Sildenafil 50mg	1 Tab/Cap	FIRST
443	146C	Psychotropics India Limited	1940	Ketoconazole Lotion- Each Bott to contain: Ketoconazole 2% w/v	50 ml Bott	FIRST
444	146C	Micron Pharmaceuticals	1942	Clotrimazole Dusting Powder- Each pack to contain: Clotrimazole Dusting Powder 1 %w/w	75 gm Pack	FIRST
445	146C	Biodeal Pharmaceuticals Pvt. Ltd.	1944	Luliconazole Cream- Each Tube to contain: Luliconazole 1%	10 gm Tube	FIRST
446	146C	Cheryl Laboratories Private Limited	1946	Minoxidil Lotion- Each Bott to contain: Minoxidil 2%	60 ml Bott	FIRST
447	146C	Cheryl Laboratories Private Limited	1947	Minoxidil Lotion- Each Bott to contain: Minoxidil 5%	60 ml Bott	FIRST

af
21/11/24

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
448	146C	Goldwin Medicare Ltd.	1956	Paraffin Gauze- Each Piece to contain: Paraffin Guaze 10cm X 10cm	10 Pieces	FIRST
449	146C	Hindustan Laboratories Limited	1958	Multi Vitamin Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Ferrous Fumarate I.P Eqv. to Elemental Iron 30 mg, Folic Acid I.P 250 mcg, Zinc Sulphate Monohydrate B.P. Eqv. to Zinc 20 mg , Thiamine Mononitrate (Vit. B1) I.P. 1.2 mg, Riboflavin (Vit. B2) I.P. 1.2 mg, Niacinamide I.P.10 mg, Pyridoxine Hydrochloride (Vit. B6) I.P. 1 mg , Cyanocobalamin (Vit. B12) I.P. 2.5 mcg Ascorbic Acid Coated (Vit. C) I.P. 40 mcg	1 Tab/Cap	FIRST
450	146C	Tablets (India) Limited	1959	Multi Vitamin With Amino Acid Tab/Cap- Each Tab/Cap to contain: L-Arginine Hydrochloride USP 13.28mg, L-Histidine Hydrochloride H2O BP 3.71mg, L-Isoleucine USP 5.9mg, L-Leucine USP 18.3mg, L-Lysine Hydrochoride USP 25.0mg, DL-Methionine BP 18.4mg, L-Phenylalanine USP 5mg, L-Threonine USP 4.2mg, L-Tryptophan USP 5mg, L-Valine USP 6.7mg, 5-Hydroxy Anthranilic Acid HCL 0.2mg, Cholecalciferol IP 200 IU, Nicotinamide IP 25mg, Pyridoxine Hydrochloride IP 1.5mg, Methylcobalamin 500mcg, Biotin USP 30mcg, Folic Acid IP 0.75mg, Copper Sulphate BP 4mg, Ferrous Sulphate IP 20.5mg, Magnesium Sulphate IP 7.43mg, Manganese Sulphate BP 1.4mg, Potassium Iodide IP 0.1mg, Sodium Selenite BP 10.0mcg, Zinc Sulphate IP 15mg, Chromium Polynicotinate 200mcg	1 Tab/Cap	FIRST
451	146C	Tablets (India) Limited	1962	Ferrous Ascorbate With Aminoacids & Zinc Tab/Cap- Each film coated Tab/Cap to contain:Ferrous Ascorbate equivalent to elemental Iron 100mg, Methylcobalamin 1000mcg, Folic Acid 1.5mg, L - Histidine Hcl H2O 4mg, L - Lysine Hcl 25mg, Glycine 10mg, Pyridoxine Hcl 1.5mg, Zinc Sulphate 50mg	1 Tab/Cap	FIRST
452	146C	Themis Medicare Limited	2103	Feracrylum With Centbucridine Hydrochloride Gel- Each Tube to contain: Feracrylum 3% w/w, Centbucridine 0.5% w/w (As Centbucridine Hcl) Water Miscible Base Q.S.	20 gm Tube	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

Sl. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
453	146C	Overseas Healthcare Pvt Ltd	2112	Each Film Coated Tab/Cap to contain: Calcium Aspartate 500mg, Calcium Orotate 500mg, Calcitriol 0.25mcg, Zinc(As Zinc Sulphate Monohydrate IP) 7.5mg, Magnesium Hydroxide IP 50mg, Hydroxocobalamin IP 100mcg, Folic Acid IP 1.5mg, Excipients q.S.	1 Tab/Cap	FIRST
454	146C	Indoco Remedies Ltd	2113	Each Tab/Cap to contain: Atorvastatin Calcium IP Equivalent to Atorvastatin 10mg, Methylcobalamin 500 mcg, Folic Acid IP 5mg , Pyridoxine Hcl IP 10mg	1 Tab/Cap	FIRST
455	146C	Tablets (India) Limited	2115	Hematinic With Amino Acids,Vitamins And Zinc Syrup: Each 10 ml to contain : Ferrous Glycine Sulphate 216.5 mg, L-Histidine Hydrochloride H2o BP 4 mg, L- Lysine Hydrochloride USP 25 mg , Pyridoxine Hydrochloride IP 1.5 mg, Nicotinamide IP 25 mg, Folic Acid IP 0.5 mg , Cyanocobalamin IP 2.5 mcg, Zinc Ascorbate 50mg	200 ml Bott	FIRST
456	146C	Tablets (India) Limited	2116	Ipriflavone,Calcium,Vit D3 Tab/Cap: Each Film Coated Tab/Cap to contain: Calcium Carbonate 1.0 gm From Organic Source(Oyster Shell) Equivalent to Elemental Calcium 400 mg, Ipriflavone 300 mg, Cholecalciferol IP 200 IU	1 Tab/Cap	FIRST
457	146C	Virchow Biotech Pvt. Ltd	2246	Silver Nitrate Gel- Each Tube to contain: Silver Nitrate Gel 0.2% w/w	15 gm Tube	FIRST
458	146C	Virchow Biotech Pvt. Ltd	2247	Papain – Urea Debriding Ointment	15 gm Tube	FIRST
459	146C	Pulse Pharmaceutical Pvt Ltd	2402	Methylcobalamin Tab/Cap: Each Tab/Cap to contain: Methylcobalamin 1500 mcg	1 Tab/Cap	FIRST
460	146C	Vivimed Labs Ltd.	2403	Sertaconazole Nitrate Powder- Each Bott to contain : Sertaconazole Nitrate 2% w/w ,Talc IP Base Q.S.	100 gm Bott	FIRST
461	146C	Signature Phytochemical Industries	2406	Fusidic Acid Oint/Cream: Each Tube to contain : Fusidic Acid 2%	15 gm Tube	FIRST
462	146C	Micron Pharmaceuticals	2408	Fluocinolone + Neomycin + Miconazole Oint/Cream- Each Tube to contain: Fluocinolone Acetonide 0.025%, Neomycin Sulphate 0.5%, Miconazole Nitrate 2.0%	15 gm Tube	FIRST

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
463	146C	Signature Phytochemical Industries	2409	Ketoconazole Oint/Cream- Each Tube to contain: Ketoconazole 2%	15 gm Tube	FIRST
464	146C	Cipla Limited	2417	Montelukast & Levocetirizine Kid Tab/Cap- Each Tab/Cap to contain: Montelukast 4mg & Levocetirizine 2.5mg	1 Tab/Cap	FIRST
465	146C	Bharat Serums And Vaccines Limited	1157b	Human Chorionic Gonadotropin Inj- Each Vial/Amp to contain : Human Chorionic Gonadotropin 5000 IU	1 ml Vial/Amp	FIRST
466	146C	Jyoti Capsulations Pvt. Ltd	1302c	Vitamin E Tab/Cap- Each Tab/Capule to contain: Vit. E (Alpha Tocopherol Acetate) 400mg	1 Tab/Cap	FIRST
467	146C	Bal Pharma Limited	1426b	Ebastine Tab/Cap- Each Tab/Cap to contain: Ebastine 20mg	1 Tab/Cap	FIRST
468	146C	Intas Pharmaceuticals Ltd	408a	Erythropoietin Inj- Each PFS to contain: Recombinant Human Erythropoietin 2000 Units	1 PFS	FIRST
469	146C	Wockhardt Ltd.	408d	Erythropoietin Inj- Each PFS to contain: Recombinant Human Erythropoietin 3000 Units	1 PFS	FIRST
470	146C	Goldwin Medicare Ltd.	546b	Paper Adhesive Tape- Paper Adhesive Tape Hypoallergenic With Acrylate Adhesive 5cmx9.14m	1 Roll	FIRST
471	146C	Hab Pharmaceuticals & Research Ltd	558b	Finasteride Tab/Cap- Each Tab/Cap to contain: Finasteride 5mg	1 Tab/Cap	FIRST
472	142C	Galpha Laboratories Limited	1828	ONDANSETRON SYP - Each 5ml to contain: Ondansetron 2mg	30ml bottle	First
473	142C	Ajanta Pharma Limited	1862	FEBUXOSTAT TAB - Each tab to contain : Febuxostat 40mg	1 Tab/Cap	First
474	143C	Overseas Healthcare Pvt Ltd	1373	ATENOLOL + AMLODEPINE Tab/Cap - Each Tab/Cap to contain: Atenolol 50mg, Amlodipine 5mg	1 Tab/Cap	First
475	143C	Maan Pharmaceuticals	1459	COUGH SYP - Each 5ml to contain: Ambroxol Hydrochloride 30mg Terbutaline Sulphate eqv to Terbutaline 1.25mg, Guaiphenesin 50mg Menthol 0.5mg	100ml bottle	First
476	143C	Baxter (India) Pvt Ltd	1670	Haemostatic- Each 5ml to contain: Haemostatic Matrix With Prefilled Gelatin Granules In Syringes	5ml	First
477	143C	Baxter (India) Pvt Ltd	2077	Hemostat- Each PFS to contain: Hemostatic Matrix With Thrombin In Prefilled Syringe 10ml	1 PFS	First

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
478	143C	Roche Products (India) Pvt Ltd	2209	Emicizumab Inj- Each Vial Contains : Emicizumab 30mg For Sub Cut Injection (R-DNA Origin)	1 Vial	First
479	143C	Roche Products (India) Pvt Ltd	2210	Emicizumab Inj- Each Vial Contains : Emicizumab 60mg For Sub Cut Injection (R-DNA Origin)	1 Vial	First
480	144C	Astra Zeneca Pharma India Ltd	526	Goserelin Inj- Each PFS to contain: Goserelin 3.6mg	1 PFS	First
481	144C	Johnson & Johnson Private Limited	600	Infliximab Inj- Each Vial to contain: Infliximab 100mg	1 Vial	First
482	144C	Baxter (India) Pvt Ltd	1456	CAPD Bag- Each bag to contain: CAPD Bag 7.5% Of Lcodextrin With Asymmetrical Y Connector	2 Ltr Bag	First
483	144C	Roche Products (India) Pvt Ltd	2117	Alectinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Alectinib 150 mg Equivalent To Alectinib Hydrochloride 161.3 mg	1 Tab/Cap	First
484	144C	Roche Products (India) Pvt Ltd	2118	Atezolizumab inj- Each 20ml Vial to contain: Atezolizumab Injection 1200mg	1 Vial	First
485	144C	Johnson & Johnson Private Limited	2128	Ibrutinib Tab/Cap- Each Cap/Tab to contain : Ibrutinib 140mg.	1 Tab/Cap	First
486	144C	Roche Products (India) Pvt Ltd	2133	Obinutuzumab Inj- Each Vial to contains: Obinutuzumab 1000 mg	1 Vial	First
487	144C	Roche Products (India) Pvt Ltd	2136	Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml)	1 Vial	First
488	144C	Dr. Reddy's Laboratories Limited	2137	Triptorelin Pamoate Inj- Each Single Dose Vial Contains:(Sterile Lypholized) Triptorelin Pamoate Equivalent to Triptorelin 11.25mg Pamorelin La 11.25 Inj.	1 Vial	First
489	144C	Pfizer Products India Private Limited	2138	Crizotinib Tab/Cap- Each Hard Geletin Tab/Cap to contain : Crizotinib 250mg	1 Tab/Cap	First
490	144C	Dr. Reddy's Laboratories Limited	2140	Panitumumab Inj- Each Single Use Vial Of 5 ml to contain: Panitumumab 100 mg (20mg/ml)	1 Vial	First
491	144C	Eli Lilly & Company (India) Pvt. Ltd.	2179	Ramucirumab Concentrate For Solution For Infusion- Each Vial to contain: Ramucirumab 500mg / 50ml Vial Component :Ramucirumab 500mg,L-Histidine 32.5mg, L-Histidine Monohydrochloride 61.0mg, Glycine 499mg, Sodium Chloride 219mg, Polysorbate 80 5.0mg, Water For Injection Q.S	50ml Vial	First

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
492	144C	Johnson & Johnson Private Limited	2181	Golimumab (r-DNA Origin)- Each Single Use Pre-Filled Syringe to contain: Golimumab 50mg/0.5ml Component [Amount Per Dose (Mg)]: Golimumab (CNTO 148) - 50mg, Sorbitol -20.5mg, L-Histidine -0.44mg, Polysorbate 80 - 0.075mg, Water For Injection - 0.5mg	1 PFS	First
493	144C	Johnson & Johnson Private Limited	2218	Daratumumab Inj- Each 5ml to contain: Daratumumab Concentrate For Solution For Infusion 100mg	1 Vial	First
494	144C	Johnson & Johnson Private Limited	2219	Daratumumab Inj- Each 20ml to contain: Daratumumab Concentrate For Solution For Infusion 400mg	1 Vial	First
495	144C	MSD Pharmaceuticals Private Limited	2220	Pembrolizumab Inj- Each ml to contain: Pembrolizumab 25mg	4ml Vial	First
496		MSD Pharmaceuticals Private Limited	2227	Human Papillomavirus- Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 16 , 18) Vaccine, Recombinant	0.5ml	First
497	144C	Glaxo SmithKline Pharmaceuticals Ltd	2319	Mepolizumab Inj- Each Vial to contain: Mepolizumab 100mg	1 Vial	First
498	144C	Pfizer Limited	2336	Pneumococcal Vaccine- Each 0.5ml to contain: Pneumococcal Polysaccharide Conjugate Vaccine (13 Valent)	1 PFS	First
499	145C	Novo Nordisk India Private Limited	1487	Insulin Aspart Inj- Each Vial to contain: Insulin Aspart (r-DNA Origin)	10ml Vial	First
500	145C	Novo Nordisk India Private Limited	1593	Insulin Detemir Inj- Each Inj to contain: Insulin Detemir 100 IU/ml (r-DNA)	3ml	First
501	145C	Eli Lilly & Company (India) Pvt. Ltd.	1691	Insulin Inj- Each Cartridge to contain: 25% Lispro And 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin]	3ml Cartridge	First
502	145C	Eli Lilly & Company (India) Pvt. Ltd.	1692	Insulin Inj- Each Cartridge to contain: 50% Lispro And 50% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin]	3ml Cartridge	First
503	145C	Novo Nordisk India Private Limited	1898	Insulin Degludec Inj- Each 1ml Of The Solution For Subcutaneous Inj to contain: Insulin Degludec (r-DNA Origin) 100 Unit/ml Pre Filled Pen	3ml PFP	First
504	145C	Sanofi India Limited	1901	Insulin Glulisine Inj- Each ml to contain: Insulin Glulisine 100 IU, m-Cresol 3.15mg (As Preservative), Excipients Q.S.	3ml Cartridge	First

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
505	145C	Baxter (India) Pvt Ltd	1964	Triple Chamber Bag- Each Bag to contain: Triple Chamber Bag With Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose And Electrolytes Separated By Peel Seals For Peripheral Intravenous	1000ml Bag	First
506	145C	Baxter (India) Pvt Ltd	1965	Triple Chamber Bag- Each Bag to contain: Triple Chamber Bag With Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose And Electrolytes Separated By Peel Seals For Central Intravenous.	2000ml Bag	First
507	145C	Johnson & Johnson Private Limited	2091	Canagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin Hemihydrate Equivalent To Canagliflozin 100mg	1 Tab/Cap	First
508	145C	Boehringer Ingelheim India Private Limited	2094	Empagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Empagliflozin 10 mg	1 Tab/Cap	First
509	145C	Eli Lilly & Company (India) Pvt. Ltd.	2230	Dulaglutide Inj- Each 0.5 ml to contain: 1.5 mg of Dulaglutide, Citric Acid Anhydrous [0.07mg], Mannitol [23.2 mg], Polysorbate 80 [0.10 mg], Trisodium Citrate Dehydrate [1.37 mg] Water for injection	1 Inj	First
510	145C	Boehringer Ingelheim India Private Limited	2231	Empagliflozin + Linagliptin- Each Tab/Cap to contain: Empagliflozin 10 mg + Linagliptin 5 mg	1 Tab/Cap	First
511	145C	Johnson & Johnson Private Limited	2233	Canagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin Hemihydrate Equivalent To Canagliflozin 300mg	1 Tab/Cap	First
512	145C	Johnson & Johnson Private Limited	2235	Canagliflozin+Metformin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin 50mg +Metformin Hydrochloride 1000mg	1 Tab/Cap	First
513	145C	Sanofi India Limited	2238	Insulin Glargine- Each pen to contain: Insulin Glargine 300 IU/ml	1 Pen	First
514	145C	Baxter (India) Pvt Ltd	2373	Desflurane Soln- Each Bott to contain : Desflurane	240ml Bott	First
515	145C	Novo Nordisk India Private Limited	2390	Insulin Degludec/Insulin Aspart (R-Dna Origin) Solution For Subcutaneous Injection- Each 1 ml Of The Solution to contain: 100 Units Insulin Degludec & Insulin Aspart (70% Soluble Insulin Degludec And 30% Soluble Insulin Aspart) Equivalent To 2.56mg Salt Free Anhydrous Insulin Degludec And 1.05mg Salt Free Anhydrous Insulin Aspart./ Insulin Degludec+ Insulin Aspart(70/30)	3ml Pen	First

List of 517 Drugs in DG-ESICRC 142C-146C

SI. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
516	146C	Pfizer Products India Private Limited	509a	Human Growth Hormone- Each Cartridge to contain: Somatropin 16 IU (R-DNA Origin)/ Somatropin 5.3mg (R-DNA Origin)	1 Cartridge	First
517	143C	Baxter (India) Pvt Ltd	2081	Anticoagulants- Each Kit to contain:Two Component Fibrin Sealant With Synthetic Aprotinin (4ml)	4ml	First

Handwritten signature and initials in blue ink.

List of 42 Imported Items of DGESIC RC 142C-146C accorded exemption by Department of Expenditure till 31.03.2027

SI.No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Preference
1	143C	Baxter (India) Pvt Ltd	1670	Haemostatic- Each 5ml to contain: Haemostatic Matrix With Prefilled Gelatin Granules In Syringes	5ml	FIRST
2	143C	Baxter (India) Pvt Ltd	2077	Hemostat- Each PFS to contain: Hemostatic Matrix With Thrombin In Prefilled Syringe 10ml	1 PFS	FIRST
3	143C	Roche Products (India) Pvt Ltd	2209	Emicizumab Inj- Each Vial Contains : Emicizumab 30mg For Sub Cut Injection (R-DNA Origin)	1 Vial	FIRST
4	143C	Roche Products (India) Pvt Ltd	2210	Emicizumab Inj- Each Vial Contains : Emicizumab 60mg For Sub Cut Injection (R-DNA Origin)	1 Vial	FIRST
5	143C	Baxter (India) Pvt Ltd	2081	Anticoagulants- Each Kit to contain:Two Component Fibrin Sealant With Synthetic Aprotinin (4ml)	4ml	FIRST
6	144C	Astra Zeneca Pharma India Ltd	526	Goserelin Inj- Each PFS to contain: Goserelin 3.6mg	1 PFS	FIRST
7	144C	Johnson & Johnson Private Limited	600	Infliximab Inj- Each Vial to contain: Infliximab 100mg	1 Vial	FIRST
8	144C	Baxter (India) Pvt Ltd	1456	CAPD Bag- Each bag to contain: CAPD Bag 7.5% Of Lcodextrin With Asymmetrical Y Connector	2 Ltr Bag	FIRST
9	144C	Roche Products (India) Pvt Ltd	2117	Alectinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Alectinib 150 mg Equivalent To Alectinib Hydrochloride 161.3 mg	1 Tab/Cap	FIRST
10	144C	Roche Products (India) Pvt Ltd	2118	Atezolizumab inj- Each 20ml Vial to contain: Atezolizumab Injection 1200mg	1 Vial	FIRST
11	144C	Johnson & Johnson Private Limited	2128	Ibrutinib Tab/Cap- Each Cap/Tab to contain : Ibrutinib 140mg.	1 Tab/Cap	FIRST

ng 1/5

MA
Till 31/03/2027

12	144C	Roche Products (India) Pvt Ltd	2133	Obinutuzumab Inj- Each Vial to contains: Obinutuzumab 1000 mg	1 Vial	FIRST
13	144C	Roche Products (India) Pvt Ltd	2136	Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml)	1 Vial	FIRST
14	144C	Dr. Reddy's Laboratories Limited	2137	Triptorelin Pamoate Inj- Each Single Dose Vial Contains:(Sterile Lypholized) Triptorelin Pamoate Equivalent to Triptorelin 11.25mg Pamorelin La 11.25 Inj.	1 Vial	FIRST
15	144C	Pfizer Products India Private Limited	2138	Crizotinib Tab/Cap- Each Hard Geletin Tab/Cap to contain : Crizotinib 250mg	1 Tab/Cap	FIRST
16	144C	Dr. Reddy's Laboratories Limited	2140	Panitumumab Inj- Each Single Use Vial Of 5 ml to contain: Panitumumab 100 mg (20mg/ml)	1 Vial	FIRST
17	144C	Eli Lilly & Company (India) Pvt. Ltd.	2179	Ramucirumab Concentrate For Solution For Infusion- Each Vial to contain: Ramucirumab 500mg / 50ml Vial Component :Ramucirumab 500mg,L-Histidine 32.5mg, L- Histidine Monohydrochloride 61.0mg, Glycine 499mg, Sodium Chloride 219mg, Polysorbate 80 5.0mg, Water For Injection Q.S	50ml Vial	FIRST
18	144C	Johnson & Johnson Private Limited	2181	Golimumab (r-DNA Origin)- Each Single Use Pre-Filled Syringe to contain: Golimumab 50mg/0.5ml Component [Amount Per Dose (Mg)]: Golimumab (CNTO 148) -50mg, Sorbitol -20.5mg, L- Histidine -0.44mg, Polysorbate 80 - 0.075mg, Water For Injection - 0.5mg	1 PFS	FIRST
19	144C	Johnson & Johnson Private Limited	2218	Daratumumab Inj- Each 5ml to contain: Daratumumab Concentrate For Solution For Infusion 100mg	1 Vial	FIRST

pg 2/5

7/11/2024

20	144C	Johnson & Johnson Private Limited	2219	Daratumumab Inj- Each 20ml to contain: Daratumumab Concentrate For Solution For Infusion 400mg	1 Vial	FIRST
21	144C	MSD Pharmaceuticals Private Ltd	2220	Pembrolizumab Inj- Each ml to contain: Pembrolizumab 25mg	4ml Vial	FIRST
22	144C	MSD Pharmaceuticals Private Ltd	2227	Human Papillomavirus- Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 16 , 18) Vaccine, Recombinant	0.5ml	FIRST
23	144C	Glaxo SmithKline Pharmaceuticals Ltd	2319	Mepolizumab Inj- Each Vial to contain: Mepolizumab 100mg	1 Vial	FIRST
24	144C	Pfizer Limited	2336	Pneumococcal Vaccine- Each 0.5ml to contain: Pneumococcal Polysaccharide Conjugate Vaccine (13 Valent)	1 PFS	FIRST
25	145C	Novo Nordisk India Private Limited	1487	Insulin Aspart Inj- Each Vial to contain: Insulin Aspart (r-DNA Origin)	10ml Vial	FIRST
26	145C	Novo Nordisk India Private Limited	1593	Insulin Detemir Inj- Each Inj to contain: Insulin Detemir 100 IU/ml (r-DNA)	3ml	FIRST
27	145C	Eli Lilly & Company (India) Pvt. Ltd.	1691	Insulin Inj- Each Cartridge to contain: 25% Lispro And 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin]	3ml Cartridge	FIRST
28	145C	Eli Lilly & Company (India) Pvt. Ltd.	1692	Insulin Inj- Each Cartridge to contain: 50% Lispro And 50% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin]	3ml Cartridge	FIRST
29	145C	Novo Nordisk India Private Limited	1898	Insulin Degludec Inj- Each 1ml Of The Solution For Subcutaneous Inj to contain: Insulin Degludec (r-DNA Origin) 100 Unit/ml Pre Filled Pen	3ml PFP	FIRST
30	145C	Sanofi India Limited	1901	Insulin Glulisine Inj- Each ml to contain: Insulin Glulisine 100 IU, m-Cresol 3.15mg (As Preservative), Excipients Q.S.	3ml Cartridge	FIRST

Ms 3/5

7/11/2023

31	145C	Baxter (India) Pvt Ltd	1964	Triple Chamber Bag- Each Bag to contain: Triple Chamber Bag With Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose And Electrolytes Separated By Peel Seals For Peripheral Intravenous	1000ml Ba	FIRST
32	145C	Baxter (India) Pvt Ltd	1965	Triple Chamber Bag- Each Bag to contain: Triple Chamber Bag With Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose And Electrolytes Separated By Peel Seals For Central Intravenous.	2000ml Ba	FIRST
33	145C	Johnson & Johnson Private Limited	2091	Canagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin Hemihydrate Equivalent To Canagliflozin 100mg	1 Tab/Cap	FIRST
34	145C	Boehringer Ingelheim India Private Lim	2094	Empagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Empagliflozin 10 mg	1 Tab/Cap	FIRST
35	145C	Eli Lilly & Company (India) Pvt. Ltd.	2230	Dulaglutide Inj- Each 0.5 ml to contain: 1.5 mg of Dulaglutide, Citric Acid Anhydrous [0.07mg], Mannitol [23.2 mg], Polysorbate 80 [0.10 mg], Trisodium Citrate Dehydrate [1.37 mg] Water for injection	1 Inj	FIRST
36	145C	Boehringer Ingelheim India Private Lim	2231	Empagliflozin + Linagliptin- Each Tab/Cap to contain: Empagliflozin 10 mg + Linagliptin 5 mg	1 Tab/Cap	FIRST
37	145C	Johnson & Johnson Private Limited	2233	Canagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin Hemihydrate Equivalent To Canagliflozin 300mg	1 Tab/Cap	FIRST
38	145C	Johnson & Johnson Private Limited	2235	Canagliflozin+Metformin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin 50mg +Metformin Hydrochloride 1000mg	1 Tab/Cap	FIRST

ng 4/5

7/11/2024

39	145C	Sanofi India Limited	2238	Insulin Glargine- Each pen to contain: Insulin Glargine 300 IU/ml	1 Pen	FIRST
40	145C	Baxter (India) Pvt Ltd	2373	Desflurane Soln- Each Bott to contain : Desflurane	240ml Bott	FIRST
41	145C	Novo Nordisk India Private Limited	2390	Insulin Degludec/Insulin Aspart (R-Dna Origin) Solution For Subcutaneous Injection- Each 1 ml Of The Solution to contain: 100 Units Insulin Degludec & Insulin Aspart (70% Soluble Insulin Degludec And 30% Soluble Insulin Aspart) Equivalent To 2.56mg Salt Free Anhydrous Insulin Degludec And 1.05mg Salt Free Anhydrous Insulin Aspart./ Insulin Degludec+ Insulin Aspart(70/30)	3ml Pen	FIRST
42	146C	Pfizer Products India Private Limited	509a	Human Growth Hormone- Each Cartridge to contain: Somatropin 16 IU (R-DNA Origin)/ Somatropin 5.3mg (R-DNA Origin)	1 Cartridge	FIRST

ng 5/5

APSA
7/11/2024

List of 86 approved imported Drugs in RC 142C to 146C

S. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
1	142C	Ferring Pharmaceuticals Pvt Ltd	2193	Mesalazine Suppository- Each Suppository to contain: Mesalazine 1 gm	1 Suppository	PENTASA 1gm
2	142C	Ferring Pharmaceuticals Pvt Ltd	2194	Mesalazine Granules: Each Sachet to contain: Mesalazine 2 gm Prolonged Release Granules	1 Sachet	PENTASA 2gm
3	143C	Baxter (India) Pvt Ltd	1670	Haemostatic- Each 5ml to contain: Haemostatic Matrix With Prefilled Gelatin Granules In Syringes	5ml	Floseal 5ml
4	143C	Servier India Private Limited (formerly known as Sirda Pharmaceuticals (India) Private Limited)	2070	Ivabradine Tab/Cap- Each Film Coated Tab/Cap to contain: Ivabradine Hcl Equivalent To Ivabradine 7.5mg	1 Tab/Cap	CORALAN 7.5MG
5	143C	Baxter (India) Pvt Ltd	2077	Hemostat- Each PFS to contain: Hemostatic Matrix With Thrombin In Prefilled Syringe 10ml	1 PFS	Floseal 10ml
6	143C	Pfizer Limited	2078	Apixaban Tab/Cap- Each Film Coated Tab/Cap to contain: Apixaban 2.5mg	1 Tab/Cap	ELIQUIS 2.5MG
7	143C	Pfizer Limited	2079	Apixaban Tab/Cap- Each Film Coated Tab/Cap to contain: Apixaban 5mg	1 Tab/Cap	ELIQUIS 5MG
8	143C	Baxter (India) Pvt Ltd	2081	Anticoagulants- Each Kit to contain: Two Component Fibrin Sealant With Synthetic Acrotinin (4ml)	4ml	Tissel LYO
9	143C	Baxalta Bioscience India Private Limited	2208	Human Albumin- Each Bott to contain- Human Albumin 25% 100 ml In Flexible, Self Collapsible- Closed System Bags	100ml Bott	Flexbumin
10	143C	Rodhe Products (India) Pvt Ltd	2209	Emicizumab Inj- Each Vial Contains : Emicizumab 30mg For Sub Cut Injection (R-DNA Origin)	1 Vial	Hemlibra 30 mg

S. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
11	143C	R odhe Products (India) Pvt Ltd	2210	Emicizumab Inj- Each Vial Contains : Emicizumab 60mg For Sub Cut Injection (R-DNA Origin)	1 Vial	Hemlibra 60 mg
12	143C	Pfizer Products India Private Limited	557a	Dalteparin Sodium Inj- Each PFS to contain: Dalteparin Sodium 2500 IU Units	1 PFS	FRAGMIN 2500 IU
13	143C	Pfizer Products India Private Limited	557b	Dalteparin Sodium Inj- Each PFS to contain: Dalteparin Sodium 5000 IU Units	1 PFS	FRAGMIN 5000 IU
14	144C	Astra Zeneca Pharma India Ltd	526	Goserelin Inj- Each PFS to contain: Goserelin 3.6mg	1 PFS	PFS, ZOLADEX 3.6mg
15	144C	Johnson & Johnson Private Limited	600	Infliximab Inj- Each Vial to contain: Infliximab 100mg	1 Vial	Remicade
16	144C	Baxter (India) Pvt Ltd	1456	CAPD Bag- Each bag to contain: CAPD Bag 7.5% Of Leodextrin With Asymmetrical Y Connector	2 Ltr Bag	Extraneal 7.5%
17	144C	Dr. Reddy's Laboratories Limited	1982	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 50mg	1 Vial	Dacotin 50mg Injection
18	144C	Dr. Reddy's Laboratories Limited	1983	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 100 Mg	1 Vial	Dacotin Injection 100mg
19	144C	Sanofi Synthelabo (India) Private Limited	1990	Sevelamer Sachet- Each Sachet to contain: Sevelamer Carbonate 800 mg	1 Sachet	Renvela 800mg
20	144C	R odhe Products (India) Pvt Ltd	2117	Alectinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Alectinib 150 mg Equivalent To Alectinib Hydrochloride 161.3 mg	1 Tab/Cap	Alecensa 150mg
21	144C	R odhe Products (India) Pvt Ltd	2118	Atezolizumab Inj- Each 20ml Vial to contain: Atezolizumab Injection 1200mg	1 Vial	Tecentriq 1200mg
22	144C	Johnson & Johnson Private Limited	2128	Ibrutinib Tab/Cap- Each Cap/Tab to contain : Ibrutinib 140mg.	1 Tab/Cap	Imbruvica™
23	144C	R odhe Products (India) Pvt Ltd	2133	Obinutuzumab Inj- Each Vial to contain: Obinutuzumab 1000 mg	1 Vial	Gazyva Vial 1000mg
24	144C	R odhe Products (India) Pvt Ltd	2136	Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml)	1 Vial	Perjeta Vial 420mg

S. No.	RC Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
25	144C Dr. Reddy's Laboratories Limited	2137	Triptorelin Pamote Inj- Each Single Dose Vial Contains: (Sterile Lyophilized) Triptorelin Pamote Equivalent to Triptorelin 11.25mg Pamorelin La 11.25 Inj.	1 Vial	Pamorelin LA 11.25mg Injection
26	144C Pfizer Products India Private Limited	2138	Crizotinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Crizotinib 250mg	1 Tab/Cap	CRIZALK 250MG
27	144C Dr. Reddy's Laboratories Limited	2139	Denosumab Inj- Each Vial to contain: Denosumab 120 mg (70mg/ml) Total Fill 1.7ml In 5ml Vial	1 Vial	Xgeva 120mg Injection
28	144C Dr. Reddy's Laboratories Limited	2140	Paritumumab Inj- Each Single Use Vial Of 5 ml to contain: Paritumumab 100 mg (20mg/ml)	1 Vial	Vectibx 100mg Injection
29	144C Pfizer Products India Private Limited	2143	Palbociclib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Palbociclib 125mg	1 Tab/Cap	PALBACE 125MG
30	144C Boehringer Ingelheim India Private Limited	2144	Afatinib Tab/Cap- Each Tab/Cap to contain: Afatinib 20 mg	1 Tab/Cap	Xovoltib 20 mg
31	144C Boehringer Ingelheim India Private Ltd	2145	Afatinib Tab/Cap- Each Tab/Cap to contain: Afatinib 30 mg	1 Tab/Cap	Xovoltib 30 mg
32	144C Pfizer Products India Private Limited	2148	Irinotecan Inj- Each 5ml Vial to contain: Irinotecan 100 mg	1 Vial	CAMPTO 100mg/ 5ml
33	144C Roche Products (India) Pvt Ltd	2149	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtrastine 160mg	1 Vial	Kadcyla Vial 160mg
34	144C Pfizer Products India Private Limited	2153	Axitinib Tab/Cap- Each Film Coated Tab/Cap to contain: Axitinib 5 Mg	1 Tab/Cap	INLYTA 5 MG
35	144C Roche Products (India) Pvt Ltd	2156	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtrastine 100mg	1 Vial	Kadcyla Vial 100mg
36	144C Boehringer Ingelheim India Private Limited	2157	Afatinib Tab/Cap- Each Tab/Cap to contain: Afatinib 40 mg	1 Tab/Cap	Xovoltib 40 mg
37	144C Ferring Pharmaceuticals Pvt Ltd	2169	Degarelix Inj- Each Vial to contain: Degarelix 80 mg	1 Vial	Firmagon 80mg
38	144C Roche Products (India) Pvt Ltd	2174	Erlotinib Tab/Cap- Each Tab/Cap to contain: Erlotinib 150 mg	1 Tab/Cap	Tarceva Tablets 150mg

S. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
39	144C	Pfizer Products India Private Limited	2176	Irinotecan Inj- Each 2ml Vial to contain: Irinotecan 40mg	1 Vial	CAMPTO 40mg/ 2 ml
40	144C	Eli Lilly & Company (India) Pvt. Ltd.	2179	Ramudrumab Concentrate For Solution For Infusion- Each Vial to contain: Ramudrumab 500mg / 50ml Vial Component :Ramudrumab 500mg,L-Histidine 32.5mg, L-Histidine Monohydrochloride 61.0mg, Glycine 499mg, Sodium Chloride 219mg, Polysorbate 80 5.0mg, Water For Injection Q.S	50ml Vial	CYRAMZA 500 MG
41	144C	Johnson & Johnson Private Limited	2181	Golimumab (r-DNA Origin)- Each Single Use Pre-Filled Syringe to contain: Golimumab 50mg/0.5ml Component [Amount Per Dose (Mg)]: Golimumab (CNTO 148) -50mg, Sorbitol -20.5mg, L-Histidine -0.44mg, Polysorbate 80 - 0.075mg, Water For Injection - 0.5mg	1 PFS	Simpsoni®
42	144C	Eisai Pharmaceuticals India Private Limited	2215	Lenvatinib Tab/Cap- Each Tab/Cap to contains: Lenvatinib 4mg	1 Tab/Cap	Lenvima 4mg
43	144C	Eisai Pharmaceuticals India Private Limited	2216	Lenvatinib Tab/Cap- Each Tab/Cap to contains: Lenvatinib 10mg	1 Tab/Cap	Lenvima 10mg
44	144C	Johnson & Johnson Private Limited	2218	Daratumumab Inj- Each 5ml to contain: Daratumumab Concentrate For Solution For Infusion 100mg	1 Vial	Darzalex™ 100mg/5mL
45	144C	Johnson & Johnson Private Limited	2219	Daratumumab Inj- Each 20ml to contain: Daratumumab Concentrate For Solution For Infusion 400mg	1 Vial	Darzalex™ 400mg/20mL
46	144C	MSD Pharmaceuticals Private Limited	2220	Pembrolizumab Inj- Each ml to contain: Pembrolizumab 25mg	4ml Vial	KEYTRUDA

S. No.	RC Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
47	144C Roche Products (India) Pvt Ltd	2223	Mycophenolate Mofetil Powder- Each Bott to contain: Mycophenolate Mofetil Powder For Oral Suspension 1gm/5ml	1 Bottle with 110gm powder for oral susp. Containing 35gm Mycophenolate Mofetil	Cellcept Suspension
48	MSD Pharmaceuticals Private Limited	2227	Human Papillomavirus- Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 16, 18) Vaccine, Recombinant	0.5ml	GARDASIL
49	144C Glaxo SmithKline Pharmaceuticals Ltd	2319	Mepolizumab Inj- Each Vial to contain: Mepolizumab 100mg	1 Vial	NUCALA 100MG
50	144C Fresenius Kabi India Pvt Ltd	2327	Alfa Ketoanalogue Tab/Cap- Each Tab/Cap to contain: Alpha Ketoanalogue 381mg, L-Histidine 38m, L-Lysine 105mg, L-Threonine 53mg, Tryptophan 23mg, Tyrosine 30mg	1 Tab/Cap	Ke tosteril Tab
51	144C Pfizer Limited	2336	Pneumococcal Vaccine- Each 0.5ml to contain: Pneumococcal Polysaccharide Conjugate Vaccine (13 Valant)	1 PFS	PREVENAR 13 PFS 0.5ML
52	144C Baxter (India) Pvt Ltd	2341	Outlet Port Clamp	1 Clamp	Blue Clamp
53	144C Pfizer Products India Private Limited	1473a	Sunitinib Malate Tab/Cap- Each Tab/Cap to contain: Sunitinib Malate 12.5mg	1 Tab/Cap	SUTENT 12.5MG
54	144C Pfizer Products India Private Limited	1473b	Sunitinib Malate Tab/Cap- Each Tab/Cap to contain: Sunitinib Malate 25mg	1 Tab/Cap	SUTENT 25MG
55	144C Pfizer Products India Private Limited	488a	Carboplatin Inj- Each Vial to contain: Carboplatin 150mg	1 Vial	Carboplatin 150mg in 15ml
56	144C Pfizer Products India Private Limited	488b	Carboplatin Inj- Each Vial to contain: Carboplatin 450mg	1 Vial	Carboplatin 450mg in 45ml
57	145C Novo Nordisk India Private Limited	1487	Insulin Aspart Inj- Each Vial to contain: Insulin Aspart (r-DNA Origin)	10ml Vial	NovoRapid 100 IU Vial

S. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
58	145C	Novo Nordisk India Private Limited	1488	Biphasic Insulin Aspart Inj- Each Penfill to contain: Biphasic Insulin Aspart (r-DNA Origin)	3ml Penfill	NovoMix 30 Penfill
59	145C	Novo Nordisk India Private Limited	1593	Insulin Detemir Inj- Each Inj to contain: Insulin Detemir 100 IU/ml (r-DNA)	3ml	Levemir Flexpen
60	145C	Astra Zeneca Pharma India Ltd	1689	Saxagliptin Tab/Cap- Each Tab/Cap to contain: Saxagliptin 5mg	1 Tab/Cap	Onglyza 5mg
61	145C	Eli Lilly & Company (India) Pvt. Ltd.	1691	Insulin Inj- Each Cartridge to contain: 25% Lispro And 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin]	3ml Cartridge	HUMALOG MIX 25
62	145C	Eli Lilly & Company (India) Pvt. Ltd.	1692	Insulin Inj- Each Cartridge to contain: 50% Lispro And 50% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin]	3ml Cartridge	HUMALOG MIX 50
63	145C	MSD Pharmaceuticals Private Limited	1766	Sitagliptin 50mg + Metformin 500mg Tab/Cap- Each Tab/Cap to contain: Sitagliptin 50mg, Metformin 500 mg.	1 Tab/Cap	JANUMET 50mg/500mg
64	145C	Novo Nordisk India Private Limited	1898	Insulin Degludec Inj- Each 1ml Of The Solution For Subcutaneous Inj to contain: Insulin Degludec (r-DNA Origin) 100 Unit/ml Pre-Filled Pen	3ml PFP	Tresiba Flextouch
65	145C	Sanofi India Limited	1900	Insulin Glulisine Inj- Each ml to contain: Insulin Glulisine 100 IU, m-Cresol 3.15mg (As Preservative). Excipients Q.S.	10ml Vial	Apidra Vial
66	145C	Sanofi India Limited	1901	Insulin Glulisine Inj- Each ml to contain: Insulin Glulisine 100 IU, m-Cresol 3.15mg (As Preservative). Excipients Q.S.	3ml Cartridge	Apidra Cartridge
67	145C	Baxter (India) Pvt Ltd	1964	Triple Chamber Bag- Each Bag to contain: Triple Chamber Bag With Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose And Electrolytes Separated By Peel Seals For Peripheral Intravenous	1000ml Bag	Olidinamol N4

S. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
68	145C	Baxter (India) Pvt Ltd	1965	Triple Chamber Bag- Each Bag to contain: Triple Chamber Bag With Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose And Electrolytes Separated By Peel Seals For Central Intravenous.	2000ml Bag	Olldinonmel N7
69	145C	Astra Zeneca Pharma India Ltd	2089	Dapagliflozin Tab/Cap- Each Tab/Cap to contains Dapagliflozin 5mg	1 Tab/Cap	Forxiga 5mg
70	145C	Johnson & Johnson Private Limited	2091	Canagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin Hemihydrate Equivalent To Canagliflozin 100mg	1 Tab/Cap	Invokana
71	145C	Boehringer Ingelheim India Private Limited	2094	Empagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Empagliflozin 10 mg	1 Tab/Cap	Jardance 10mg
72	145C	Eli Lilly & Company (India) Pvt. Ltd.	2230	Dulaglutide Inj- Each 0.5 ml to contain: 1.5 mg of Dulaglutide, Citric Acid Anhydrous [0.07mg], Mannitol [23.2 mg], Polysorbate 80 [0.10 mg], Trisodium Citrate Dehydrate [1.37 mg] Water for injection	1 Inj	TRULICITY 1.5 MG
73	145C	Boehringer Ingelheim India Private Limited	2231	Empagliflozin + Linagliptin- Each Tab/Cap to contain: Empagliflozin 10 mg + Linagliptin 5 mg	1 Tab/Cap	Glyxambi 5/10MG
74	145C	Boehringer Ingelheim India Private Limited	2232	Linagliptin + Metformin Tab/Cap- Each Tab/Cap to contain: Linagliptin 2.5mg + Metformin 500mg	1 Tab/Cap	Trajenta 2.5mg/500mg Duo
75	145C	Johnson & Johnson Private Limited	2233	Canagliflozin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin Hemihydrate Equivalent To Canagliflozin 300mg	1 Tab/Cap	Motvyst
76	145C	Johnson & Johnson Private Limited	2235	Canagliflozin+Metformin Tab/Cap- Each Film Coated Tab/Cap to contain: Canagliflozin 50mg +Metformin Hydrochloride 1000mg	1 Tab/Cap	VOKANAMET 50/1000MG
77		Sanofi India Limited	2238	Insulin Glargine- Each pen to contain: Insulin Glargine 300 IU/ml	1 Pen	Toujeo Solostar

S. No.	RC Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
78	145C Baxter (India) Pvt Ltd	2244	Multiple Electrolyte Injection- Each to contain: Type I: A self collapsible bag contain isotonic solution in a single dose container for intravenous administration. Each bott has an ionic concentration of 140mEq Sodium, 5mEq Potassium, 3mEq Magnesium, 98mEq Chloride, 27mEq Acetate and 23mEq Gluconate. The osmolarity is 294mOsmol/L. The caloric content is 21Kcal.	500ml bag	Plasmalyte-A
79	145C Fresenius Kabi India Pvt Ltd	2364	Lipid Soln- Each Bag to contain - Glucose Solution 13%, Amino Acid Solution With Electrolytes And Lipid Emulsion Corresponding To : Glucose 85 g, Amino Acid 38 g, Nitrogen 6.2 g, Lipids 34 g, Energy 800 Kcal, Osmolarity 850 Mosmol/L (3 Chamber Bag)	1206ml Bag	SMOFKabiven Bag
80	145C Baxter (India) Pvt Ltd	2373	Desflurane Soln- Each Bott to contain : Desflurane	240ml Bott	Suprane
81	145C Novo Nordisk India Private Limited	2390	Insulin Degludec/Insulin Aspart (R-Dna Origin) Solution For Subcutaneous Injection- Each 1 ml Of The Solution to contain: 100 Units Insulin Degludec & Insulin Aspart (70% Soluble Insulin Degludec And 30% Soluble Insulin Aspart) Equivalent To 2.56mg Salt Free Anhydrous Insulin Degludec And 1.05mg Salt Free Anhydrous Insulin Aspart./ Insulin Degludec-Insulin Aspart/2/30.	3ml Pen	Ryzodeg Flextouch
82	145C Baxter (India) Pvt Ltd	587b	Sevoflurane Inj- Each 250ml to contain: Sevoflurane	250ml Bott	
83	146C Lupin Limited	2049	Ferric Carboxy Maltose Eqv. To Elemental Iron 50 mg Inj- Each ml to contain: Ferric Carboxy Maltose Eqv. to Elemental Iron 50mg	10 ml Vial	Revofer Inj
84	146C Fulford (India) Limited (A Subsidiary of Merck Sharp & Dohme Corp., Usa)	2104	Posaconazole Soln- Each Phial to contain : Posaconazole Oral Soln 40mg/ml	105 ml Bott	NOXAFIL

S. No.	RC	Name of the Firm	Item no	Item Name and Description as per Drug Schedule	Unit	Brand
85	146C	Pfizer Products India Private Limited	509a	Human Growth Hormone- Each Cartridge to contain: Somatropin 16 IU (R-DNA Origin)/ Somatropin 5.3mg (R-DNA Origin) Paper Adhesive Tape- Paper Adhesive Tape Hypoallergenic With Acrylate Adhesive 2.5cmx9.14m	1 Cartridge	GENOTROPIN (5.3mg)/ml
86	146C	Essity India Private Limited (Formerly Bsn Medical Private Limited)	546a		1 Roll	Leukapor 2.5cmX 9.14m



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE
CORPORATION
(Ministry of Labour & Employment, Govt. of
India)



मुख्यालय/HEADQUARTERS*
पंचदीप भवन, सी०आई०जी मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.nic.in, 011-23234334, dmc-rc@esic.nic.in

No. U-25/12/142C-146C/Amendment/2021-Med.V / 348

Dated: 28.10.2021

To,

Director(Medical)Delhi/Noida,
Medical Superintendent – ESIC Hospitals
Dean of all the ESIC PGIMSR/ Medical College/ Dental College
Director, ESI Scheme – All States

Amendment- RC 144C & 145C/03

Sub: Purchase of drugs & dressing under ESI Rate contract 144C & 145C
Ref: No. U-25/12/142C-146C/2019-Med.V(RC 144C & 145C) Valid from 14.10.2021 to 31.10.2023.

Sir/Madam,

The following amendment may please be noted:-

Firm Name	Item name	RC No./ Item No./ Page No.	Rates approved in DG ESIC -RC	Pref. in DG ESIC- RC	Amended reduced price w.e.f. 14.10.2021	Change in preference
M/s ASTRA ZENECA PHARMA INDIA LTD	Goserelin Inj- Each PFS to contain: Goserelin 3.6mg	144C / 526 / 2	3675.00 per I PFS	L1	Rs. 3500/- per 1 PFS (Rs. Three Thousand Five Hundred only) +GST as applicable	No change
	Saxagliptin Tab/Cap- Each Tab/Cap to contain: Saxagliptin 5mg	145C/ 1689/ 13	29.79 per 1 Tab/Cap	L1	Rs. 26.60 per 1 Tab/Cap (Rs. Twenty Six AND Paise Six Zero Only) +GST as applicable	No change
	Dapagliflozin Tab/Cap- Each Tab/Cap to contains Dapagliflozin 5mg	145C/ 2089/ 23	20.73 per 1 Tab/Cap	L1	Rs. 17.40 per 1 Tab/cap (Rs. Seventeen AND Paise Four Zero Only) +GST as applicable	No change

All DDOs are advised to recover the excess amount paid to the firm (if any) from the subsequent/ incoming bills of the firm and maintain records at their respective unit.

This issued with the approval of Competent Authority.

Assistant Director(RC)

Copy for information to :-

1. M/s Astra Zeneca Pharma India Ltd, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560045, Email Id - Institution.az@astrazeneca.com for information please.
2. Website Content Manager with request for uploading on ESIC Website
3. Guard file / Spare copy

Assistant Director(RC)



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE
CORPORATION
(Ministry of Labour & Employment, Govt. of
India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी०आई०जी मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.nic.in, 011-23234334, dmc-rc@esic.nic.in

No. U-25/12/142C-146C/Amendment/2021-Med.V / 350

Dated: 28.10.2021

To,

Director(Medical)Delhi/Noida,
Medical Superintendent – ESIC Hospitals
Dean of all the ESIC PGIMSR/ Medical College/ Dental College
Director, ESI Scheme – All States

Amendment- RC 146C/ 02

Sub: Purchase of drugs & dressing under ESI Rate contract 146C
Ref: No. U-25/12/142C-146C/2019-Med.V(RC 146C) Valid from 14.10.2021 to 31.10.2023.

Sir/Madam,

The following amendment may please be noted:-

Name of Firm	RC No/Item No.	Item Description	Amendment (Brand Name added)
M/s Unimarck Pharma (India) Ltd	146C/ 1718	Adapelene Gel- Each Tube to contain: Adapelene 0.1percent	ADMARK Gel

This issued with the approval of Competent Authority.

Assistant Director(RC)

Copy for information to :-

1. M/s M/s Unimarck Pharma (India) Plot No. 76, Industrial Area, JLPL, Sector 82, MOHALI (Pb.) Ltd (Email ID manager.mdoffice@unimarckpharma.com, gm.logistics@unimarckpharma.com for information please.
2. Website Content Manager with request for uploading on ESIC Website
3. Guard file / Spare copy

Assistant Director(RC)



No. U-25/12/142C-146C/Amendment/2021-Med.V /355

Dated: 08.11.2021

To,

Director(Medical)Delhi/Noida,
Medical Superintendent – ESIC Hospitals
Dean of all the ESIC PGIMS/ Medical College/ Dental College
Director, ESI Scheme – All States

Amendment- RC 144C /04

Sub: Purchase of drugs & dressing under ESI Rate contract 144C

Ref: No. U-25/12/142C-146C/2019-Med.V(RC 144C) Valid from 14.10.2021 to 31.10.2023.

Sir/Madam,

The following amendment may please be noted:-

Firm Name	Item name	RC No./ Item No./ Page No.	Rates approved in DG ESIC -RC	Prof. in DG ESIC- RC	Amended reduced price w.e.f. 25.10.2021	Change in preference
M/s Johnson & Johnson Private Limited	Daratumumab Inj- Each 5ml to contain: Daratumumab Concentrate For Solution For Infusion 100mg	144C / 2218/ 25	Rs. 13041/- per 100mg vial	L1	Rs. 13001/- per 100mg Vial (Rs. Thirteen Thousand One Only) +GST as applicable	No change
	Daratumumab Inj- Each 20ml to contain: Daratumumab Concentrate For Solution For Infusion 400mg	144C/ 2219/ 25	Rs. 52095.22 per 400mg vial	L1	Rs. 51900/- per 400mg Vial (Rs. Fifty One Thousand Nine Hundred Only) +GST as applicable	No change

All DDOs are advised to recover the excess amount paid to the firm (if any) from the subsequent/ incoming bills of the firm and maintain records for final reconciliation at their respective unit.

This Issued with the approval of Competent Authority.

Assistant Director(RC)

Copy for information to :-

1. M/s Johnson & Johnson Private Limited, 501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060 Email Id - rsinghal@its.jnj.com, tenderspharma@its.jnj.com, jba-wetia@its.jnj.com for information please.
2. Website Content Manager with request for uploading on ESIC Website
3. Guard file / Spare copy

Assistant Director(RC)



कर्मचारी राज्य बीमा निगम
(एम एंड रोडगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE
CORPORATION
(Ministry of Labour & Employment, Govt. of
India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.डी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.nic.in, 011-23234334, dmc-cd@esic.nic.in

No. U-25/12/142C-146C/Amendment/2021-Med.V/38

Dated: 30.11.2021

To,

Director(Medical)Delhi/Noida,
Medical Superintendent – ESIC Hospitals
Dean of all the ESIC PGIMS/ Medical College/ Dental College
Director, ESI Scheme – All States

Amendment- RC 143C & 146C/ 06

Sub: Purchase of drugs & dressing under ESI Rate contract 143C & 146C
Ref: No. U-25/12/142C-146C/2019-Med.V(RC 143C & 146C) Valid from 14.10.2021 to 31.10.2023.

Sir/Madam,

The following amendment may please be noted:-

Name of Firm	RC No/ Item No.	Item Description	Brand Name in RC	Amended Name
M/s Boehringer Ingelheim India Private Ltd	143C/ 2080	Dabigatran Tab/Cap-Each Tab/cap to contain: Dabigatran Etxelate 110mg	Pradaxa 150mg	Pradaxa 110mg
M/s Boehringer Ingelheim India Private Ltd	143C/ 2302	Dabigatran Tab/Cap-Each Tab/cap to contain: Dabigatran Etxelate 150mg	Pradaxa 110mg	Pradaxa 150mg
M/s HAB Pharmaceuticals & Research Ltd	146C/ 558b	Finasteride Tab/Cap- Each Tab/Cap to contain: Finasteride 5mg	Prostride	Prosteride

This issues with the approval of Medical Commisisoner.

Assistant Director(RC)

Copy for information to :-

1. M/s Boehringer Ingelheim India Private Ltd , 1102, 11th Floor, Hallmark Business Plaza, Gurunanak Hospital Road, Near Gurunanak Hospital, Bandra East, Mumbai, India – 400051 for information please.
2. M/s HAB Pharmaceuticals & Research Ltd, 308 3rd Floor T.V Industrial Estate, S. K Ahire Marg, Worli Mumbai 30 for information please.
3. Website Content Manager with request for uploading on ESIC Website.
4. Guard file / Spare copy

Assistant Director(RC)



No. U-25/12/142C-146C/Amendment/Med V

Date: 17.02.2022

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

AMENDMENT – DG ESIC RC 143C & 144C / 08

विषय: Change In Pack Size and Specification under DG ESIC Rate Contract-143C & 144C – reg.

संदर्भ: No. U-25/12/142C-146C/2019-Med V, for RC 143C & 144C (14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

S. No.1

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO. PAGE NO.	Existing Pack size in DG ESIC RC-143C	Amended Pack size in DG ESIC RC-143C
M/s Sun Pharma Laboratories Limited	Sumatriptan Tab. 50mg	143C 1674 18	10 Tabs Rs. 33.00 for 1 Tab + GST	1 Tab Rs. 33.00 for 1 Tab + GST

S.No.2

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO. PAGE NO.	Existing Specification in DG ESIC RC-143C	Amended Specification in DG ESIC RC-143C
M/s Sun Pharma Laboratories Limited	Sevelamer Hcl 800mg Tab. (Revlamer 800)	144C 1738 7	Sevelamer Hcl 800mg Tab (Revlamer 800)	Sevelamer Carbonate 800mg Tab (Revlamer 800mg)

यह चिकित्सा आयुक्त (Procurement) के अनुमोदन से जारी किया गया है।

Yours faithfully

(Jai Singh)

Assistant Director (RC)

Copy for information to:-

1. M/s Sun Pharma Laboratories Limited, Sun House, Plot No. 201/B/1, Western Express Highway, Goregaon (E), Mumbai-400063
2. Website content manager with request for uploading on ESIC website
3. Guard file / Spare copy

Assistant Director (RC)



U-25/12/142C-146C/Amendment/2021-Med V/41

Dated:08.03.2022

To

Director (Medical) Delhi/Noida
Medical Superintendent- ESIC Hospitals
Dean of all the ESIC PGIMSR/Medical College/Dental College
Director, ESI Scheme- All States

AMENDMENT – DG ESIC RC 143C /09

Sub: Amendments in item nos. 2209 & 2210 under DG ESIC Rate Contract-143C – reg.
Ref: No. U-25/12/142C-146C/2019-Med V for RC 143C (14.10.2021 to 31.10.2023).

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO. PAGE NO.	Existing Rate in DG ESIC RC-143C	Amendment in DG ESIC RC-143C w.e.f. 19.10.2021 till the validity of Rate Contract as per Access Initiative Program of M/s Roche Products (India) Pvt. Ltd. [for eligible ESI Beneficiaries]
M/s Roche Products (India) Pvt. Ltd.	Emicizumab Injection 30mg (Hemlibra 30MG)	143C 2209 33	Rs. 40754.00 per 1 vial + GST	Rs. 40754.00 per 1 vial + GST (No change in firm rate/unit) (For every purchase of 1 vial, the firm shall supply 02 extra vials of same strength i.e. Total of 03 vials of same strength without additional cost)
	Emicizumab Injection 60mg (Hemlibra 60MG)	143C 2210 33	Rs. 81437.00 per 1 vial + GST	Rs. 81437.00 per 1 vial + GST (No change in firm rate/unit) (For every purchase of 1 vial, the firm shall supply 02 extra vials of same strength i.e. Total of 03 vials of same strength without additional cost)


This issues with the approval of Director General.

Yours faithfully


(Jai Singh)
Assistant Director (RC)

Copy for information to: -

1. M/s Roche Products (India) Pvt. Ltd., 146-B, 166A, Unit No. 7,8,9, 8th Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar, Mumbai-400086.
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy


Assistant Director (RC)



No. U-25/12/142C-146C/Amendment/2021-Med V /222

Date: 23.05.2022

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

AMENDMENT – DG ESIC RC 143C / 10

विषय: Addition of Brand Name for receipt of supplies of M/s Sun Pharma Laboratories Limited under DG ESIC Rate Contract-143C- reg.

संदर्भ: No. U-25/12/142C-146C/2019-Med V, for RC 143C (14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name/ Brand Name In RC 143C	R.C NO. ITEM NO. PAGE NO.	Existing description in DG ESIC RC-143C	Addition of Brand Name to be read alongwith description in DG ESIC RC-143C
M/s Sun Pharma Laboratories Limited	Levodopa 250mg, Carbidopa 25mg Tab.	143C 1132 12	Levodopa 250mg, Carbidopa 25mg Tab.	Syndopa 275
	Sumatriptan 50mg Tab	143C 1674 18	Sumatriptan 50mg Tab	Suminat 50
	Carbamazepin 200mg CR Tab	143C 1127a 40	Carbamazepin 200mg CR Tab	Zeptol CR 200
	Mirtazapine 15mg Tab	143C 1430b 41	Mirtazapine 15mg Tab	Mirtaz 15


इसे महानिदेशक के अनुमोदन से जारी किया जाता है।

Yours faithfully


(Jai Singh)
Assistant Director (RC)

Copy for information to:-

1. M/s Sun Pharma Laboratories Limited, Sun House, Plot No. 201/B/1, Western Express Highway, Goregaon (E), Mumbai-400063
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy


Assistant Director (RC)



No. U-25/12/142C-146C/Amendment/2021-Med V / 27 Date: 25.05.2022

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

AMENDMENT – DG ESIC RC 145C / 11

Sub: Change of Manufacturing site for M/s Boehringer Ingelheim India Private Ltd. in DG ESIC RC-145C – reg.

Ref: No. U-25/12/142C-146C/2019-Med V for RC 145C, Date-14.10.2021
(14.10.2021 to 31.10.2023)

Sir/Madam,

In-supersession of previous Sites of M/s Boehringer Ingelheim India Private Ltd. existing in DG ESIC RC 145C, the following amendment may please be noted: -

Name of the Firm	Item Name / Brand name	RC No. Item No. Page No.	Existing Manufacturing sites in DG ESIC RC 145C as	Amended: SOLE Manufacturing Site in DG ESIC RC 145C as
M/s Boehringer Ingelheim India Private Ltd.	Tab. Linagliptin 2.5mg + Metformin 500mg (Trajenta DUO 2.5mg/500mg)	145C 2232 28	1.Boehringer Ingelheim Pharma GmbH & Co., K.G. Binger Strass 173, 55216, Ingelheim am Rhein, Germany 2.Boehringer Ingelheim Elias, A.E.5 th km Palania-Markopoulo, Koropi Attiki, 19400, Greece	M/s Dragenopharm Apotheker Puschl GmbH, Gollstrasse 1 84529 Tittmoning Germany

This issues with the approval of Director General.

Yours faithfully

(Dr. Sangeeta Mathur)

Dy. Medical Commissioner (RC)

Copy for information to:-

1. M/s Boehringer Ingelheim India Private Ltd., 1402, 11th Floor, Hallmark Business Plaza, Gurunank Hospital, Bandra East, Mumbai-400051
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy

Dy. Medical Commissioner (RC)



No. U-25/12/142C-146C/Amendment/2021-Med V / 28

Date: 03.06.2022

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

AMENDMENT – DG ESIC RC 144C / 12,

Sub: Change of Manufacturing site for: M/s Johnson & Johnson Private Ltd. in
DG ESIC RC-144C – reg.

Ref: No. U-25/12/142C-146C/2019-Med V for RC 144C, Date-14.10.2021
(14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

Name of the Firm	Item Name / Brand name	RC No. Item No. Page No.	Existing Manufacturing site in DG ESIC RC 144C as	Amended: SOLE Manufacturing Site in DG ESIC RC 144C as
M/s Johnson & Johnson Private Ltd.	Inj. Infliximab 100mg (Remicade)	144C 600 2	M/s Cilag AG, Hochstrasse 201, CH-8205 , Schaffhausen, Switzerland	M/S Cilag AG Hochstrasse 201, CH-8200 , Schaffhausen, Switzerland

This issues with the approval of Medical Commissioner(Procurement)

Yours faithfully

(Signature)
3.6.22

(Dr. Sangeeta Mathur)

Dy. Medical Commissioner (RC)

Copy for information to:-

1. M/s Johnson & Johnson Private Limited, 501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai-400060
2. Website Content Manager with request for uploading on ESIC website, नई दिल्ली-2
3. Guard file / Spare copy

Dy. Medical Commissioner (RC)



No. U-25/12/142C-146C/Amend/2021-Med V (E/687)/267

Date: 05.07.2022

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC Medical Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States.

AMENDMENT – RC 144C/16

Sub: Rate Revision under DG ESIC Rate Contract-144C – reg.

Ref: No. U-25/12/142C-146C/2019-Med.V for RC 144C (14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO. PAGE NO.	Existing Price in DG ESIC RC- 145C	Pref. in RC	Amended reduced Price w.e.f. 17.01.2022	Change in Pref.
Johnson & Johnson Private Limited	Infliximab 100mg in 10ml vial (REMICADE)	144C 600 2	Rs.15155.58 per vial (Rs. Fifteen thousand one hundred fifty-five & paise five eight only) + GST Extra	First & only	Rs.14158.11 per vial (Rs. Fourteen thousand one hundred fifty-eight & paise one one only)+ GST Extra	No Change in pref.

All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.

All reconciliation / recovery is the sole responsibility of the DDOs.

This issues with the approval of Director General.

Yours faithfully

(Dr. Sangeeta Mathur)

डॉ. संगीता मथुर / Dr. SANGEETA MATHUR
Dy. Medical Commissioner (RC)

क.रा.बी.नि. (सु. १०३३) पंचदीप भवन (H.Q.)

श्रम एवं रोजगार मंत्रालय, भारत सरकार

मुद्रामार्ग बस डिपॉट, ऑफिस लिंक

पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-2

Panchdeep Bhawan, C.I.G. Marg, New Delhi-2

Copy for information to:-

1. M/s Johnson & Johnson Pvt. Ltd., 501, ARENA SPACE, BEHIND ROAD, JOGESHWARI, (EAST) MUMBAI, MAHARASHTRA-400050
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy

Dy. Medical Commissioner (RC)



No. U-25/12/142C-146C/Amend/2021-Med V (E/687)/268

Date: 05.07.2022

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC Medical Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States.

AMENDMENT – RC 146C/17

Sub: Rate Revision under DG ESIC Rate Contract-146C – reg.

Ref: No. U-25/12/142C-146C/2019-Med.V For RC 146C (14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO. PAGE NO.	Existing Price in DG ESIC RC- 145C	Pref. in RC	Amended reduced Price w.e.f. 14.10.2021	Change in Pref.
Fulford (India) Limited (A Subsidiary of Merck Sharp & Dohme Corp, USA)	Posaconazole Oral Solution 40mg/ml, 105ml Bottle (NOXAFIL)	146C 2104 26	Rs.10593.33/ per Bottle (Rs. Ten thousand five hundred ninety-three & paise three three only) + GST Extra	First & only	Rs.10270/ per Bottle (Rs. Ten thousand two hundred seventy only) + GST Extra	No Change in pref.

All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.

All reconciliation / recovery is the sole responsibility of the DDOs.

This issues with the approval of Director General.

Yours faithfully

(Signature)
5.7.22

(Dr. Sangeeta Mathur)

डॉ. संगीता मथुर
Dy. Medical Commissioner (RC) (RC)

क.रा.बी.नि. (H.Q.)

श्रम एवं रोजगार मंत्रालय, भारत सरकार

Ministry of Labour & Employment, Govt. of India

पंचदीप भवन, सीआईजी मार्ग, नई दिल्ली - 110 002

Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

Copy for information to:-

1. M/s Fulford (India) Limited (A Subsidiary of Merck Sharp & Dohme Corp, USA), 8th floor, Platina Bldg, Next to Citi bank, C-59, Block – G, Bandra Kurla Complex, Bandra (E), Mumbai 400098
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

(Signature)
5.7.22
Dy. Medical Commissioner (RC)



No. U-25/12/142C-146C/Amend/2021-Med V (E/687)/269

Date: 05.07.2022

To,

Director (Medical) Delhi / Director (Medical) Noida,

Dean, All ESIC Medical Colleges

Medical Superintendents – All ESIC Hospitals,

Directors, ESI Scheme, All States.

AMENDMENT – RC 145C/18

Sub: Rate Revision under DG ESIC Rate Contract-145C – reg.

Ref: No. U-25/12/142C-146C/2019-Med.V For RC 145C (14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO. PAGE NO.	Existing Price in DG ESIC RC- 145C	Pref. in RC	Amended reduced Price w.e.f. 01.05.2022	Change in Pref.
MSD Pharmaceuticals Pvt Ltd	Tab Sitagliptin 100mg (Januvia 100mg)	145C 1490 11	Rs. 30.60 per tab (Rs. Thirty & paise six zero only) + GST Extra	First & only	Rs. 26.235 per tab (Rs. Twenty-six & paise two three five only) + GST Extra	No Change in pref.
MSD Pharmaceuticals Pvt Ltd	Tab Sitagliptin 50mg , Metformin 500mg (Janumet 50mg/500mg)	145C 1766 17	15.70 per tab (Rs. Fifteen & paise seven zero only) + GST Extra	First & only	13.147 per tab (Rs. Thirteen & paise one four seven only) + GST Extra	No Change in pref.

All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.

All reconciliation / recovery is the sole responsibility of the DDOs.

This issues with the approval of Director General.

Yours faithfully

(Dr. Sangeeta Mathur)

डॉ. संगीता मथुर / Dr. SANGEETA MATHUR
Dy. Medical Commissioner (RC)

क.रा.बी.नि. (डी), ए.सी. कॉरपोरेशन (H.Q.)

श्रम एवं रोजगार मंत्रालय, भारत सरकार
पंचदीप भवन, सी०आई०जी मार्ग, नई दिल्ली-2

पंचदीप भवन, सी०आई०जी मार्ग, नई दिल्ली-2
Panchdeep Bhawan, CIG Marg, New Delhi-2

Dy. Medical Commissioner (RC)

Copy for information to:-

1. M/s MSD Pharmaceuticals Pvt Ltd, 10TH Floor, Platina Building, Next to City Bank, C-59, Block - G, Bandra Kurla Complex, Bandra(E), Mumbai 400098
- 2 Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy



कर्मचारी राज्य बीमा निगम
(भारत सरकार, भारत सरकार)
EMPLOYEES' STATE INSURANCE
CORPORATION
(Ministry of Labour & Employment, Govt.
of India)



मुख्यालय / Headquarters office
पंचदीप भवन, सी आई जी मार्ग, नई दिल्ली 110002
PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-
110002
Phone: 011-23234334, E-mail: dmc-rc@esic.nic.in
Website: www.esic.nic.in / www.esic.in

e-file (83185) :U-25/12/142C-146C/Amendment/ Price Revision/2022-Med.V /657 Dated: 07.11.2022

To

Director (Medical) Delhi/Director(Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment -DGESIC RC 145C/ 21

Sub:Rate Revision under DGESIC Rate Contract 145C-reg.

Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 145C dated 14.10.2021 (14.10.21 to 31.10.23)

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	R.C No. Item No. Page No.	Existing Price in DG ESIC RC- 145C	Pref. in RC	Amended reduced Price w.e.f. 01.07.2022
M/s Boehringer Ingelheim India Private Ltd.	Tab. Unaglipatin 2.5mg + Metformin 500mg (Trijenta DUO 2.5mg/500mg)	145C 2232 28	Rs. 16.50 per Tablet (Rs. Sixteen, paise fifty only) per Tablet + GST Extra	First & Only	Rs. 13.40 per Tablet (Rs. Thirteen, paise forty only) per Tablet + GST Extra

- All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.
- Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority/DDOs of the respective Institution.

This issues with the approval of Director General, ESI Corporation.

Yours faithfully

(Dr. Sangeeta Mathur)

Dy. Medical Commissioner (RC)

डा. संगीता मथुर / Dr. SANGEETA MATHUR

Copy for information to:-

- M/s Boehringer Ingelheim India Private Ltd., Unit No. 202 and Part 201, 2nd Floor, Godrej 2, Pirojsha Nagar, Eastern Express Highway Vikhroli (East), Mumbai, Maharashtra- 400079, India for information (e-mail: Pmbtender.in@boehringer-ingelheim.com & COMMScontact.IN@boehringer-ingelheim.com).
- Website Content Manager with request for uploading on ESIC website.
- Guard file / Spare copy

Dy. Medical Commissioner (RC)

1/105317/2022

 ए.एस.आई. ESIC	कर्मचारी राज्य बीमा निगम (मानव संसाधन विभाग, भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India)	 राज्य बीमा निगम	मुख्यालय / Headquarters office पंचदीप भवन, सी.आई.डी. मार्ग, नई दिल्ली-110002 - PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-110002 Phone: 011-23234334, E-mail: dmc- rc@esic.nic.in Website: www.esic.nic.in / www.esic.in
---	--	---	--

E-File (85591): U-25/12/142C-146C/Amendment/Site/2022-Med.V

Dated: 18.11.2022

To

Director (Medical) Delhi/Director (Medical) NOIDA
 Dean, All ESIC PGIMSR's, Medical & Dental Colleges
 Medical Superintendents-All ESIC Hospitals
 Director, ESI Scheme-All States

Amendment -DGESIC RC 144C/ 22

Sub: Amendment in Manufacturing site for M/s Johnson & Johnson Private Limited in DGESIC RC 144C-reg.

Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 144C valid from 14.10.2021 to 31.10.2023.

Sir/Madam,

Reference captioned subject and on the request of M/s Johnson & Johnson Private Limited, following amendment in manufacturing site may please be noted:

Name of the Firm	Item Name/ Brand Name/ Manufacturer Name	R/C Item Page No.	Existing detail of Manufacturer and Mfg. Site etc. in DG ESIC RC-144C	Pref. in RC	In supersession of informed Manufacturing Site in DG ESIC RC 144C
M/s Johnson & Johnson Private Limited	Ibrutinib 140mg cap. (Imbruvica) Manufactured by: M/s Pharmacyclics, LLC., 995 East Arques Avenue, Sunnyvale, CA 94085, USA	144C 2128 15	M/s Pharmacyclics, LLC., 995 East Arques Avenue, Sunnyvale, CA 94085, USA	First & Only	To be read as: M/s Cilag AG, Hochstrasse 201, Schaffhausen Schaffhausen (Switzerland) CH-8200

This issues with the approval of Director General, ESI Corporation.

Yours faithfully

Signed by Jai Singh**Date: 18-11-2022 13:46:36****Reason: Approved**Copy for information to:-

1. M/s Johnson & Johnson Private Limited, 501, Arena Space, Behind Majas Bus Depot Off.J.V. Link Road, Jogeshwari (East), Mumbai-400060 (e-mail:rasawale@its.jnj.com, tandespharma@its.jnj.com.)
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

Asst. Director (Rate Contract Cell)

I/140677/2022

 ए.एस.ई.सी. ESIC	कर्मचारी राज्य बीमा निगम (एन एवं एमएसएल, भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India)	 राज्यपाल कार्यालय	मुख्यालय/Headquarters Office पंचदेव भवन, सी.आई.डी. मार्ग, नई दिल्ली-110002 - PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-110002 Phone: 011-23604773, E-mail: dmo-rc@esic.nic.in Website: www.esic.nic.in / www.esic.in
---	--	--	--

U-25/12/142C-146C/Amendment/Price Revision/2022-Med.V/677 Dated: 19.12.2022

To

Director (Medical) Delhi/Director (Medical) Noida

 Dean, All ESIC PGIMS's, Medical & Dental Colleges
 Medical Superintendents-All ESIC Hospitals
 Director, ESI Scheme-All States

Amendment -DGESIC RC 144C/ 24 E(63125)

 Sub: Rate Revision under DGESIC Rate Contract 144C-reg.
 Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 144C valid from 14.10.21 to 31.10.23.

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	R.C No. Item No. Page No.	Existing Price in DG ESIC RC-144C	Rate in RC	Amended reduced Price in DG ESIC RC- 144C w.e.f. 20.09.2022
M/s MSD Pharmaceuticals Pvt. Ltd.	Vaccine Human Papillomavirus- 0.5ml Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 18, 18) Vaccine, Recombinant Gardasil	144C 2227 26	Rs. 2550.00 per 0.5ml vial (Rs. Two thousand five hundred fifty only) per 0.5 ml vial +GST Extra	First & Only	Rs. 2500.00 per 0.5ml vial (Rs. Two thousand five hundred only) per 0.5 ml vial +GST Extra

1. The said amendment has been issued on the request of Firm M/sMSD Pharmaceuticals Pvt. Ltd.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.
3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.
4. Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority/DDOs of the respective Institution.

This issues with the approval of Director General, ESI Corporation.

Yours faithfully

Signed by Jai Singh

Date: 20-12-2022 10:14:00

Asst. Director (Rate Contract Cell)
Reason: Approved

Copy for information to:-

1. M/sMSD Pharmaceuticals Pvt. Ltd., 10th Floor, Platina Building, Next to CITI Bank, C-59, Block -G, Bandra Kurla Complex, Bandra (East), Mumbai- 400098 for information.

(e-mail: indpub@merck.com, amit.kohli2@merck.com, vivek.bhatia@merck.com).

2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE
CORPORATION
(Ministry of Labour & Employment, Govt.
of India)



मुख्यालय Headquarters office
पंचदीपभवन, सी आई प्री मार्ग, नई दिल्ली 110002
PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-
110002
Phone: 011-23604773, E-mail: dmc-rc@esic.nic.in
Website: www.esic.nic.in / www.esic.in

U-25/12/142C-146C/Amendment/Firm Name/2022-Med.V/679
To

Dated: 21.12.2022

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment -DGESIC RC 143B,145B,143C & 145C / 25

Sub: Amendment in Name of approved pharmaceutical Firm under DGESIC Rate Contracts-reg.

Ref: 1. No. U-25/12/148/2018-Med V (Valid from 30.03.2020 to 29.03.2022 & extended till 30.09.2022).
2. No. U-25/12/142C-146C/2019-Med.V (Valid from 14.10.2021 to 31.10.2023).

Sir/Madam,

The following amendment may please be noted:

Existing name of approved Pharmaceutical Firm in DG ESIC Rate Contracts	Amended Name of approved Pharmaceutical firm in supersession of previous approved name
M/s Serdia Pharmaceuticals (India) Private Limited	M/s Servier India Private Limited

- 1) The said amendment has been issued on the request of the firm M/s Servier India Private Limited (formerly known as M/s Serdia Pharmaceuticals (India) Private Limited), duly documented with the valid relevant Licenses issued by DCGI & State Drug Licensing Authority and Certificate of Incorporation with New Name in Registrar of Companies-Ministry of Corporate Affairs.
- 2) The drug(s) supplies by M/s Servier India Private Limited shall continue to adhere to composition, strength, standards and packing as approved under the respective DGESIC Rate Contract(s) & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.
- 3) M/s Servier India Private Limited (formerly known as M/s Serdia Pharmaceuticals (India) Private Limited) shall continue to be governed by the Terms & Conditions of respective DGESIC Rate Contract(s).
- 4) ERP Mapping of M/s Servier India Private Limited has been completed online in respective Rate Contracts.

This issues with the approval of Director General, ESI Corporation.

Yours faithfully

Asst. Director (Rate Contract Cell)

Copy for information to:-

1. M/s Servier India Private Limited (formerly known as Serdia Pharmaceuticals (India) Private Limited), 1703, 17th Floor, Parinee Crescenzo, 'B' Wing, Plot Nos. C 38 & 39, 'G' Block, Behind MCA, Bandra Kurla Complex, Bandra (East), Mumbai - 400051 for information (e-mail: m.gunlingam@servier.com).
2. Website Content Manager with request for uploading on ESIC website.
3. Concerned Dealing Assistant(s)/Pharmacists in Medical- V Branch for the purpose of release of EMD/NSQ/Recovery etc.
4. Guard file / Spare copy

Asst. Director (Rate Contract Cell)

I/322999/2023



कर्मचारी राज्य बीमा निगम
(एच एच ईएसआई कॉर्पोरेशन, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(MINISTRY OF LABOUR & EMPLOYMENT,
GOVERNMENT OF INDIA)



मुख्यालय/ Headquarters office
पंचदीप भवन, जी. आई. जी. मार्ग, नई दिल्ली- 110002
PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-110002
Phone: 011-23004773, E-mail: dmc-rc@esic.nic.in
Website: www.esic.nic.in / www.esic.in

U-25/12/142C-146C/Amendment/Misc./2022-Med.V/E-114124 Dated: 27.03.2023

To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment -DGESIC RC 142C / 27

Sub: Amendment in brand name of item no. 2024 for approved pharmaceutical firm under DGESIC Rate Contracts-reg.

Ref: 1. No. U-25/12/142C-146C/2019-Med.V(142C) (Valid from 14.10.2021 to 31.10.2023).

Sir/Madam,

The following amendment may please be noted:

Name of the approved Pharmaceutical Firm	Item Description Preference	Item No. DG ESIC RC No. Page No.	Existing brand name for item in valid DG ESIC Rate Contract 142C	Amended brand name in supersession of previous approved name
Glaxo Smithkline Pharmaceuticals Limited	Paracetamol Tab/Cap- Each Tab/Cap to contain: Paracetamol 650mg 1st Preference	2024 142C Page 25 of 38	Calpol 650mg Tab	Calpol 650+ (with Optizorb Formulation)

1. The said amendment has been issued on the request of the firm M/s Glaxo Smithkline Pharmaceuticals Limited duly documented with the valid relevant Licenses issued by State Drug Licensing Authority.
2. The drug(s) supplies by M/s Glaxo Smithkline Pharmaceuticals shall continue to adhere to composition, strength, standards and packing as approved under the respective DGESIC Rate Contract(s) & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.
3. M/s Glaxo Smithkline Limited shall continue to be governed by the Terms & Conditions of respective DGESIC Rate Contract(s).

This issues with the approval of Director General, ESI Corporation.

Yours faithfully

Signed by Jai Singh

Date: 27-03-2023 16:53:57

Reason: Approved

Asst. Director (Rate Contract Cell)

I/322999/2023

Copy for information to:-

1. M/s GlaxoSmithKline Pharmaceuticals Limited, GSK House, 252, Dr. Annie Besant Road, Worli, Mumbai-400030, E-mail: Pradyumna.5.dash@gsk.com, askus@gsk.com, esic.orders@gsk.com
2. Website Content Manager with request for uploading on ESIC website.
3. Concerned Dealing Assistant(s)/Pharmacists in Medical- V Branch for necessary correction/up-dation in ERP module (if any).
4. Guard file / Spare copy

I/400884/2023



कर्मचारी राज्य बीमा निगम
(कर्म एवं रोजगार संवर्धन, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, पी.आर.जी. मार्ग, लक्ष्मी नगर - 110 002
Panchdeep Bhawan, C.O. Marg, New Delhi-110002
www.esic.gov.in, 011-23404779, 011-23404780

No. U-25/12/142C-146C/Amendment/FirmName/2022-Med.V(E-103870)

Date: 03.05.2023

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSI/MSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

Amendment RC 145C/2023

Sub: Amendment in Name of approved Pharmaceutical firm under DG ESIC RC 145C reg.
Ref: No. U-25/12/142C-146C/2019-Med.V (RC 145C) Dated 14.10.2021
(14.10.2021 to 31.10.2023)

The following amendment may please be noted: -

Existing Name of approved Pharmaceutical firm in DG ESIC RC 145C.	Amended Name of approved Pharmaceutical firm in DG ESIC RC 145C in supersession of previous approved name.
M/s Cadila Healthcare Limited	M/s Zydus Lifesciences Ltd

1. This said amendment has been issued on the request of Firm M/s Zydus Lifesciences Ltd, duly documented with the relevant licenses issued by DCGI & Certificate of Incorporation with New Name issued by Registrar of Companies.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act.
3. M/s Zydus Lifesciences Ltd (formerly known as M/s Cadila Healthcare Limited) shall continue to be governed under the Terms & Conditions of Rate Contract 145C.

This issues with the approval of Director General.

Yours faithfully,

Signed by Shrishkumar
Gulab Rao Chavan
Dy. Medical Commissioner(RC)
Date: 03-05-2023 18:35:44
Reason: Approved

Copy for information to:-

1. M/s Zydus Lifesciences Ltd, Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishno devi Circle, Ahmedabad-382481, Email ID: rajiv.kumar@zyduslife.com
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

Dy.
Medical Commissioner(RC)

I/400888/2023



कर्मचारी राज्य बीमा निगम
(एन एस् ईसिकॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
चिदम्बरम् बाजार, पो.आई.सी मार्ग, नई दिल्ली - 110 002
Ferozshah Bagh, C.I.E. Marg, New Delhi-110002
www.esic.gov.in, ☎ 011-23604772, ✉ esic@esic.gov.in

No. U-25/12/142C-146C/Amendment/FirmName/2022-Med.V(E-103870) Date:03.05.2023

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

Amendment RC 142C, 143C & 145C/2023

Sub: Amendment in Name of approved Pharmaceutical firm under DG ESIC RC's 142C, 143C & 145C reg.

Ref: No. U-25/12/142C-146C/2019-Med.V (RC 142C, 143C & 145C) Dated 14.10.2021
(14.10.2021 to 31.10.2023)

The following amendment may please be noted: -

Existing Name of approved Pharmaceutical firm in DG-ESIC RC 142C, 143C & 145C	Amended Name of approved Pharmaceutical firm in DG ESIC RC 142C, 143C & 145C in supersession of previous approved name.
M/s Windlas Biotech Private Ltd	M/s Windlas Biotech Ltd

1. This said amendment has been issued on the request of Firm **M/s Windlas Biotech Ltd**, duly documented with the relevant licenses issued by DCGI & Certificate of Incorporation with New Name issued by Registrar of Companies.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act.
3. **M/s Windlas Biotech Ltd** (formerly known as **M/s Windlas Biotech Private Ltd**) shall continue to be governed under the Terms & Conditions of Rate Contract 142C, 143C & 145C.

This issues with the approval of Director General.

Yours faithfully,

Signed by Shriehkumar

Gulab Rao Chavan

Dy. Medical Commissioner(RC)

Reason: Approved

Copy for information to:-

1. **M/s Windlas Biotech Ltd** 705-706, Vatika Professional point, sector-66, Golf course Ext Road, Gurgaon-122001 Haryana, Email ID: institutionalhead@windlasbiotech.com
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy

Dy. Medical Commissioner(RC)

I/423608/2023



कर्मचारी राज्य बीमा निगम
(एम् एस् ईसि एल्लु मंत्रालय भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, सी.आई.डी मार्ग, नई दिल्ली - 110 002
Panchdeev Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in ☎ 011-23607773 ✉ esic@esic.gov.in

No. U-25/12/CourtCase/MDC/2021-MedV(E-158417) / 320

दिनांक: 12.05.2023

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

ADDENDUM – DG ESIC RC 145C**विषय: Purchase of drugs & Dressings under DG ESIC Rate Contract 145C,**

संदर्भ: No. U-25/12/142C-146C/2019-Med V for RC 145C, Date-14.10.2021 valid from
14.10.2021 to 31.10.2023.

महोदय/महोदय,

This is in reference to the Rate Contract no 145C, the following item is included :-

Item No.	Item Name and Description	Packing	Name of the Firm	Firm Rate per unit (in Figures)	Firm Rate per unit (in Words)	Preference	Description of stores accepted
466a	Methylprednisolone Tab/Cap-	1 Tab/Cap	M/s MDC PHARMACEUTICALS LIMITED	Rs. 1.32	Rupees One AND Paise Thirty Two Only	FIRST	MYLONE 4 Same as in the item
	Each Tab/Cap to contain: Methylprednisolone 4mg		M/s Mesmer Pharmaceuticals	Rs. 1.36	Rupees One AND Paise Three Six Only	SECOND	MP 4 Same as in the item

All terms & conditions of the DGESIC RC 145C will be applicable.

This issues with the approval of Director General.

Dy. Med. Commissioner (RC)**Copy for information to:-**

1. PPS/PS to DG/FC/MC.
2. WCM for uploading on ESIC website
3. M/s M/s MDC Pharmaceuticals Limited, Plot No. 213, First Floor, Industrial Area, Phase I, Chandigarh 160002 for information please.
4. M/s Mesmer Pharmaceuticals, Vedha No 13, Mangala Nagar, 1st Main Road, Porur, Chennai-600116, Tamil Nadu for information please. Email: gvsmani.mesmer@iconlife.in, tenders.mesmer@iconlife.in.
5. Guard file / Spare copy

I/423608/2023

6. Hindi cell for translation

Signed by Shirishkumar
Gulabrao Chavan
Date: 14-05-2023 21:31:14
Reason: Approved

Dy. Med. Commissioner (RC)

I/423611/2023



कर्मचारी राज्य बीमा निगम
(कर्म एवं रोजगार मंत्रालय भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.ओ.डी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.O. Marg, New Delhi-110002
मुख्यालय/HEADQUARTERS

No. U-25/12/CourtCase/MDC/2021-MedV(E-158417) 1318

दिनांक: 12.05.2023

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

ADDENDUM – DG ESIC RC 142Cविषय: **Purchase of drugs & Dressings under DG ESIC Rate Contract 142C.**

संदर्भ: No. U-25/12/142C-146C/2019-Med V for RC 142C, Date-14.10.2021 valid from 14.10.2021 to 31.10.2023.

महोदय/महोदय,

This is in reference to the Rate Contract no 142C, the following item is included :-

Item No.	Item Name and Description	Packing	Name of the Firm	Firm Rate per unit (in Figures)	Firm Rate per unit (in Words)	Preference	Description of stores accepted
	Tolperisone Hcl Tab/Cap-		M/s MDC PHARMACEUTICALS LIMITED	Rs. 1.36	Rupees One AND Paise Thirty Six Only	FIRST	PAINACT MR Same as in the item
1545a	Each Tab/Cap to contain: Tolperisone Hcl 150 mg	1 Tab/Cap	M/s THEMIS MEDICARE LIMITED	Rs. 3.18	Rupees Three AND Paise One Eight Only	SECOND	TOLPIDOL 150 Same as in the item

All terms & conditions of the DGESIC RC 142C will be applicable.

This issues with the approval of Director General.

Dy. Med. Commissioner (RC)**Copy for information to:-**

1. PPS/PS to DG/FC/MC.
2. WCM for uploading on ESIC website
3. M/s M/s MDC Pharmaceuticals Limited, Plot No. 213, First Floor, Industrial Area, Phase I, Chandigarh 160002 for information please.
4. M/s Themis Medicare Limited, 11/12, Udyog Nagar, S.V. Road, Goregaon(W), Mumbai-400104 for information please.
5. Guard file / Spare copy.
6. Hindi cell for translation.

I/423611/2023

Signed by Shirishkumar

Gulabrao Chavan

Date: 14-05-2023 21:37:44

Dy. Med. Commissioner (RC)

I/423610/2023



कर्मचारी राज्य बीमा निगम
(एम् एंड ईएसआई कॉर्पोरेशन, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, सी.आई.डी मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in ☎ 011-23604773 ✉ info@esic.gov.in

No. U-25/12/CourtCase/MDC/2021-MedV(E-158417) 1319

दिनांक: 12.05.2023

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

ADDENDUM – DG ESIC RC 143C**विषय: Purchase of drugs & Dressings under DG ESIC Rate Contract 143C.**

संदर्भ: No. U-25/12/142C-146C/2019-Med V for RC 143C, Date-14.10.2021 valid from 14.10.2021 to 31.10.2023.

महोदय/महोदया,

This is in reference to the Rate Contract no 143C, the following item is included :-

Item No.	Item Name and Description	Packing	Name of the Firm	Firm Rate per unit (in Figures)	Firm Rate per unit (in Words)	Preference	Description of stores accepted
1570	Hydroxyzine Hydrochloride Syrup Each 5ml to contain: Hydroxyzine Hydrochloride 10mg	100ml Bott	M/s MDC PHARMACEUTICALS LIMITED	Rs. 24.80	Rupees Twenty Four AND Paise Eight Zero Only	FIRST & Only	ANXIDOL SYRUP Same as in the item
2075	Potassium + Magnesium Syrup Each 5ml to contain: Potassium Citrate IP 1100mg, Magnesium Citrate USP 375mg, Pyridoxine Hcl IP 20mg, (Each ml to contain: Approx 1mEq Magnesium Ion, 2mEq Potassium Ion, 3mEq Citrate Ion and 4mg Of Pyridoxine Hcl)	200ml Bott	M/s MDC PHARMACEUTICALS LIMITED	Rs. 61.40	Rupees Sixty One AND Paise Four Zero Only	FIRST & Only	POTRIN M B6 Same as in the item

All terms & conditions of the DGESIC RC 143C will be applicable.

This issues with the approval of Director General.

Dy. Med. Commissioner (RC)

I/423610/2023

Copy for information to:-

1. PPS/PS to DG/FC/MC.
2. WCM for uploading on ESIC website
3. M/s M/s MDC Pharmaceuticals Limited, Plot No. 213, First Floor, Industrial Area, Phase I, Chandigarh 160002 for information please.
4. Guard file / Spare copy.
5. Hindi cell for translation.

Signed by Shirishkumar

Gulabrao Chavan

Date: 14-05-2023 21:32:51

~~By: Med. Commissioner~~
By: Med. Commissioner (RC)

I/425368/2023



कर्मचारी राज्य बीमा निगम
(एम् एच ईएसआई कोर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, सी.आई.डी मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
मुख्यालय/HEADQUARTERS

No. U-25/12/142C-146C/Amendment/Misc./2022-Med.V /322

Date: 15.05.2023

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States.

AMENDMENT – RC 142C/2023 (E 114124)

Sub: Change in Brand Name under DG ESIC Rate Contract-142C- reg.
Ref: No. U-25/12/142C-146C/2019-Med.V (RC 142C) Dated 14.10.2021
(14.10.2021 to 31.10.2023)

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name	R.C NO. ITEM NO. PAGE NO.	Pre. in RC	Existing Brand Name	Amended Brand Name
Vivimed Labs Limited	Wax Softner Ear Drops- Each Vial to contain: Para Dichlorobenzene 2 % w/v Benzocaine 7.7% w/v, Chlorbutol 5%, Turpentine Oil 15% w/v	142C 1234 10 of 38	First	Cerkulin Drops	Ceruminolytic Drops

1. This said amendment has been issued on the request of Firm M/s. Vivimed Labs Limited.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act

This issues with the approval of Director General.

Yours faithfully

Signed by Shirishkumar
Gulshan Chawan
Dy. Medical Commissioner (RC)
Date: 15-05-2023 15:18:59
Reason: Approved

Copy for information to:-

1. M/s Vivimed Labs Limited, 34th Floor, NorthEnd Building, Road No. 2, BanjaraHills, Hyderabad, Telangana - 500055 Email: vivek.am@vivimedlabs.com for information and necessary action.
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

1/425368/2023

Dy. Medical Commissioner (RC)

I/425353/2023

Signed by Shirishkumar
Gulabrao Chavan
Date: 15-05-2023 15:14:53
Reason: Approved

Dy. Medical Commissioner (RC)

Copy for information to:-

1. M/s Cipla Limited, Cipla House Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013, Email: Institution@Cipla.com, manish.s@Cipla.com, Vishwas.Ahuja@Cipla.com for information and necessary action.
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

**Dy.
Medical Commissioner (RC)**

I/443384/2023



कर्मचारी राज्य बीमा निगम
(नम एड स्टेट इन्सुरेंस कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव शाहन, सी.ई. मार्ग, नई दिल्ली - 110 002
Panchdeep Shahan, C.I.E. Marg, New Delhi-110002
www.esic.gov.in ☎011-23604779, 23610000@esic.gov.in

No. U-25/12/142C-146C/Amendment/FirmName/2022-Med.V(E-103870)

Date:19.05.2023

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

Amendment RC 142C, 143C & 144C/2023

Sub: Amendment in Name of approved Pharmaceutical firm under valid DG ESIC RC's 142C, 143C & 144C reg.

Ref: No. U-25/12/142C-146C/2019-Med.V (RC 142C, 143C & 144C) Dated 14.10.2021
(14.10.2021 to 31.10.2023)

The following amendment may please be noted: -

Existing Name of approved Pharmaceutical firm in DG-ESIC RC 142C, 143C & 144C	Amended Name of approved Pharmaceutical firm in DG ESIC RC 142C, 143C & 144C in supersession of previous approved name.
M/s Sanofi Synthelabo(India) Private Limited	M/s Sanofi Healthcare India Pvt Ltd.

1. This said amendment has been issued on the request of Firm **M/s Sanofi Healthcare India Pvt Ltd**, duly documented with the relevant licenses issued by DCGI & Certificate of Incorporation with New Name issued by Registrar of Companies.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act.
3. The name of the firm **M/s Sanofi Synthelabo(India) Private Limited** and **M/s Sanofi Pasteur India Pvt Limited** may be read as **M/s Sanofi Healthcare India Pvt Ltd** in respect of expired DGESIC Rate contracts only for the purpose of release of any pending payments, returning of EMD/Security Deposit, recovery etc.
4. **M/s Sanofi Healthcare India Pvt Ltd** (formerly known as **M/s Sanofi Synthelabo(India) Private Limited/ M/s Sanofi Pasteur India Pvt Limited**) shall continue to be governed under the Terms & Conditions of Rate Contract 142C, 143C & 144C.

This issues with the approval of Director General.

Yours faithfully,

Signed by Shirishkumar

Gulab Rao Chavan

Dy. Medical Commissioner(RC)

Date: 23-05-2023 09:52:43

Reason: Approved

Copy for information to:-

1. **M/s Sanofi Healthcare India Pvt Ltd** Sanofi House, CTS 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai-400072. E-mail: institution.business@sanofi.com
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy

Dy. Medical Commissioner(RC)

I/443377/2023



कर्मचारी राज्य बीमा निगम
(कम एड स्टेट्स इन्सुरन्स कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, सी.आई.डी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in ☎011-23604773 ☮esic@esic.gov.in

No. U-25/12/142C-146C/Amendment/FirmName/2022-Med.V(E-103870)

Date:19.05.2023

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGSIMSR's, Medical and Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

Amendment RC 144C & 145C/2023

Sub: Amendment in Name of approved Pharmaceutical firm under valid DG ESIC RC's 144C & 145C reg.

Ref: No. U-25/12/142C-146C/2019-Med.V (RC 144C & 145C) Dated 14.10.2021
(14.10.2021 to 31.10.2023)

The following amendment may please be noted: -

Existing Name of approved Pharmaceutical firm in DG-ESIC RC 144C, & 145C.	Amended Name of approved Pharmaceutical firm in DG ESIC RC 144C & 145C in supersession of previous approved name.
M/s Biocon Biologics India Limited	M/s Biocon Biologics Limited

1. This said amendment has been issued on the request of Firm **M/s Biocon Biologics Limited**, duly documented with the relevant licenses issued by DCGI & Certificate of Incorporation with New Name issued by Registrar of Companies.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act.
3. The name of the firm **M/s Biocon Biologics India Limited** may be read as **M/s Biocon Biologics Limited** in respect of expired DGESIC Rate contracts only for the purpose of release of any pending payments, returning of EMD/Security Deposit, recovery etc.
4. **M/s Biocon Biologics Limited** (formerly known as **M/s Biocon Biologics India Limited**) shall continue to be governed under the Terms & Conditions of Rate Contract 144C & 145C.

This issues with the approval of Director General.

Yours faithfully,

Signed by Shirishkumar

Gulabrao Chavan

Date: 23-05-2023 09:50:23

Dy. Medical Commissioner(RC)

Reason: Approved

Copy for information to:-

1. M/s Biocon Biologics Limited, Biocon House, Tower-3, Semicon Park, Electronics City, Phase II, Hosur Road, Bengaluru, Karnataka, PIN 560100. Email: marketaccess.bbi@biocon.com.
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy

Dy. Medical Commissioner(RC)

I/561494/2023



कार्मिकी राज्य बीमा निगम
(एम् एस् ईसी आर कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



HEADQUARTERS/HEADQUARTERS
पंचदेव भवन, जी.आई.डी मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in ☎011-23464779 ☐ pan001@esic.nic.in

No. U-25/12/142C-146C/Amendment/Misc/2022-MedV

Date: 14.07.2023

To,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States.

AMENDMENT – RC 144C/2023 (E 114124)Sub: Rate Revision under DG ESIC Rate Contract-144C- reg.Ref: No. U-25/12/142C-146C/2019-Med.V for RC 144C (21.10.2022 to 31.10.2024)

Sir/Madam,

The following amendment may please be noted: -

Firm Name	Item Name/ Brand Name	R.C NO. ITEM NO.	Existing Price in DG ESIC RC-151	Pref. in RC	Amended reduced Price w.e.f. 29.05.2023	Change in Pref.
M/s Dr. Reddy's Laboratories Ltd.	Oxaliplatin Inj. Each vial to contain: Oxaliplatin 50mg	144C 1982 12	Rs. 2269.52 per 1 Vial (Rupees Two Thousand Two Hundred Sixty Nine and paise Fifty Two only) + GST Extra	First & only	Rs. 1987.52 per 1 Vial (Rupees One Thousand Nine Hundred Eighty Seven and paise Fifty Two only)+ GST Extra (5%)	No Change in pref.

1. This said amendment has been issued on the request of Firm M/s Dr. Reddy's Laboratories Ltd.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act.
3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.
4. Reconciliation/ recovery under the said amendment is the sole responsibility of the Competent Authority/ DDO's of the respective institution.

This issues with the approval of Director General.

Yours faithfully

Signed by Shirishkumar
Gulabrao Chavan
Date: 14-07-2023 08:33:53
Reason: Approved

I/561494/2023

Dy. Medical Commissioner (RC)

Copy for information to:-

1. M/s Dr. Reddy's Laboratories Ltd, 7-1-27, Ameerpet, Hyderabad-500016, Telangana, India.
Email id ibtpricing@drreddys.com, ibt@drreddys.com for information and necessary action.
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

**Dy.
Medical Commissioner (RC)**

I/590228/2023



कर्मचारी राज्य बीमा निगम
(एम्प्लोयर्स स्टेट इन्सुरन्स कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(MINISTRY OF LABOUR & EMPLOYMENT,
GOVERNMENT OF INDIA)



मुख्यालय/ Headquarters office
पंचदेव भवन, सी. आई. पी. मार्ग, नई दिल्ली- 110002
PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-110002
Phone: 011-23604773, E-mail: dmc-rc@esic.nic.in
Website: www.esic.nic.in / www.esic.in

E-file (85591): U-25/12/142C-146C/Amendment/Site/2022-Med.V

Date: 26.07.2023

To

Director (Medical) Delhi/Director (Medical) Noida
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment-DGESIC RC 145C/27**Sub: Amendment in Manufacturing site for M/s Boehringer Ingelheim India Private Limited in****DGESIC Rate Contract 145C-reg.**

Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 145C valid from 14.10.2021 to 31.10.2023.

Sir/Madam,

Reference captioned subject, on the request of M/s Boehringer Ingelheim India Private Limited, following amendment in manufacturing site may please be noted:

Name of the Firm	Item Name/ Brand Name/ Manufacturer Name	R.C. Item Page No.	Existing detail of Manufacturer and Mfg. Site etc. in DG ESIC RC-145C	Prst. in RC	Amended Manufacturing Site:
M/s Boehringer Ingelheim India Private Limited	Empagliflozin Tab/Cap: Each film coated Tab/Cap to contain: Empagliflozin 10mg (Jardiance 10mg) Manufactured by: M/s Boehringer Ingelheim Pharma GmbH & Co., KG, Binger Str.173, 55216 Ingelheim am Rhein, Germany	145C 2094 25	M/s Boehringer Ingelheim Pharma GmbH & Co., KG, Binger Str.173, 55216 Ingelheim am Rhein, Germany	First	M/s Rotterdam Pharma GmbH, Ostfelder Str 51-61, 593210 Ennigerloh, Germany

This issues with the approval of Director General, ESI Corporation.

Yours faithfully

Signed by Shirishkumar



Gulabao Chavan

Date: 26-07-2023 20:20:11

Reason Approved
Director General, Commissioner
(Rate Contract Cell)

Copy for information to:-

1. M/s Boehringer Ingelheim India Private Limited, 1102, 11TH Floor, Hallmark Business Plaza, Gurunanak Hospital Road, Near Gurunanak Hospital, Bandra East, Mumbai, India-400051 (e-mail: rattan.sharma@boehringer-ingelheim.com and pmibtender.in@ingelheim.com).
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file/ Spare copy



U-25/12/142C-146C/Amendment/Firm Name/2022-Med.V/E-103870/394 dated 27-10-2023
To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment- DGESIC RC 143C/53

Sub: Amendment in Name of approved pharmaceutical firm under DGESIC Rate Contracts-reg.
Ref: 1. U-25/12/142C-146C/2019-Med.V (Valid from 14.10.2021 to 31.10.2023).

Sir/Madam,

The following amendment may please be noted:

Existing name of the approved Pharmaceutical firm in DG ESIC Rate Contract 143C	Amended Name of approved Pharmaceutical firm in supersession of previous approved name w.e.f 27.10.2023
M/s Baxalta Bioscience India Pvt Ltd.	M/s Takeda Biopharmaceuticals India Pvt Ltd.

1. The said amendment has been issued on the request of the firm M/s Takeda Biopharmaceuticals India Pvt Ltd (formerly known as M/s Baxalta Bioscience India Pvt Ltd.)
2. The drug supplied by M/s Takeda Biopharmaceuticals India Pvt Ltd. shall adhere to composition, strength, standards and packing as approved under the respective DGESIC Rate Contract & conform to the standards and specification as per Drugs & Cosmetic Act and any amendment thereof.
3. M/s Takeda Biopharmaceuticals India Pvt Ltd (formerly known as M/s Baxalta Bioscience India Pvt Ltd.) shall continue to be governed by the Terms & Conditions of respective DGESIC Rate Contract.
4. ERP mapping of M/s Takeda Biopharmaceuticals India Pvt Ltd has been completed online in respective Rate Contract (Supplier code: SUP0000001849).

यह महानिदेशक कर्मचारी राज्य बीमा निगम के अनुमोदन से जारी किया जाता है।

Warm Regards

Dy. Medical Commissioner (Rate Contract):

Copy for information to:

1. Medical Commissioners (All Zones)
2. Zonal M/s Takeda Biopharmaceuticals India Pvt. Ltd., 6th Floor, Tower-C, Building No.8, DLF Cyber City, DLF Phase II, Gurgaon, Haryana-122001. (e-mails: takeda.tenders@takeda.com and ritesh.chauhan@takeda.com)
3. Website Content Manager with request for uploading on ESIC Website.
4. Guard file/spare copy

/990313/2024



कर्मचारी राज्य बीमा निगम
(एम् एच ईएसआई कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, सी.आई.डी. मार्ग, नई दिल्ली - 110 002
Panchdev Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in, 011-23604773, esicmstr@esic.gov.in

U-25/12/142C-146C/Amendment/Site/2022-MedV(E-85591)

Dated 16.01.2024

To

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESI PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Schemes-All States

Amendment- DGESIC RC 144C/56

Sub: Change in overseas manufacturer of M/s MSD Pharmaceuticals Private Limited-reg

Ref: U-25/12/142C-146C/2019-Med.V (144C) valid from 14.10.21 to 31.10.23 and extended up to 30.04.24.

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name.	R.C Item Page No.	Existing detail of Manufacturer and address in DG ESIC RC- 144C	Preference in RC	Amended Manufacturer & Address
MSD Pharmaceuticals Private Limited	Pembrolizumab Inj- Each ml to contain: Pembrolizumab 25mg 4ml Vial KEYTRUDA	144C 2220 Page 25 of 33	Schering Plough Labo NV Belgium	First and Only	Merck Sharp & Dohme B.V. Waarderweg 39, Haarlem, 2031 BN, Netherlands.

/990313/2024

1. The said amendment has been issued on the request and undertaking of the DG ESIC RC approved pharmaceutical firm M/s MSD Pharmaceuticals Private Limited duly documented with the valid relevant licenses issued by Drug Controller General of India.
2. The drug supplied by M/s MSD Pharmaceuticals Private Limited shall continue to adhere to composition, strength, standard and packing as approved under the respective DGESIC Rate Contract(s) & conform to standards and specifications as per the Drug & Cosmetic Act and any amendment thereof.
3. M/s MSD Pharmaceuticals Private Limited shall continue to be governed by the Terms & conditions of respective DGESIC Rate Contract (s).
4. **Procurement of the abovesaid item through DG ESIC RC 144C is valid upto 31.03.2024 as per the validity granted in OM No. F. 4/1/2023-PPD(I), Department of expenditure, Procurement Policy Division, Ministry of Finance, Govt. of India, dated 19.12.2023 and web upload No.15539 dated. 05.01.2024.**

This issues with the approval of Director General, ESI Corporation.

Yours Faithfully
Signed by Jai Singh
Date: 16-01-2024 16:36:21
Reason: Approved
Asstt. Director (Rate Contract)

Copy for information to:

1. M/s MSD Pharmaceuticals Private Limited,
2. Website Content Manager with request for uploading on ESIC website.
3. Guard File/spare copy.



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.E. Marg, New Delhi-110002
www.esic.gov.in, 011-23804773, 23804774, 23804775

U-25/12/149-153/Amendment/Misc./2023-Med.V(E-164533)/714

Dated:04.03.2024

To

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents - All ESIC Hospitals,
Directors, ESI Scheme, All States.

AMENDMENT - RC 143C/57

Sub: Change in Pack Size under DG ESIC Rate Contract-143C - reg.

Ref: No. U-25/12/142C-146C/2019-Med.V(RC 143C) (14.10.2021 to 30.04.2024)

Sir/Madam,

The following amendment may please be noted w.r.t DG ESIC RC 143C: -

Firm Name	Item Name/Brand Name	RC No. Item No. Page No.	Existing Firm Pack size in DG ESIC RC 143C	Amended Firm Pack size in DG ESIC RC 143C
M/s Intas Pharmaceuticals Ltd	Paroxetine CR Tab/Cap- Each CR Tab/Cap to contain: Paroxetine 25mg	143C 1873 23 of 50	10 Tab	15 Tab

1. The said amendment has been issued on the request of Firm.
2. The drug shall adhere to composition, strength and standards as approved under the Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act.

This issues with the approval of Director General, ESIC.

With Regards

04.03.2024
Dy. Medical Commissioner (RC)
उप निदेशक आदर (आर.सी.) / Dy. Medical Commissioner (RC)
कर्मचारी नि. (स.) / E.S.I. Corporation (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी. आई. जी. मार्ग, नई दिल्ली-2
Panchdeep Bhawan, CIG Marg, New Delhi-2
04.03.2024
Dy. Medical Commissioner (RC)

Copy for information to:

1. M/s Intas Pharmaceuticals Ltd, Corporate House, Near Solitaire Bridge, S.G. Highway, Thaltej, Ahmedabad- 380054, e-mail: tenderpro@intaspharma.com
2. Website Content Manager with request for uploading on ESIC Website.
3. Guard File/Spare Copy.



कर्मचारी राज्य बीमा निगम
(एम एस ईआईसी कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.एम. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.E. Marg, New Delhi-110002
फोन: 23389773, 23389774, 23389775, 23389776, 23389777, 23389778, 23389779, 23389780, 23389781, 23389782, 23389783, 23389784, 23389785, 23389786, 23389787, 23389788, 23389789, 23389790, 23389791, 23389792, 23389793, 23389794, 23389795, 23389796, 23389797, 23389798, 23389799, 23389800, 23389801, 23389802, 23389803, 23389804, 23389805, 23389806, 23389807, 23389808, 23389809, 23389810, 23389811, 23389812, 23389813, 23389814, 23389815, 23389816, 23389817, 23389818, 23389819, 23389820, 23389821, 23389822, 23389823, 23389824, 23389825, 23389826, 23389827, 23389828, 23389829, 23389830, 23389831, 23389832, 23389833, 23389834, 23389835, 23389836, 23389837, 23389838, 23389839, 23389840, 23389841, 23389842, 23389843, 23389844, 23389845, 23389846, 23389847, 23389848, 23389849, 23389850, 23389851, 23389852, 23389853, 23389854, 23389855, 23389856, 23389857, 23389858, 23389859, 23389860, 23389861, 23389862, 23389863, 23389864, 23389865, 23389866, 23389867, 23389868, 23389869, 23389870, 23389871, 23389872, 23389873, 23389874, 23389875, 23389876, 23389877, 23389878, 23389879, 23389880, 23389881, 23389882, 23389883, 23389884, 23389885, 23389886, 23389887, 23389888, 23389889, 23389890, 23389891, 23389892, 23389893, 23389894, 23389895, 23389896, 23389897, 23389898, 23389899, 23389900, 23389901, 23389902, 23389903, 23389904, 23389905, 23389906, 23389907, 23389908, 23389909, 23389910, 23389911, 23389912, 23389913, 23389914, 23389915, 23389916, 23389917, 23389918, 23389919, 23389920, 23389921, 23389922, 23389923, 23389924, 23389925, 23389926, 23389927, 23389928, 23389929, 23389930, 23389931, 23389932, 23389933, 23389934, 23389935, 23389936, 23389937, 23389938, 23389939, 23389940, 23389941, 23389942, 23389943, 23389944, 23389945, 23389946, 23389947, 23389948, 23389949, 23389950, 23389951, 23389952, 23389953, 23389954, 23389955, 23389956, 23389957, 23389958, 23389959, 23389960, 23389961, 23389962, 23389963, 23389964, 23389965, 23389966, 23389967, 23389968, 23389969, 23389970, 23389971, 23389972, 23389973, 23389974, 23389975, 23389976, 23389977, 23389978, 23389979, 23389980, 23389981, 23389982, 23389983, 23389984, 23389985, 23389986, 23389987, 23389988, 23389989, 23389990, 23389991, 23389992, 23389993, 23389994, 23389995, 23389996, 23389997, 23389998, 23389999

U-25/12/142C-146C/Amendment/2021-Med.V/E-114124/730

Dated: 22.03.2024

सेवा में,

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme - All States

Amendment- Office Address/57

Sub: Change of company address in respect of M/s Novo Nordisk India Private Limited across all DG ESIC Rate Contracts-reg.

Sir/Madam,

Reference captioned subject, following amendment may please be noted:

Firm Name	Existing Address	New Address
M/s Novo Nordisk India Private Ltd.	Plot No. 32, 47-50, EPIP area, Whitefield, Bangalore-560066	M/s Novo Nordisk India Private Ltd. Institution Business Department, NXT Tower-2, Floor 1&2, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore -560045, Karnataka

The said amendment has been issued:

1. On the request of M/s Novo Nordisk India Private Ltd.
2. Supplier has been updated on ERP (supplier code no. SUP0000001046).

इसे चिकित्सा आयुक्त (प्र.प.ण) कर्मचारी राज्य बीमा निगम के अनुमोदन से जारी किया जाता है।

With Regards,

Dy. Medical Commissioner



Rate Contracts & Procurement

उप निदेश

क.रा.बी.नि.

Copy for information to:-

1. M/s Novo Nordisk India Private Limited, Institution Business Department, Novo Nordisk India Private Limited, NXT Tower-2, Floor 1&2, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore -560045, Karnataka (e-mail: novoindia@novonordisk.com)
Panchdeep Bhawan, CIG Marg, New Delhi-2
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy



Dated:04.04.2024

Director (Medical) Delhi / Director (Medical) NOIDA
Dean, All ESIC PGIMS/R's Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

विषय: Amendment in name of approved pharmaceutical firm under DGESIC Rate Contract-reg.
संदर्भ: य-25/12/142C-146C/2019-Med.V (Valid from 14.10.2021 to 30.04.2024).

The following amendment may please be noted:

Existing Name of the approved Pharmaceutical firm in DG ESIC Rate Contract 146C	Amended Name of the approved Pharmaceutical firm in supersession of previous name
M/s Biodeal Pharmaceuticals Pvt. Ltd	M/s Biodeal Pharmaceuticals Ltd

1. The said amendment has been issued on the request of the firm M/s Biodeal Pharmaceuticals Ltd.
2. The drug supplied by M/s Biodeal Pharmaceuticals Ltd shall adhere to composition, strength, standards and packing as approved under the respective DGESIC Rate Contract & conform to the standards and specification as per Drugs & Cosmetics Act and any amendment thereof.
3. M/s Biodeal Pharmaceuticals Ltd shall continue to be governed by the Terms & Conditions of respective DGESIC Rate Contract.
4. ERP mapping of has been completed online in respective Rate Contract (supplier code no. SUP0000010635).

यह महानिदेशक कर्मचारी राज्य बीमा निगम के अनुमोदन से जारी किया जाता है।

Warm Regards

Dy. Medical Commissioner (Rate Contract)

Copy for information to:

1. Medical Commissioners (All Zones)
2. M/s Biodeal Pharmaceuticals Ltd., 710-712, 7th Floor, Jangpura District Centre, New Delhi-110025 (e-mail: institution@biodealpharma.com)
3. New Delhi-110025 (e-mail: institution@biodealpharma.com)
4. Website Content Manager with request for uploading on the Website
5. Guard file/Spare copy

Dy. Medical Commissioner (Rate Contract)



U-25/12/142C-146C/Amendment/Price Revision/2022-Med.V(E:83125)/78/

Dated: 08.04.2024

To
Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMS's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment -DGESIC RC 144C/ 59 (E:83125)

Sub: Rate Revision under DGESIC Rate Contract 144C-reg.

Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 144C valid from 14.10.21 to 31.10.23 and further
extended upto 31st March, 2024 (for the mentioned item)

Sir/Madam,

The following amendment may please be noted:

Name of the Firm	Item Name/ Brand Name	RC No./ Item No./ Page No.	Existing Price in DG ESIC RC- 144C	Pref. in RC	Amended reduced Price in DG ESIC RC -144C w.e.f. 23.02.2024 (Upto 31.03.2024 for the mentioned item)
M/s. Johnson & Johnson Private Limited.	Inj. Golimumab 50mg, 05 ml PFS Brand Name SIMPONI 1X50 MG AUTOINJ.	144C 2181 23	Rs. 39,123.00 (Rs. Thirty Nine Thousand One Hundred and Twenty Three) + GST Extra	First And Only	Rs. 19,561.50 (Rs. Nineteen Thousand Five Hundred Sixty One and Fifty Paise only) + GST Extra

1. The said amendment has been issued on the request of the firm M/s. Johnson & Johnson Private Limited.
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.
3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.
4. Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institution.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

शुभेच्छु

सं. मा.उ.र.
8.4.24

Copy for information to:

1. M/s. Johnson & Johnson Private Limited, 501, Arena Space, Behind New Bus Depot, Off. J.V. Link Road, (I.I.) Jogeshwari (East), Mumbai-400060.
(Email: resawale@jil.inj.com, tenderspharma@jil.inj.com)
2. Website Content Manager with request for uploading on ESIC website
3. Guard file / Spare copy

डॉ. उम चिकित्सा आयुक्त (दर संविदा)
उप चिकित्सा आयुक्त (दर संविदा)
क.रा.बी.नि. (दर संविदा)
अम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.डी मार्ग, नई दिल्ली-2
Panchdeep Bhawan, C.I.D. Marg, New Delhi-2
उप चिकित्सा आयुक्त (दर संविदा)



कर्मचारी राज्य बीमा निगम
(एम एंड एंजोयर्स मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



महानिदेशक/HEADQUARTERS
पंचदीप भवन, सी.आई.डी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in, 011-23604773, dmc-rc@esic.nic.in

U-25/12/142C-146C/Amendment/Misc./2022-Med.V (E:114124)/810 Dated: 20.05.2024

To
Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSRS, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

Amendment -61/ DGESIC RC 142C

Sub: Revision in Pack size of approved item no.16 in DGESIC Rate Contract 142C - Colimex Drops from existing 10ml Bottle to 15ml Bottle of the M/s Wallace Pharmaceuticals Pvt. Ltd.-reg.

Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 142C valid from 14.10.21 to 31.10.23 and further extended upto 31st Oct, 2024

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name/ Brand Name	RC No. Item No. Page No. Pref. in RC	Existing Firm Pack Size in DGESIC RC 142C	Amended Firm Pack Size in DGESIC RC 142C	Change in Price (if any)
M/s Wallace Pharmaceuticals Pvt. Ltd.	Antispasmodic Drop/ Susp - Each ml to contain : Dicyclomine Hcl 10 mg, Activated Dimethicone 40mg	142C 16 1 L-1 and ONLY	10ml Bottle	15ml Bottle	No change

1. The said amendment has been issued on the request of firm M/s. Wallace Pharmaceuticals Pvt. Ltd.
2. The drug supplied by m/s. Wallace Pharmaceuticals Pvt. Ltd. shall continue to adhere to composition, strength, etc as approved under the respective DGESIC Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

शुभेच्छु

Signed by Anita Karanwal

Date: 20-05-2024 17:28:38

उप-चिकित्सा आयुक्त

(दर संविदा)

Copy for information to:

1. M/s. Wallace Pharmaceuticals Pvt. Ltd., A 303/312 Floral Deck Plaza, Off. Central MIDC Road, Andheri (East), Mumbai-400093. (Email: pravinwani@wallacepharma.net, institution@wallacePharma.net).
2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy

उप-चिकित्सा आयुक्त



कर्मचारी राज्य बीमा निगम
(एम् एंड ईएसआई कॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.ओ. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.O. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604775, ✉esic@esic.gov.in

U-25/12/Misc./2024-MedV (ई-771310)/299

दिनांक- 20.08.2024

सेवा में,

Director (Medical) Delhi/Director (Medical) Noida
Deans- All PGIMS's/Medical/Dental Colleges
Medical Superintendents-All ESI Hospitals
Dispensary Incharges- Delhi/NCR/States
Directors ESI Schemes- All States

विषय: Corrigendum in r/o DG-ESIC Rate Contract No. 144C valid w.e.f 14.10.2021 to 31.10.2023 and extended up to 31.10.2024-reg.

संदर्भ: U-25/12/142C-146C/2019-Med.V (RC 144C) dated 14th October 2021.

It is hereby informed that following items have been deleted from the approved item list of DG-ESIC Central Rate Contract No.144C (w.e.f 06.08.2024) :

S.No.	Name of approved Pharmaceutical Firm	Item No.	Item Description	Rate/Unit	Preference	Remarks
01	M/s Roche Products (India) Pvt Ltd	2149	Inj. Transtuzumab Emtasine 160MG	169080	1st Preference	Deleted
02	M/s Roche Products (India) Pvt Ltd	2156	Inj. Transtuzumab Emtasine 100MG	105680	1st Preference	Deleted

This is for your information and necessary action.

This issues with the approval of Competent Authority.

Yours Sincerely

Signed by Anita Karanwal

Date: 09-08-2024 14:33:46

Deputy Medical Commissioner

Rate Contract/Procurement

Copy to:

1. M/s Roche Products (India) Pvt Ltd, 146-B,166A, Unit No.7,8,9, 8th Floor, R City, Ghatkopar, Mumbai-400086 (e-mail:hemelin.karekar@roche.com,rajenderan.krishnamurthy@roche.com) for information.
2. Website Content Manager with a request to upload the same on ESIC HQ website.

Deputy Medical Commissioner



कर्मचारी राज्य बीमा निगम
(एम्प्लॉय स्टेट इन्सुरन्स कॉर्पोरेशन)
EMPLOYEES STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, ई.आई.डी.सी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, G.I.D. Marg, New Delhi-110002
www.esic.gov.in 011-23461773, 23461774

U-25/12/142C-146C/Amendment/Price Revision/2022-Med.V (E:83125)
To

1371

Director (Medical) Delhi Director (Medical) NOIDA

Dean, All ESIC PGIMS's, Medical & Dental Colleges

Medical Superintendents-All ESIC Hospitals

Director, DIMS, ESI Scheme-All States

Amendment -75

Sub: Downward Rate Revision under DGESIC Rate Contract 144C-reg.

Ref: No. U-25/12/142C-146C/2019-Med.V for DGESIC RC 144C valid from 14.10.21 to 31.10.23,
further extended upto 31st Oct., 2024.

Sir/Madam,

The following amendment may please be noted:

Firm Name	Item Name Brand name	RC No Item No. Pref. in RC	Existing Price in DGESIC RC-144C	Amended reduced price wef 27.9.2024	Recovery/ difference of rates (if any)
M/s Johnson & Johnson Private Limited	Inj. Infliximab 100mg in 10ml	144C 600 First & only	Rs. 15,155.58 amended to Rs. 14,158.11 per vial in previous amendment letter dt 5.7.2022	Rs. 13,500 per vial	Difference in rates to be deducted for supply orders placed w.e.f 27.9.2024, if any

1. The said amendment has been issued on the request of the firm M/s. Johnson & Johnson Private Limited.

2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.

3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.

4. Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institution.

यह पत्र महानिदेशक, क.रा.बी. निगम के अनुमोदन से जारी किया जाता है।

[Signature] 23/10/2024

उप निदेशिका आयुक्त (वर संविदा)

Copy for information to:

- M/s. Johnson & Johnson Private Limited, 501, Arena Space, Behind Majes Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai-400060. (Email: rasawale@its.jnj.com, tenderspharma@its.jnj.com)



कर्मचारी राज्य बीमा निगम
(कर्म एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dms:rs@esic.nic.in

No. U-25/12/NSQ/2023-Med V (E-178406)

दिनांक: 24.05.2023

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSRS's, Medical & Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

NSQ/2023

विषय: परीक्षण पर दवा "Not of Standard Quality" की घोषणा के संबंध में

महोदय/महोदया,

It is hereby informed that the Drug as detailed below has been reported as "Not of Standard Quality", you are directed to **stop use of the batch of the following item immediately** which has been reported as "Not of Standard Quality": (copy enclosed)

NSQ Reported by	Name of the Firm	Item Name/ Brand Name	RC No/ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/ Report No. & Date/	Reason of NSQ
MS, ESIS Hospital Modi Nagar, Ghaziabad	Bajaj Healthcare Limited Address: 602-606, 6th Floor, Bhoomi Velocity Infotech Park, Plot No: B-39, Road No. 23, Above ICICI Bank, Wagle Industrial Estate, Thane(W)-400604	Vildagliptin +Metformin Tab/Cap- Each Tab/Cap to contain: Vildagliptin 50mg+ Metformin Hydrochloride 1000mg	145C 2237 29	VMC03K21 11.2021 10.2023	Sima Labs (Sophisticated Industrial Materials Analytic Labs Pvt Ltd. FT1013005622 Dt.-12.11.2022	The sample is declared Not of Standard Quality for the reason stated under "Description" Category 'C'

It is also directed that action may be taken as per clause for "Testing of Drugs-Quality Control" of Terms & Conditions of respective DG-ESIC RC. Replacement of supplies or cost of the material is to be recovered along with testing charges, if any, from the firm.

Action taken is to be maintained as record in respective user units.

यह चिकित्सा आयुक्त (Procurement) के अनुमोदन से जारी किया जाता है।

भवदीय,

संलग्नक: उपरोक्त अनुसार

Signed by Jai Singh

Date: 26-05-2023 11:50:41

Reason: Approved


सहायक निदेशक (दर सविदा कक्ष)

I/451178/2023

Copy for information to: -

1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi 110002.
2. Office of the Assistant Commissioner, Food & Drugs Control Administration, C/o Food & Drugs Laboratory, Nr. Polytechnic, Vadodra-390002 with the request to take appropriate action on NSQ reported for the above said batch under information to this office.
3. Office of the Commissioner, Food & Drugs Control Administration(Drugs), Block No 8, 1st floor, Dr. Jivraj Bhavan, Gandhinagar-382010 with the request to take appropriate action on NSQ reported for the above said batch under information to this office.
4. Office of the Assistant Commissioner (Drug) Food Safety & Administration, Govt of Uttar Pradesh with the request to take appropriate action on NSQ reported for the above said batch under information to this office.
5. M/s Bajaj Healthcare Limited 602-606, 6th Floor, Bhoomi Velocity Infotech Park, Plot No: B-39, Road No. 23, Above ICICI Bank, Wagle Industrial Estate, Thane(W)-400604
6. Website Content Manager with request for uploading on ESIC website
7. Guard file

सहायक निदेशक (दर संविदा कक्षा)



Dated: 17-02-2023

NSQ/02/2023

Copy for information to:

I/247163/2023

1. The Drug Controller General of India, CDSCO, Kotla Road, New Delhi-110002, E-mail: dci@nic.in for information.
2. Office of the Assistant Commissioner, Food & Drugs Control Administration, C/O Food & Drugs Laboratory, Nr. Polytechnic, Vadodara -390002 with the request to take appropriate action on "NSQ" reported for the above said batches under information to this office (Copy of Test Report enclosed).
3. Office of the Commissioner, Food & Drugs Control Administration (Drugs), Block No-8, 1st floor, Dr. Jivraj Mehta Bhavan, Gandhinagar-382010 with the request to take appropriate action on "NSQ" reported for the above said batches under information to this office (Copy of Test Report enclosed).
4. Office of The Asstt. Drug Controller, Athani Ln, Kalthamukku, Thiruvananthapuram, Kerala. 695024 Kerala State, Thiruvananthapuram, E-mail: dc.drugs @ kerala.gov.in. with the request to take appropriate action on "NSQ" reported for the above mentioned batch under information to this office (Copy of Test Report enclosed).
5. M/s Bajaj Healthcare Limited ,602-606, 6th Floor, Bhoomi Velocity Infotech Park, Plot No.B-39, Road No. 23,Above ICICI Bank, Wagle Industrial Area Thane (W)-400604.
6. Website Content Manager with request to upload on ESIC Website.



कर्मचारी राज्य बीमा निगम
(एन एच सीआईएस कॉर्पोरेशन, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचसरोज भवन, सी.आई.डी मार्ग, नई दिल्ली - 110 002
Panchsaroj Bhawan, C.I.D. Marg, New Delhi-110002
www.esic.gov.in, 011-23304773, @esic@esic.nic.in

U-25/12/NSQ/2023-Med V (E-178406) /356 Dated:

To,
Director (Medical) Delhi/ Director (Medical) Noida
Deans/Medical Superintendents -All ESIC Medical College & Hospitals
Directors, ESI Scheme, All State

NSQ/2024

Subject: Declaration of Drug "Not of Standard Quality" on Testing - reg

Sir/Madam

It is hereby informed that the Drug as detailed below has been reported as "Not of Standard Quality". It is directed to stop use of the said batch of the following said item immediately (copy enclosed)

NSQ reported by Institution	Name of the Firm	Item Name/ Brand Name	RC No/ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/Report No. & Date	Reason of NSQ
ESIC Model Hospital, Beltola, Guwahati, Assam	M/s Signature Phytochemical Industries 122,M, Selaqui Industrial Area, Dehradun-248011	Fexofenadine Tab - Each tab to contain: 120mg	146C 1145 48	658-021 Nov-2023/Oct-2025	Regional Drug Testing Laboratory (RDTL)- Guwahati GUW/LS/2024-25/863, Dated.- 26.02.2024	The sample does not conform to I.P. with respect to the test for "Dissolution" Category 'B'

It is also directed that action may be taken as per clause for "Testing of Drugs-Quality Control" of Terms & Conditions of respective DG-ESIC RC. Replacement of supplies or cost of the material is to be recovered along with testing charges, if any, from the firm.

Action taken is to be maintained as record in respective user units.

This issues with the approval of Medical Commissioner (Procurement).

Yours Faithfully,

Enclosures: As above

Signed by Neeta Garbiyal
Date: 09-10-2024 15:11:51
Dy. Medical Commissioner(RC)

Copy to:

1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi 110002(dci@nic.in).
2. Office of Commissioner, Food & Drug Administration, Assam Secretariat, Block-A, Dispur, Guwahati-781006, with the request to take appropriate action on NSQ reported for the above said batch under information to this office (foodsafety.assam@gmail.com).
3. State Drug Controller, Office of Drugs Controller(Uttarakhand), Director General of Medical, Health & Family Welfare, Sahastradhara Road, Dehradun, Uttarakhand with the request to take appropriate action on NSQ reported for the above said batch under information to this office (drugcontroluk@gmail.com).
4. The State Drug Controller, Food & Drug Administration, Survey No.341, 2nd Floor, Bandra Kurla Complex, Opposite RBI, Kala Nagar, Bandra East, Mumbai-400051, with the request to take appropriate action on NSQ reported for the above said batch under information to this office (whogmp.mahafda@gmail.com).
5. M/s Signature Phytochemical Industries, 310, 3rd Floor T.V Industrial Estate, S.K Ahire Marg Worli, Mumbai 30, Maharashtra (marketing@signaturepi.in).
6. Website Content Manager with request for uploading on ESIC website.
7. Guard file.



मुख्यालय, कर्मचारी राज्य बीमा निगम
HEADQUARTERS, EMPLOYEES' STATE INSURANCE CORPORATION
पंचदीप भवन, सी०आई०जी० मार्ग, नई दिल्ली-110002
PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI - 110 002
TelFax: 011-23234334, E-mail: dmc-rc@esic.nic.in



No. U-25/12/NSQ/2023- Med. V / E-178406

Dated: 10.02.2023

To,
Director (Medical) Delhi / Director (Medical) Noida
Deans/Medical Superintendents - All ESIC Medical Colleges/Hospitals.
Directors, ESI Schemes - All states

Corrigendum w.r.t NSQ Web Upload Console No.11982, Date-27.01.2023

विषय : Not of Standard Quality drug batch of item no. 1962- reg.

Ref.: 1. NSQ, U-25/12/NSQ/2023-Med.V / E-178406/95, Date- 27.01.2023 (copy enclosed)
2. Letter of CDL, Kolkatta, Date-06.02.2023 (copy enclosed)

महोदया/महोदय,

In continuation of the above letter no. U-25/12/NSQ/2023-Med.V / E-178406/95, date-27.01.2023, it is hereby informed that a Corrigendum has been received from Central Drugs Laboratory, Kolkatta w.r.t. the **Batch No. of the item** declared NSQ on 22.12.2022.

Keeping the above in context, all users are hereby informed that the Batch No. in the above said NSQ web upload may be read as detailed below :

NSQ Reported by	Name of the Firm	Item Name/Brand Name	RC No/ Item No/Page No	Batch No. mentioned earlier on 27.01.2023	Batch No. to be read as below	Informed by/No. & Date
MS, ESIC Model Hospital, Beltola, Guwahati, Assam	Tablets (India) Limited 179, T.H. Road, Chennai-600081	Ferrous Ascorbate with Aminoacids & Zinc Tab/Cap (Astyfer XT)	146C 1962 & 25	TTQ2P5 DOM:08.2022 DOE:07.2024	TTQ2P3 DOM:08.2022 DOE:07.2024	Dr. R.K. Rishi, The Government Analyst, Central Drugs Laboratory, Kolkatta No. 32-88/2022-SS/3361, date-06.02.2023

This is for kind information & necessary action.

भवदीय,

संलग्नक: उपरोक्त अनुसार

सहायक निदेशक (दर संविदा कक्ष)

Copy for information to: -

1. M/s Tablets (India) Limited, 72, Marshall's Road, Jhaver Centre, Raja Annamalai Building, 4th Floor, Egmore, Chennai- 600008
2. Website Content Manager with request for uploading on ESIC website.

I/204767/2023



कर्मचारी राज्य बीमा निगम
(एम् एंड सोशल सेक्योरिटी, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(MINISTRY OF LABOUR & EMPLOYMENT,
GOVERNMENT OF INDIA)



मुख्यालय/ Headquarters office
पंचदीप भवन, सी. आई. जी. मार्ग, नई दिल्ली- 110002
PANCHDEEP BHAWAN, C.I.G. MARG NEW DELHI-110002
Phone: 011-23604773, E-mail: dmc-rc@esic.nic.in
Website: www.esic.nic.in / www.esic.in

No. U-25/12/NSQ/2023- Med. V / E-178406

Dated: 27 .01.2023

To,
Director (Medical) Delhi / Director (Medical) Noida
Deans/Medical Superintendents - All ESIC Medical Colleges/Hospitals.
Directors, ESI Schemes - All states

NSQ/01/2023

विषय : परीक्षण पर दया "Not of Standard Quality" की घोषणा के संबंध में

महोदय/महोदय,

It is hereby informed that the Drug as detailed below has been reported as "Not of Standard Quality": (copy enclosed)

NSQ Reported by	Name of the Firm	Item Name/ Brand Name	Instance of NSQ reported for Firm for year 2023	RC No/ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/ Report No. & Date/	Reason of NSQ
MS, ESIC Model Hospital, Beltoia, Guwahati, Assam-	Tablets (India) Limited 179, T.H. Road, Chennai- 600081	Ferrous Ascorbate with Aminoacids & Zinc Tab/Cap Each film coated Tab/Cap to contain: Ferrous Ascorbate equivalent to elemental Iron 100mg, Methylcobalamin 1000mcg, Folic Acid 1.5mg, L-Histidine Hcl H2O 4mg, L- Lysine Hcl 25mg, Glycine 10mg, Pyridoxine Hcl 1.5mg, Zinc Sulphate 50mg (Astyfer XT)	First & instance, Date of sample collection: 26.10.2022	146C 1962 25	TTQ2P5 08.2022 07.2024	The Government Analyst, Central Drugs Laboratory, Kolkata No. 32-88/2022- SS/DCA(GW)- 43/2866, Dt.-22.12.2022	The sample does not conform to claim with respect to the test for Disintegration. Category 'B'

1. You are directed to **stop use of the batch of the following item immediately**
2. Further action as per clause for 'Testing of Drugs-Quality Control' of Terms & Conditions of DG-ESIC RC should be initiated.
3. Replacement of supplies or cost of the material is to be recovered along with testing charges (if any) from the firm.
4. Action taken is to be maintained as record in respective user units.

I/204767/2023

यह धिक्रित्ता आयुक्त (Procurement) के अनुमोदन से जारी किया जाता है।

संलग्नक: उपरोक्त अनुसार

भवदीय,

Signed by Jai Singh

Date: 27-01-2023 15:51:23

Reason: Approved

सहायक निदेशक (दर संचिदा कष)

Copy for information to: -

- Central Drugs Laboratory, 3, Kyd St, Fire Brigade Head Quarter, Taltala, Kolkata, West Bengal 700016, email: cdtlchennai@cdsco.nic.in, cdtl-chennai@cdsco.nic.in with the request to take appropriate action on 'NSQ' reported for the above said batches under intimation to this office. (Copy of Test Report enclosed)
- Office of the Director of Drugs Control, No. 359, Anna Salai, Teynampet, Chennai-6, Email: indcad@gmail.com with the request to take appropriate action on 'NSQ' reported for the above said batches under intimation to this office. (Copy of Test Report enclosed)
- M/s Tablets (India) Limited, 72, Marshall's Road, Jhaver Centre, Raja Annamalai Building, 4th Floor, Egmore, Chennai- 600008
- Website Content Manager with request for uploading on ESIC website.

/877719/2023



कर्मचारी राज्य बीमा निगम
(एम् एस् ईसिकॉर्पोरेशन)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदेव भवन, सी.आई.डी. मार्ग, नई दिल्ली - 110 002
Panchdev Bhawan, C.I.D. Marg, New Delhi-110002
मुख्यालय, फ़ोन-23604773, टेलीग्राफिक-110002

No.U-25/12/NSQ/2023-MedV (E-178406)

dated:04.12.2023

सेवा में,
Director (Medical) Delhi/Director (Medical) Noida,
Dean, All ESIC PGIMS's Medical & Dental Colleges,
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme, All States

NSQ/08/2023

विषय: परीक्षण पर उठा "Not of Standard Quality" की घोषणा के संबंध में।

महोदय/ महोदया,

It is informed that the drug as detailed below has been reported as "Not of Standard Quality"

NSQ Reported By	Name of the Firm	Item Name/ Brand Name	Instance of NSQ for Firm for year 2023	RC No/ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/ Report No. & Date	Reason of NSQ
Medical Superintendent, Employees State Insurance Scheme Hospital, Satpur Nashik-422007	Windlas Biotech Private Limited 705-706, Vatika Professional Point, Sec -66 Golf Course Ext. Road Gurgaon - 122001 Haryana	Each Tab/ Cap to contain Ethamsylate 250 mg (FIXOHEAM-250)	First instance	143C 68a 50	WF123001G 03.2023 02.2025	Central Drugs Testing Laboratory- Mumbai-400008 MUM/LS/2023-24/371 Dt.-25.10.2023	The Sample received does not conform to the manufacturer's specification with respect to the test for Hardness

In context to above, it is directed to:

1. Stop use of the batch of the above mentioned item immediately which has been reported as "Not of Standard Quality" (Copy enclosed).
2. Initiate action as per clause for Testing of Drugs-Quality Control of Terms & Conditions of respective DG-ESIC RC.
3. Replacement of supplies or cost of the material is to be recovered along with testing charges (if any) from the firm.
4. Maintain record of action taken at respective user units.

यह विकिरसा अधुन के अनुमोदन से जारी किया जाया है।

संलग्न: उपरोक्त अनुसार।

अवधीय

Signed by Jai Singh

Date: 05-12-2023 09:20:42

महोदय/ महोदया (दूर संचित कक्षा)
Reason: Approved



मुख्यालय, कर्मचारी राज्य बीमा निगम
HEADQUARTERS, EMPLOYEES' STATE INSURANCE CORPORATION
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-110002
PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI - 110 002
Tel/Fax: 011-23234334, E-mail: dmc-rc@esic.nic.in



No. U-25/12/NSQ/2022 - Med V / 553

दिनांक: 17.10.2022

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida

Deans/Medical Superintendents - All ESIC Medical Colleges/Hospitals.

Directors, ESI Schemes - All States

NSQ/10/2022

विषय: परीक्षण पर दवा "Not of Standard Quality" की घोषणा के संबंध में

महोदय/महोदया,

It is hereby informed that the Drug as detailed below has been reported as "Not of Standard Quality", you are directed to **stop use of the batch of the following item immediately** which has been reported as "Not of Standard Quality": (copy enclosed)

NSQ Reported by	Name of the Firm	Item Name/ Brand Name	Instance of NSQ reported for Firm for year 2022	RC No./ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/ Report No. & Date	Reason of NSQ
Medical Superintendent, ESIC Hospital & Medical College & PGIMS, K.K. Nagar, Chennai-600078	M/s Sai Parenterals Pvt. Ltd. D4, Phase-V, IDA, Jeedimelta, Hyderabad, Telangana-500055	Heparin Sodium Inj. Each ml to contain: Heparin Sod. 5000 IU Sml vial	First instance In the year 21-22 & in validity of Rate Contract	143C 71 1	22HE05 03.2022 02.2024	Satiare Research & Anatech Pvt. Ltd. Plot No. 264, 1 st & 2 nd Floor, HSIIDC, Barwala-134118, Distt. Panchkula, Haryana Report No.- SA/FP-040722/046 Dated -12.08.2022	The sample is NSQ with respect to Assay of Heparin Sodium. Category 'B'

It is also directed that action may be taken as per clause for "Testing of Drugs-Quality Control" of Terms & Conditions of DG-ESIC RC. Replacement of supplies or cost of the material is to be recovered along with testing charges, if any, from the firm.

Action taken is to be maintained as record in respective user units.

यह चिकित्सा आयुक्त (Procurement) के अनुमोदन से जारी किया जाता है।

संलग्नक: उपरोक्त अनुसार

भवदीय,

(जय सिंह)

सहायक निदेशक (दर संविदा कक्ष)

Copy for information to: -

- Deputy Director & Licensing Authority, Warangal, Drugs Control Administration: Vengal Rao Nagar, Hyderabad-500038, Telangana with the request to take appropriate action on "NSQ" reported for the above said batch under intimation to this office. (Copy of Test Report enclosed)
- M/s Sai Parenterals Pvt. Ltd., D4, Phase-V, IDA, Jeedimelta, Hyderabad, Telangana-500055
- M/s Sai Parenterals Pvt. Ltd., 8-2-700, Srida Anushka Pride, Road No. 12, Banjara Hills, Hyderabad-500034
- Website Content Manager with request for uploading on ESIC website
- Guard file

सहायक निदेशक (दर संविदा कक्ष)

I/649934/2023



कर्मचारी राज्य बीमा निगम
(कर्म एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.डी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmsr@esic.nic.in

No. U-25/12/NSQ/2023-Med V (E-178406)

दिनांक: 23.08.2023

सेवा में,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

NSQ/2023

विषय: परीक्षण पर दवा "Not of Standard Quality" की घोषणा के संबंध में

महोदय/महोदया,

It is hereby informed that the Drug as detailed below has been reported as "Not of Standard Quality", you are directed to **stop use of the batch of the following item immediately** which has been reported as "Not of Standard Quality": (copy enclosed)

NSQ Reported by	Name of the Firm	Item Name/ Brand Name	RC No/ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/ Report No. & Date/	Reason of NSQ
Medical Superintendent ESIC Super Speciality Hospital, Sanathnagar, Hyderabad	M / s Sai Parenterals Pvt Ltd, Mid at : D1 & D4, Survey No 280, Phase V, IDA, Jeedimetla, Hyderabad-500055, Telangana	Heparin Sodium Inj- Each ml to contain: Heparin Sod. 5000IU	143C 71 1	22HE17 10/2022 09/2024	Central Drug Laboratory, Kolkatta No. 32-12/2023-SS/DCA(H)-21/367 Dated 09.05.2023	The sample is declared Not of Standard Quality for the reason stated does not conform to IP with respect to Assay only Category 'B'

It is also directed that action may be taken as per clause for "Testing of Drugs-Quality Control" of Terms & Conditions of respective DG-ESIC RC. Cost of the material is to be recovered along with testing charges, if any, from the firm.

Action taken is to be maintained as record in respective user units.

यह चिकित्सा आयुक्त (Procurement) के अनुमोदन से जारी किया जाता है।

भवदीय,

संलग्नक: उपरोक्त अनुसार

Signed by Jai Singh

Date: 23-08-2023 10:54:48

Reason: Approved

सहायक निदेशक (दर सविद्या कक्षा)

I/649934/2023

Copy for information to: -

1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi 110002.
2. Drug Control Administration, Head Quarters, 79, Vengal Rao Nagar, Hyderabad-500038, email: dg_dca@telangana.gov.in, dcatelangana@gmail.com with the request to take appropriate action on 'NSQ' reported for the above said batches under intimation to this office. (Copy of Test Report enclosed)
3. M/s Sai Parenterals Pvt Ltd, 8-2-700, Srida Anushka Pride , Road No.12, Banjara Hills, Hyderabad - 500 034
4. M/s Sai Parenterals Pvt Ltd, D1 & D4, Survey No 280, Phase V, IDA, Jeedimetla, Hyderabad-500055, Telangana
5. Website Content Manager with request for uploading on ESIC website
6. Guard file

सहायक निदेशक (दर संविदा कक्षा)

I/610183/2023



कर्मचारी राज्य बीमा निगम
(कर्म एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, 011-23604773, dms@esic.nic.in

No. U-25/12/NSQ/2023-Med V (E-178406)

दिनांक: 04.08.2023

सेवा में,
Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

NSQ/2023

विषय: परीक्षण पर दवा "Not of Standard Quality" की घोषणा के संबंध में

महोदय/महोदया,

It is hereby informed that the Drug as detailed below has been reported as "Not of Standard Quality", you are directed to **stop use of the batch of the following item immediately** which has been reported as "Not of Standard Quality": (copy enclosed)

NSQ Reported by	Name of the Firm	Item Name/ Brand Name	RC No/ Item No/ Page No	Batch No./ DOM/ DOE	Name of the Laboratory/ Report No. & Date/	Reason of NSQ
Medical Superintendent, ESIC Model Hospital, Jaipur	M / s Galpha Laboratories Limited 1, Pharmacy, Selaqui, Dehradun-248011, Uttarakhand	Pantoprazole Inj-Each Inj to Contain: Pantoprazole 40mg	142C 536 5	PLI-112102 11/2021 10/2023	Drug Testing Laboratory, Jaipur 2185/2023-2024/DTL/2023 Dated 07.07.2023	The sample is declared Not of Standard Quality for the reason stated under Assay, uniformity of dosage units and uniformity of weight (Mass) Category 'B'

It is also directed that action may be taken as per clause for "Testing of Drugs-Quality Control" of Terms & Conditions of respective DG-ESIC RC. Replacement of supplies or cost of the material is to be recovered along with testing charges, if any, from the firm.

Action taken is to be maintained as record in respective user units.

यह चिकित्सा आयुक्त (Procurement) के अनुमोदन से जारी किया जाता है।

संलग्नक: उपरोक्त अनुसार

भवदीय,

Signed by Jai Singh

Date: 07-08-2023 13:12:14

सहायक निदेशक (आपूर्ति व वित्त)

I/610183/2023

Copy for information to: -

1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi 110002.
2. State Drug Controller, Office of Drugs Controller (Uttarakhand) Directorate General of Medical Health & Family Welfare, Sahasthradhara Road, Dehradun, Uttarakhand, Email ID: drugcontroluk@gmail.com with the request to take appropriate action on 'NSQ' reported for the above said batch under intimation to this office. (Copy of Test Report enclosed)
3. The State Drug Controller, Food & Drug Administration, Survey No. 341, 2nd Floor, Bandra Kurla Complex, Opposite RBI, Kala Nagar, Bandra East, Mumbai-400051 with the request to take appropriate action on 'NSQ' reported for the above said batch under intimation to this office. (Copy of Test Report enclosed)
4. M/s Galpha Laboratories Limited, E-221, Kanakia Zillion Junction of LBS & CST Road, BKC Annexe, Kurla West, Mumbai- 400070.
5. Website Content Manager with request for uploading on ESIC website
6. Guard file

सहायक निदेशक (दर संविदा कक्षा)